mifepristone has been researched along with misoprostol in 843 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.12) | 18.7374 |
| 1990's | 100 (11.86) | 18.2507 |
| 2000's | 262 (31.08) | 29.6817 |
| 2010's | 308 (36.54) | 24.3611 |
| 2020's | 172 (20.40) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Baird, DT; Glasier, AF; Norman, JE; Thong, KJ | 1 |
| Baulieu, EE | 2 |
| Baird, DT; Dewar, MH; Thong, KJ | 1 |
| Baird, DT; Thong, KJ | 1 |
| Baird, DT; Norman, JE; Thong, KJ | 1 |
| Aubeny, E; Baulieu, EE | 1 |
| Baird, DT; Sukcharoen, N; Thong, KJ | 1 |
| Peyron, R; Silvestre, L; Ulmann, A | 1 |
| Sanchez-Ramos, L | 1 |
| el-Refaey, H; Hinshaw, K; Rispin, R; Templeton, A | 1 |
| Potts, M | 1 |
| Cheng, LN; Du, MK; Lu, YL; Sang, GW; Shao, QX; Weng, LJ; Wu, XZ | 1 |
| Creinin, MD | 2 |
| Sang, GW; Shao, QX; Weng, LJ | 1 |
| Cen, HX; Jin, YC; Xu, MF | 1 |
| Liu, B; Sun, J; Tao, W | 1 |
| el-Refaey, H; Templeton, A | 4 |
| Abdalla, M; Calder, L; el-Refaey, H; Rajasekar, D; Templeton, A | 1 |
| Peplow, PV | 1 |
| Bygdeman, M; Gemzell-Danielsson, K; Gottlieb, C; Swahn, ML | 1 |
| Silvestre, L; Ulmann, A | 1 |
| Bygdeman, M | 1 |
| Baird, DT; McKinley, C; Thong, KJ | 1 |
| el-Refaey, H; Hinshaw, K; Templeton, A | 1 |
| Courtieu, C; Déchaud, H; Marès, P; Marsollier, C; Tailland, ML | 1 |
| von Werder, K | 1 |
| Baird, DT | 1 |
| Bygdeman, M; Gemzell Danielsson, K; Swahn, ML | 1 |
| Aubény, E; Baulieu, EE; Elkik, F; Leclerc, P; Peyron, R; Renault, M; Silvestre, L; Targosz, V; Ulmann, A | 1 |
| Rosenfield, A | 1 |
| Elstein, M; Macrow, P | 1 |
| Hoffman, RS; Perrone, J | 1 |
| Grunberg, SM | 1 |
| Jiao, L; Tang, X; Weng, L | 1 |
| Aubény, E; Baulieu, EE; Peyron, R; Renault, M; Silvestre, L; Targosz, V; Turpin, CL; Ulmann, A | 1 |
| Penney, GC; Templeton, A; Webster, D | 1 |
| Chan, YF; Ho, PC; Lau, W | 1 |
| Berry, C; Mathers, AM; Phillips, K | 1 |
| Aflak, N; Chemla, JP; Jannet, D; Marpeau, L; Milliez, J | 1 |
| Ho, PC; Lao, T; Ngai, SW; Yeung, KC | 1 |
| Cabezas, E; Coyaji, KJ; Du, MK; Ellertson, C; Eschen, A; Gu, S; Krishna, UR; Sivin, I; Winikoff, B; Xiao, B | 1 |
| Eisinger, SH; Franks, P; Schaff, EA; Stadalius, LS | 1 |
| Abankwa, A; Aflak, N; Carbonne, B; Jannet, D; Marpeau, L; Milliez, J | 1 |
| Anderson, MR; Gold, M; Luks, D | 1 |
| Schneider, AP | 1 |
| Hahlin, M; Nielsen, S; Platz-Christensen, JJ | 1 |
| Henshaw, RC | 1 |
| Bell, SM; Evans, AJ; Healy, DL; Lavelle, AL; Mamers, PM; Rusden, JR | 1 |
| Ho, PC; Lee, SW; Liu, KL; Ngai, SW; Wong, GC | 1 |
| Chen, S; Gao, W; Li, L | 1 |
| Milliez, J | 1 |
| Aubeny, E | 3 |
| Lefebvre, P; Monniez, N; Norel, G; Prévost, D; Scharfman, W | 1 |
| Bardin, CW; Benton, L; Robbins, A; Spitz, IM | 1 |
| Astruc, M; Boulot, P; Charlier, C; Giacalone, PL; Hoffer, MC; Zimbris, L | 1 |
| Jurkovic, D | 1 |
| Cheng, L; Gao, PP; Ho, PC; Lee, S; Tang, OS | 1 |
| Ballantyne, ES; Blanch, G; Gosden, CM; Holland, K; Neilson, JP; Quenby, S | 1 |
| Ghosh, D; Nayak, NR; Sengupta, J | 2 |
| Davey, A; Sakiz, E; Sitruk-Ware, R | 1 |
| Ewart, WR; Winikoff, B | 1 |
| Ashok, PW; Flett, GM; Templeton, A | 2 |
| French, L; Randel, J | 1 |
| Ashok, PW; Flett, GM; Penney, GC; Templeton, A | 1 |
| Barley, G; O'Brien-Gonzales, A; Westfall, JM | 1 |
| Blinder, V; Elul, B; Winikoff, B | 1 |
| Coyaji, K; Ellertson, C; Harper, C; Winikoff, B | 1 |
| Cabezas, E | 1 |
| Bygdeman, M; Chang, WF; Chen, JK; Gemzell-Danielsson, K; Qian, ML; Song, S; Swahn, ML; Yang, PJ; Yang, QY | 1 |
| Ulmann, A | 1 |
| Brennand, J; Greer, I | 1 |
| Cheng, L; Gao, PP; Ho, PC; Lee, SW; Tang, OS | 1 |
| Bagchi, D; Ellertson, C; Simonds, W; Springer, K; Winikoff, B | 1 |
| Eisinger, SH; Franks, P; Gore, BZ; Poppema, S; Schaff, EA; Stadalius, LS | 1 |
| Coyaji, K; Ellertson, C; Elul, B; Winikoff, B | 1 |
| Cruickshank, DJ; Gouk, EV; Haslock, J; Khair, A; Knight, J; Lincoln, K | 1 |
| Ashok, PW; Templeton, A | 1 |
| Scheepers, HC; van den Bergh, AS; van Erp, EJ | 1 |
| Jain, JK; Meckstroth, KR; Mishell, DR | 1 |
| Creinin, MD; Spitz, IM | 1 |
| Bangou, J; Ellertson, C; Elul, B; Guengant, JP | 1 |
| Bourne, T; Jermy, K; Oyelese, O | 1 |
| Eisinger, SH; Fielding, SL; Fuller, L; Schaff, EA; Stadalius, LS | 1 |
| Clarke, S; Dasmahapatra, R; Westhoff, C; Winikoff, B | 1 |
| von Hertzen, H | 1 |
| Fielding, SL; Schaff, EA | 1 |
| Davis, A; De Nonno, L; Westhoff, C | 1 |
| Elul, B; Pearlman, E; Simonds, W; Sorhaindo, A; Westhoff, C | 1 |
| Clark, S; Ellertson, C; Winikoff, B | 1 |
| Coyaji, K | 1 |
| Wu, S | 1 |
| Beckman, LJ; Harvey, SM; Jensen, JT | 1 |
| Newhall, EP; Winikoff, B | 1 |
| Agarwal, N; Buckshee, K; Sehgal, R; Takkar, D | 1 |
| Fassett, MJ; Mishell, DR; Wing, DA | 1 |
| Ho, PC; Ngai, SW; Tang, OS | 1 |
| Eisinger, SH; Ellertson, C; Fielding, SL; Fuller, L; Schaff, EA; Stadalius, LS; Westhoff, C | 1 |
| Anjum, ZK | 1 |
| Nemecek, S | 1 |
| Aubeny, E; Chatellier, G | 1 |
| Darney, PD; Goldberg, AB; Greenberg, MB | 1 |
| Hale, RW; Zinberg, S | 1 |
| Child, TJ; MacKenzie, IZ; Rees, M; Thomas, J | 1 |
| Curry, M; Simpson, D | 1 |
| Richardson, CR | 1 |
| Chen, H; Ma, T; Wu, X; Xu, J | 1 |
| De Nonno, LJ; Fielding, S; Schaff, E; Westhoff, C | 1 |
| Dasmahapatra, R; Schaff, E; Westhoffa, C | 1 |
| El-Refaey, H; Hoffman, L; le Roux, PA; Nooh, R; Pahal, GS; Rodeck, CH | 1 |
| Cheng, L | 1 |
| Li, D; Qiu, X; Zhou, X | 1 |
| Chen, X; Huang, L; Shi, Y | 1 |
| Li, R; Wang, Z; Wu, R | 1 |
| Ellertson, C; Elul, B; Hajri, S; Ngoc, NN; Pearlman, E; Slama, CB; Winikoff, B | 1 |
| Creinin, MD; Fink, W; Pymar, HC; Schwartz, JL | 1 |
| Allen, RH; De Nonno, L; Fielding, SL; Schaff, EA; Westhoff, C | 1 |
| Knudsen, UB | 1 |
| Eisinger, S; Fielding, SL; Schaff, EA; Stadalius, L | 1 |
| Ashok, PW; Narvekar, N; Smith, NC; Templeton, A; Wagaarachchi, PT | 1 |
| Creinin, MD; Pymar, HC; Schwartz, JL | 2 |
| Baird, DT; Bartley, J; Brown, A; Elton, R | 1 |
| Kolata, G | 1 |
| Nathanson, BN | 1 |
| Augestad, G; Bjørge, L; Helland, H; Iversen, OE; Johnsen, SL; Midbøe, G; Stray-Pedersen, S; Økland, I | 1 |
| Fielding, SL; Schaff, EA; Westhoff, C | 2 |
| Ashok, PW; Fitzmaurice, A; Flett, GM; Graham, W; Kidd, A; Templeton, A | 1 |
| Cheng, L; Ho, PC; Lee, SW; Tang, OS; Xu, J | 2 |
| Wang, Z | 1 |
| Huang, L; Shi, Y | 2 |
| Norel, G | 1 |
| Ellertson, C; Harper, C; Winikoff, B | 1 |
| Moreno, C; Trupin, SR | 1 |
| Dunn, S; Guilbert, E; Jacot, F; Lugtig, L; Wiebe, E | 1 |
| Ashok, PW; Narvekar, NN; Smith, NC; Templeton, A; Wagaarachchi, PT | 1 |
| Ashok, PW; Smith, NC; Templeton, A; Wagaarachchi, PT | 1 |
| Dutton, C; Harwood, B; Jain, JK; Meckstroth, KR; Mishell, DR | 1 |
| Lee, JN; Tsai, EM; Yang, CH | 1 |
| Ellertson, C; Waldman, SN | 1 |
| Honkanen, H; von Hertzen, H | 1 |
| Ambardekar, S; Bopardikar, A; Coyaji, K; Ellertson, C; Elul, B; Krishna, U; Otiv, S; Raote, V; Winikoff, B | 1 |
| Hunter, A; Kyle, P; Porter, H | 1 |
| Gao, PP; Gao, XH; Lu, YL; Ying, YP | 1 |
| Gao, P; Wang, P | 1 |
| Ho, PC; Lee, SW; Tang, OS | 1 |
| Creinin, MD; Fox, MC; Harwood, B | 1 |
| Bygdeman, M; Danielsson, KG | 1 |
| Andersen, B; Clevin, L; Grønlund, A; Grønlund, L; Lidegaard, Ø; Palmgren, N | 1 |
| Alder, J; Bitzer, J; Holzgreve, W; Horner, E; Schwendke, A; Zarkadas, M | 1 |
| Ashok, PW; Flett, GM; Templeton, A; Wagaarachchi, PT | 2 |
| Baird, DT; Bartley, J | 1 |
| Body, G; de Poncheville, L; Lansac, J; Marret, H; Perrotin, F | 1 |
| Corona, G; Ellertson, C; Gould, H | 1 |
| Heikinheimo, O; Honkanen, H; Jänne, OA; Raivio, T; Ranta, S | 1 |
| Chia, KV; Ogbo, VI | 1 |
| Dai, M; Liu, Q; Peng, D; Zi, X | 1 |
| Haukkamaa, M; Heikinheimo, O; Suhonen, S; Tikka, M | 1 |
| Creinin, MD; Holovanisin, M; Janczukiewicz, L; Meyn, L; Potter, C; Pymar, HC; Schwartz, JL | 1 |
| Nash, ES | 1 |
| Creinin, MD; Murthy, A | 1 |
| Lichtenberg, ES | 1 |
| Ashok, PW; Flett, GM; Hamoda, H; Templeton, A | 5 |
| Tenore, JL | 1 |
| Hausknecht, R | 1 |
| Nilas, L; Petersen, MB; Rørbye, C | 1 |
| Bygdeman, M; Fiala, C; Gemzell-Danielsson, K; Safar, P | 1 |
| Basu, R; Gundlach, T; Tasker, M | 1 |
| Darney, PD; Meckstroth, KR | 1 |
| Bartfai, G; Erdenetungalag, R; Gemzell-Danielsson, K; Gopalan, S; Honkanen, H; Horga, M; Jerve, F; Mittal, S; Ngoc, NT; Peregoudov, A; Piaggio, G; Prasad, RN; Pretnar-Darovec, A; Shah, RS; Song, S; Tang, OS; von Hertzen, H; Wu, SC | 1 |
| Backe, B; Heimstad, R | 1 |
| Fang, RY; He, QJ; Wang, WF; Wu, HH; Yang, B | 1 |
| Chan, CC; Ho, PC; Lee, SW; Ng, EH; Tang, OS | 1 |
| Augestad, G; Bjørge, L; Helland, H; Iversen, OE; Johnsen, SL; Midbøe, G; Strray-Pedersen, S; Økland, I | 1 |
| Ashok, PW; Dow, J; Flett, GM; Hamoda, H; Templeton, A | 1 |
| Fletcher, J; Sharma, A; Stewart, P | 1 |
| Heikinheimo, O; Honkanen, H; Rutanen, EM | 1 |
| Coughlin, LB; Haddad, NG; Long, A; Roberts, D | 1 |
| Bugg, G; Greenland, H; Ogunbiyi, I; Tasker, M | 1 |
| Piaggio, G; von Hertzen, H; Xiao, B; Zhao, H | 2 |
| Blum, J; Chélli, H; Gueddana, N; Hajri, S; Mansour, FB; Winikoff, B | 1 |
| Grimes, DA; Smith, MS; Witham, AD | 1 |
| Aubény, E; Dagousset, I; Fourrier, E; Taurelle, R | 1 |
| Coyaji, K; Ellertson, C; Hedley, A; Ngoc, NT; Trussell, J; Turner, AN; Winikoff, B | 1 |
| Amin, P; Kiran, U; Penketh, RJ | 2 |
| Campana, A; Cheng, LN; Gülmezoglu, AM; Hofmeyr, GJ; Kulier, R | 2 |
| Haukkamaa, M; Heikinheimo, O; Suhonen, S | 1 |
| Jiang, S; Lei, ZW; Li, Q; Li, YP; Lü, L; Zou, Y | 1 |
| Acharya, G; Bråthen, A; Haugen, M; Maltau, JM; Nilsen, I | 1 |
| Carles, G; El Guindi, W; Largeaud, M; Montoya, Y; Perotti, F; Seve, B | 1 |
| Creinin, MD; Grimes, DA | 1 |
| Chen, A; Creinin, MD; Fox, MC; Meyn, LA; Schaff, EA; Teal, S | 1 |
| Cohen, LS; Cowett, AA; Lichtenberg, ES; Stika, CS | 1 |
| Chen, HJ; Hwang, JL; Lin, YH | 1 |
| Bártfai, G; Erdenetungalag, R; Gemzell-Danielsson, K; Gopalan, S; Hertzen, H; Honkanen, H; Horga, M; Jerve, F; Mittal, S; Peregoudov, A; Piaggio, G; Prasad, RN; Pretnar-Darovec, A; Shah, RS; Song, S; Tang, OS; Thi Nhu Ngoc, N; Wu, SC | 1 |
| Nothnagle, M; Taylor, JS | 1 |
| Bruinse, HW; Christiaens, GC; De Heus, R; Graziosi, GC; Mol, BW | 1 |
| Han, XJ; Liao, AH; Wu, SY; Wu, XR; Xiao, DZh; Xiong, CL | 1 |
| Creinin, MD; Meyn, LA; Rossi, B | 1 |
| Willems, FE | 1 |
| Bagga, R; Chaudhary, N; Kalra, J | 1 |
| Hajri, S | 1 |
| Martikainen, H; Niinimäki, M; Talvensaari-Mattila, A | 1 |
| Aubény, E; Coyaji, K; Ellertson, C; Hedley, A; Ngoc, NT; Trussell, J; Turner, AN; Winikoff, B | 1 |
| Fairley, TE; Mackenzie, F; Mackenzie, M; Owen, P | 1 |
| Balasubramanian, S; Creinin, MD; Harwood, B; Shore, E | 1 |
| Heikinheimo, O; Honkanen, H; Ranta, S; Ylikorkala, O | 1 |
| Blumenthal, PD; Goldberg, R; Hausknecht, R; Oyer, D; Sankey, H; Schaff, E; Shannon, CS; Winikoff, B; Wolff, J | 1 |
| Flett, GM; Hamoda, H | 1 |
| Ashima, T; Shalini, R; Vinita, A | 1 |
| Chen, YJ; Ho, ES; Lin, SK | 1 |
| Creinin, MD; Harwood, B; Murthy, AS; Schreiber, C | 1 |
| Baunot, N; Faucher, P; Madelenat, P | 1 |
| Creinin, MD; Harwood, B; Murthy, AS; Schreiber, CA | 1 |
| Bibi, M; Chaieb, A; Essaidi, H; Fekih, M; Hidar, S; Jerbi, M; Khairi, H; Sahraoui, W | 1 |
| Rose, SB; Shand, C; Simmons, A; Sparrow, MJ | 1 |
| Chan, CC; Ho, PC; Kan, AS; Tang, OS | 1 |
| Fiala, C; Gemzell-Danielsson, K; Stephansson, O; Swahn, ML | 1 |
| Dahiya, K; Hooda, R; Khosla, AH; Madan, S; Sangwan, K | 1 |
| Choudhary, N; Gopalan, S; Saha, SC | 1 |
| Lu, S; Wang, Z; Wu, R | 1 |
| Chien, P; Guest, J; Kosseim, ML; Thomson, M | 1 |
| Agarwal, S; Batra, A; Kumar, S; Mittal, S | 1 |
| Darney, PD | 1 |
| Knudsen, UB; Kristiansen, FV; Rasmussen, A; Ravn, P | 1 |
| Fielding, SL; Middleton, T; Scahill, M; Schaff, E; Shannon, C; Westheimer, E; Wilkinson, T; Winikoff, B | 1 |
| Arvidsson, C; Gemzell-Danielsson, K; Hellborg, M | 1 |
| Chauvelot-Moachon, L; Sicard, D | 1 |
| Ganatra, B; Manning, V; Pallipamulla, SP | 1 |
| Akin, A; Akin, L; Kocoglu, GO | 1 |
| Tamang, A; Tamang, J | 1 |
| Clark, WH; Fiala, C; Gemzell-Danielsson, K; Hassoun, D; Winikoff, B | 1 |
| Bhatnagar, J; Cheung, M; Dassey, DE; Fischer, M; Guarner, J; Hacker, JK; Iton, A; Poukens, V; Reagan, S; Shieh, WJ; Van Meter, SH; Whiteman, DB; Zaki, SR | 1 |
| Kotsuji, F; Nishijima, K; Shukunami, K | 1 |
| Bettahar-Lebugle, K; Garbin, O; Nisand, I; Vayssiere, C | 1 |
| Berer, M | 2 |
| Bretelle, F; Gamerre, M; Guidicelli, B; Heckenroth, H; Mazouni, C; Porcu, G; Provensal, M | 1 |
| El-Refaey, H; Mitchel, H; Ozturk, O; Rodeck, C; Sharma, S | 1 |
| Borgatta, L; Chen, AY; Mottl-Santiago, J; Vragovic, O; Wasserman, S | 1 |
| Sicard, D | 1 |
| Goh, SE; Thong, KJ | 1 |
| Borgatta, L; Ellis, SC; Kapp, N; Stubblefield, P | 1 |
| Kleiverda, G | 1 |
| Dunn, S; Guilbert, E; Jacot, F; Shannon, C; Sheldon, WR; Wiebe, E; Winikoff, B | 1 |
| Couzin, J | 1 |
| Li, YP; Liang, Y; Mei, L; Tong, L; Wu, SC; Yan, L; Zhang, JQ; Zou, Y | 1 |
| Jouppila, P; Martikainen, H; Niinimäki, M; Talvensaari-Mattila, A | 1 |
| Marions, L | 1 |
| Aronsson, A; Bygdeman, M; Gemzell-Danielsson, K | 1 |
| Cahill, S; Castleman, L; Gallo, MF; Mitchell, EM | 1 |
| Schaff, E | 1 |
| Sitruk-Ware, R | 1 |
| Fiala, C; Gemzel-Danielsson, K | 1 |
| Bosković, V; Dukanac, J; Jeremić, K; Ljubić, A; Radunović, N; Stojnić, J; Tulić, I | 1 |
| Hickey, M; Neilson, JP; Vazquez, J | 1 |
| Coyte, PC; Daniel, I; Dunn, S; Isaacksz, S; Laporte, A; Limacher, JJ; Payne, GJ | 1 |
| Diaz-Olavarrieta, C; Foster, AM; Rouhana, A; Schaffer, K; Trussell, J; Wynn, L | 1 |
| Blumenthal, P; Creinin, M; Shulman, L | 1 |
| Economides, DL; El-Matary, A; Navaratnarajah, R | 1 |
| Dulitzky, M; Goldenberg, M; Machtinger, R; Schiff, E; Seidman, DS; Soriano, D; Stockheim, D; Wiser, A | 1 |
| Winikoff, B | 1 |
| Ho, PC; Tang, OS | 1 |
| Rose, SB; Shand, C; Simmons, A | 1 |
| Creinin, MD; Harwood, BJ; Reeves, MF; Schreiber, CA | 1 |
| Chen, FM; Chen, TH; Kuo, TC; Li, YT; Lin, M; Tsai, CW; Wu, SF | 1 |
| Chen, FM; Chen, ML; Chen, TH; Kuo, TC; Li, SC; Li, YT | 1 |
| Ambardekar, S; Bracken, H; Coyaji, K; Krishna, U; Mandlekar, A; Raote, V; Winikoff, B | 1 |
| Chen, CY; Chiang, HK; Chou, SY; Chow, PK; Hsu, CS; Wang, CC | 1 |
| McGill, J; Shetty, A | 1 |
| Gamerre, M; Guidicelli, B; Mazouni, C; Pellegrin, V; Voiret, C | 1 |
| Dempsey-Fanning, A; Teal, SB; Westhoff, C | 1 |
| Bermudez, SB; Carbonell, JL; Gallego, FG; González, LV; Llorente, MP; Sala, ES; Texido, CS | 1 |
| Chen, BA; Creinin, MD | 2 |
| Chien, PF; Guest, J; Kosseim, ML; Thomson, MA | 1 |
| Bednarek, P; Creinin, MD; Lintu, H; Meyn, LA; Schreiber, CA; Wagner, MS | 1 |
| Ambardekar, S; Bracken, H; Coyaji, K; Ngoc, NT; Schaff, E; Westheimer, E; Winikoff, B | 1 |
| Heydanus, R; Papatsonis, DN; Verhulsdonk, MT | 1 |
| Blanchard, K; McLeod, S; Schaffer, K; Winikoff, B | 1 |
| Arbel, R; Brzezinski, A; Haimov-Kochman, R; Laufer, N; Sciaky-Tamir, Y; Yagel, S | 1 |
| Heikinheimo, O; Nuutila, M; Väyrynen, W | 1 |
| Anand, A; Elul, B; Kalyanwala, S; Mundle, S; Ughade, S | 1 |
| Creinin, MD; Harwood, B; Hayes, JL; Lohr, PA; Reeves, MF | 1 |
| Glavind-Kristensen, M; Knudsen, UB; Nilas, L; Vejborg, T | 1 |
| Bjørge, L; Iversen, OE; Midbøe, G; Myking, O; Parashar, P | 1 |
| Eskild, A; Jerve, F; Jørgensen, H; Melseth, E; Nielsen, CS; Qvigstad, E | 1 |
| Baker, ER; George, KE; Kapp, N; Lauria, MR; Mackenzie, T; Prairie, BA | 1 |
| Bhatnagar, J; Blossom, DB; Cohen, AL; D'Angeli, MA; Duchin, JS; Fischer, M; Guarner, J; Jernigan, J; Killgore, G; Kwan-Gett, TS; McDonald, LC; Reagan, S; Shieh, WJ; Zaki, SR; Zane, SB | 1 |
| Li, Q; Liu, M; Mu, YL; Yang, ZL; Yin, FB | 1 |
| Fu, MF; Li, CL; Li, M; Wei, M | 1 |
| Heikinheimo, O; Leminen, R; Suhonen, S | 1 |
| Barker, MA; Christianson, MS; Lindheim, SR | 1 |
| Gemzell-Danielsson, K; Hayes, JL; Lohr, PA | 1 |
| Chen, TH; Kuo, TC; Li, YT | 1 |
| Amram, D; Bos-Thompson, MA; Faillie, JL; Hillaire-Buys, D; Roux, C | 1 |
| Lipp, A | 1 |
| Bermúdez, SB; Esteve, JL; Gallego, FG; González, LV; Llorente, MP; Sala, ES; Texidó, CS | 1 |
| Davies, S; Gemzell-Danielsson, K; Gomperts, RJ; Jelinska, K; Kleiverda, G | 1 |
| Gemzell-Danielsson, K; Lalitkumar, S | 1 |
| Blanchard, K; Blumenthal, P; Grossman, D | 1 |
| Creinin, MD; Kudva, A; Reeves, MF | 1 |
| Jansen, NE; Pasker-De Jong, PC; Zondervan, HA | 1 |
| Jones, HE; Lichtenberg, ES; O'Connell, K; Paul, M; Westhoff, CL; Wiegerinck, MM | 1 |
| Ford, SM; Lim, K; Scherf, C; Willmott, FJ | 1 |
| Davies, S; Gemzell, K; Gomperts, R; Jelinska, K; Kleiverda, G | 1 |
| Creinin, MD; Crowden, WA; Dzuba, IG; Goldberg, AB; Gonzales, J; Howe, M; Moskowitz, J; Prine, L; Shannon, CS; Winikoff, B | 1 |
| Chai, J; Chen, QF; Cheng, LN; Ho, PC; Hong, QQ; Ng, E; Tang, OS | 1 |
| Haldane, J | 1 |
| Arya, VK; Bagga, R; Choudhary, N; Kaur Dhaliwal, L; Mahajan, U; Rani Gupta, K; Suri, V; Vijayverghia, R | 1 |
| Shannon, C; Winikoff, B | 1 |
| Cotte, M; Lefebvre, P; Monniez, N; Norel, G | 1 |
| Parsons, JH; Samuel, MI | 1 |
| Bracken, H; Comendant, R; Digol, I; Friptu, V; Raghavan, S; Ungureanu, S; Winikoff, B | 1 |
| Chudnoff, S; Daif, JL; Kaiser, B; Levie, M; Shahabi, S | 1 |
| Anh, ND; Dickson, K; Erdenetungalag, R; Fang, AH; Horga, M; Kalmar, L; Kapamadzija, A; Marions, L; Mittal, S; My Huong, NT; Peregoudov, A; Piaggio, G; Pretnar-Darovec, A; Tai, NV; Tang, OS; Tuyet, HT; von Hertzen, H; Wojdyla, D; Wu, SC | 1 |
| Chawdhary, R; Pradhan, N; Rana, A | 1 |
| Au, HK; Chien, LW; Liu, WM; Tzeng, CR | 1 |
| Bloigu, A; Gissler, M; Heikinheimo, O; Hemminki, E; Niinimäki, M; Pouta, A; Suhonen, S | 1 |
| Bracken, H; Karki, C; Kushwaha, A; Manandhar, D; Pokharel, H; Winikoff, B | 1 |
| Huang, L; Li, L; Zhou, Z | 1 |
| Hartikainen, AL; Karinen, P; Niinimäki, M; Pouta, A | 1 |
| Bartz, D; Goldberg, A | 1 |
| Diedrich, J; Vargas, J | 1 |
| Coyaji, K; Elul, B; Ganatra, B; Kalyanwala, S; Tewari, S | 1 |
| Goodyear-Smith, F; Knowles, A | 1 |
| Lièvre, M; Sitruk-Ware, R | 2 |
| Atalla, R; Morgan, M | 1 |
| Akin, A; Aksan, G; Aktün, H; Dabash, R; Dilbaz, B; Doğan, B; Dursun, P; Kiran, S; Winikoff, B | 1 |
| Cleland, K; Cullins, V; Fjerstad, M; Lichtenberg, ES; Sivin, I; Trussell, J | 2 |
| Faĭzrakhmanova, FM; Pogorel'tsev, VI; Smirnova, GA | 1 |
| Creemers, JW; Ebbers, S; Lotgering, FK | 1 |
| Dong, B; Li, D; Manconi, F; Sun, B; Wang, G; Zhang, Y | 1 |
| Ben Regaya, L; Bibi, M; Bouguizane, S; Chaieb, A; Fathallah, K; Fekih, M; Khairi, H | 1 |
| Fitzgibbon, A; Furedi, A; Lohr, PA; Riley, L; Wade, J | 1 |
| Bracken, H; Clark, W; Lichtenberg, ES; Schweikert, S; Tanenhaus, J; Winikoff, B | 1 |
| Borrás, A; Carceller, A; Coll, O; Gómez, O; Gratacós, E; Palacio, M; Rabanal, A | 1 |
| Chen, BA; Creinin, MD; Hayes, J; Hohmann, HL; Perriera, LK; Reeves, MF | 1 |
| Creinin, MD; Lohr, PA; Reeves, MF | 1 |
| Hayes, JL; Kapp, N; Lohr, PA; Ngo, TD | 1 |
| Fiala, C; Gemzell-Danielsson, K; Kopp Kallner, H; Stephansson, O | 1 |
| Chen, CY; Chiang, HK; Chou, SY; Chow, PK; Hsu, CS; Hsu, MI | 1 |
| Choe, YS; Jang, MC; Kim, OS; Ko, WS; Pyo, HS; Tran, NT | 1 |
| Brownell, P; Dickinson, JE; McGinnis, K; Nathan, EA | 1 |
| Bennasar, M; Berge, R; Eixarch, E; Font, C; Illa, M; Palacio, M | 1 |
| Elsandabesee, D; Wedisinghe, L | 1 |
| Badis, CM; Bechir, Z; Dalenda, C; Ezzeddine, S; Fathia, B; Hela, C; Ines, N; Malika, A | 1 |
| Ho, PC; Lee, VC; Ng, EH | 1 |
| Napolitano, R; Thilaganathan, B | 1 |
| Bjørge, L; Dahle, GS; Ertzeid, L; Iversen, OE; Løkeland, M; Nappen, MH | 1 |
| Hamoda, H; Templeton, A | 1 |
| Chen, Q; Cheng, L; Fang, A; Hou, S; Zhang, L | 2 |
| Borrás, A; Gómez, O; Martínez, JM; Puerto, B; Sanz, M | 1 |
| Bayalag, M; Cabezas, E; Chaturachinda, K; Fang, AH; Gemzell-Danielsson, K; Hinh, ND; Huong, NT; Khomassuridge, A; Mittal, S; Ng, EH; Peregoudov, A; Piaggio, G; Pinter, B; Puscasiu, L; Savardekar, L; Shenoy, S; Tuyet, HT; Velasco, A; von Hertzen, H | 1 |
| Dahiya, K; Mann, S; Nanda, S | 1 |
| Dalve-Endres, A; Diedrich, JT; Drey, EA; Meckstroth, K; Newmann, SJ; Steinauer, JE | 1 |
| Brouns, JF; Burger, MP; van Wely, M; van Wijngaarden, WJ | 1 |
| Brouns, JF; Burger, MP; van Wijngaarden, WJ | 1 |
| Kero, A; Lalos, A; Wulff, M | 1 |
| Hewison, J; Howel, D; Kelly, T; Robson, S; Suddes, J | 1 |
| Gould, C; Meites, E; Zane, S | 1 |
| Comendant, R; Digol, I; Dondiuc, I; Raghavan, S; Turcanu, S; Ungureanu, S; Winikoff, B | 1 |
| Joensuu-Manninen, H; Kuvaja, P; Talvensaari-Mattila, A | 1 |
| Bornstein, J; Kais, M; Odeh, M; Ophir, E; Sosnovsky, V; Tendler, R | 1 |
| Alpert, L; Barajas, A; Bracken, H; Clark, W; Lichtenberg, ES; Schweikert, SM; Tanenhaus, J; Winikoff, B | 1 |
| Goel, P; Prabhakar, S; Saha, PK; Tandon, R | 1 |
| Chia, KV; Church, E; Sengupta, S | 1 |
| Ho, PC; Lee, VC; Ng, EH; Tang, OS; Yeung, WS | 1 |
| Harrison, DJ; Mitroka, JG | 1 |
| Both, MI; Kapp, N; Medema, S; Thomee, E; Wildhagen, MF; Wildschut, H | 1 |
| Boersma, AA; Kleiverda, G; Meyboom-de Jong, B | 1 |
| Creinin, MD; Kollitz, KM; Lohr, PA; Meyn, LA | 1 |
| Edelman, A; Kaneshiro, B; Ponce de Leon, RG; Sneeringer, RK | 1 |
| Dyer, C | 2 |
| Goel, N; Mehta, S; Rajaram, S | 1 |
| Bracken, H; Hassoun, D; Winikoff, B | 1 |
| Cullins, V; Fjerstad, M; Lichtenberg, ES; Sivin, I; Trussell, J | 1 |
| Kauppila, T; Kivinen, S; Suhonen, S; Tikka, M | 1 |
| Faundes, A | 2 |
| Attri, S; Goel, A; Mittal, S; Singal, N; Taneja, BK | 1 |
| Baird, DT; Huong, NT; Meirik, O; Shah, I; Tamang, A; Thapa, K; Wang, D; Warriner, IK | 1 |
| Blum, J; Dabash, R; Diop, A; Nga, NT; Ngoc, NT; Raghavan, S; Winikoff, B | 1 |
| Chen, TH; Chu, YC; Hou, GQ; Hsieh, JC; Kuan, LC; Kuo, TC; Li, YT; Lin, M; Lin, TC; Tang, HH | 1 |
| Gissler, M; Heikinheimo, O; Hemminki, E; Mentula, M; Niinimäki, M; Suhonen, S | 1 |
| Grimes, DA; Raymond, EG | 1 |
| Boulot, P; Cayrac, M; Faillie, JL; Flandrin, A | 1 |
| Aggarwal, P; Dadhwal, V; Mittal, S | 1 |
| Greasley, K | 1 |
| Free, C; Ngo, TD; Park, MH; Shakur, H | 1 |
| Borgatta, L; Kapp, N | 1 |
| Chen, QJ; Cheng, LN; Hong, QQ; Hou, SP; Huang, YM; Meads, C; Zhu, HP | 1 |
| Bauville, E; Bernard, O; Boyer, L; Briand, E; Grouin, A; Lavoué, V; Lemeut, P; Morcel, K; Poulain, P; Vandenbroucke, L | 1 |
| Lyus, R | 1 |
| Blanchard, K; Buchacker, T; Grindlay, K; Grossman, D; Lane, K | 1 |
| Clark, TJ; Cooper, NA; Khan, KS; Smith, P | 1 |
| Heikinheimo, O; Mentula, M; Suhonen, S | 1 |
| Chen, OJ; Chen, QF; Cheng, LN; Fang, AH; Hou, SP; Huang, YM | 1 |
| Creinin, MD; Ratcliffe, S; Schreiber, CA; Sober, S | 1 |
| Blum, J; Minh, NTH; Nga, NTB; Ngoc, NTN; Phan, VQ; Raghavan, S; Shochet, T; Winikoff, B | 1 |
| Bagga, R; Choudhary, N; Dhaliwal, LK; Raveendran, A; Saha, SC | 1 |
| Gemzell-Danielsson, K; Gomperts, R; Jelinska, K; Kleiverda, G; Petow, SA; Steen, L | 1 |
| Lam, TH; She, S; Xia, W | 1 |
| Ahuja, K; Dahiya, K; Dhingra, A; Duhan, N; Nanda, S | 1 |
| Achilles, SL; Creinin, MD; Hayes, JL; Reeves, MF | 1 |
| Paul, A; Sharma, D; Singhal, SR | 1 |
| Chen, FH; Li, CW; Li, JP; Li, X; Lu, WG; Yuan, FL; Zhao, YQ | 1 |
| Gillott, DJ; Matah, A; Ojha, K; Talaulikar, VS; Valcarcel, E; Wood, P | 1 |
| Ngo, TD; Park, MH | 1 |
| Dayananda, I; Fitzmaurice, G; Fortin, JM; Goldberg, AB; Jackson, AV | 1 |
| Campana, A; Cheng, L; Gülmezoglu, AM; Hofmeyr, GJ; Kapp, N; Kulier, R | 1 |
| Kestler, E | 1 |
| Heikinheimo, O; Mentula, M | 1 |
| Avraham, S; Duvdevani, NR; Frenkel, Y; Gat, I; Haas, J; Seidman, DS | 1 |
| Chong, E; Nguyen, NN; Tsereteli, T; Winikoff, B | 1 |
| Bordoloi, A; Godfrey, EM; Moorthie, M; Pela, E | 1 |
| Ngo, TD; Nguyen, TH; Park, MH | 1 |
| Bussieres, L; Camus, E; Fauconnier, A; Huchon, C; Machevin, E; Torre, A | 1 |
| de Weerd, S; Stibbe, KJ | 1 |
| Foster, AM; Jackson, CB | 1 |
| Blum, J; Chelli, H; Conkling, K; Dabash, R; Hajri, S; Ngoc, Nt; Raghavan, S; Winikoff, B | 1 |
| Dhakal, N; Giri, A; Maharjan, M; Tuladhar, AS; Tuladhar, H | 1 |
| Camargo, RP; Duarte, GA; Faúndes, A; Fernandes, KG; Maia Filho, NL; Pacagnella, RC; Sousa, MH | 1 |
| Akin, A; Doğan, BG; Mihçiokur, S; Ozvaris, SB | 1 |
| Arnesen, M; Blum, J; Blumenthal, PD; Fischer, D; Lichtenberg, ES; Lynd, K; Shochet, T; Winikoff, B | 1 |
| Raymond, EG; Shannon, C; Weaver, MA; Winikoff, B | 1 |
| Crost, M; Esterle, L; Gaudu, S | 1 |
| Carrette, M; de Costa, CM | 1 |
| Goldstone, P; Michelson, J; Williamson, E | 2 |
| Adevai, T; Jensen, J; Martin, L; Micks, E; Riefenberg, S; Shekell, T; Stanley, J; Zelinski, M | 1 |
| Ball, C; Chong, E; Crowden, WA; Dean, G; Dzuba, IG; Goldberg, AB; Lichtenberg, ES; Sacks, D; Swica, Y; Winikoff, B | 1 |
| Chai, J; Ho, PC; Wong, CY | 1 |
| Bloigu, A; Gissler, M; Heikinheimo, O; Hemminki, E; Männistö, J; Mentula, M; Niinimäki, M | 1 |
| Gemzell-Danielsson, K; Sääv, I; Stephansson, O | 1 |
| Li, Z; Min, W; Xing, A; Yao, Q | 1 |
| Brahmi, D; Jackson, E; Kapp, N; Tang, J; Whyte, P | 1 |
| Cleland, K; Creinin, MD; Nshom, M; Nucatola, D; Trussell, J | 1 |
| Chen, DJ; Du, PL; Li, CL; Liu, MX; Liu, Q; Sheng, XJ; Wei, M; Weng, HN | 1 |
| Amar, E; Barjhoux, CE; Bernard, N; Bos-Thompson, MA; Carlier, P; Descotes, J; Elefant, E; Tebacher, M; Vial, T | 1 |
| Jymagylova, D; Kamilov, A; Kasimova, F; Kurbanbekova, D; Raghavan, S; Tsereteli, T; Winikoff, B; Yusupov, D | 1 |
| Bannikov, V; Lishchuk, V; Maistruk, G; Posohova, S; Raghavan, S; Shochet, T; Winikoff, B; Zhuk, S | 1 |
| Chen, OJ; Cheng, LN; Hou, SP; Huang, LH; Teng, YC | 1 |
| Shankhwar, P; Singh, N; Singh, U; Srivastava, D; Verma, ML | 1 |
| Cameron, S | 1 |
| Banerjee, AK; Emembolu, JO; Habiba, M | 1 |
| Chen, J; Guo, Q; Huang, B; Qiu, L; Ren, Z; Wan, R; Wang, M; Wang, X; Wang, Y; Ying, J; Yu, H; Yu, J | 1 |
| Burke, A; Edelman, AB; Perritt, JB | 1 |
| Blumenthal, PD; Shaw, JG; Shaw, KA; Topp, NJ | 1 |
| Alam, A; Bracken, H; Islam, N; Johnston, HB; Raghavan, S; Reichenbach, L; Winikoff, B | 1 |
| McKay, RJ; Rutherford, L | 1 |
| Ali, R; Arnesen, M; Dean, G; Lichtenberg, ES; Louie, KS; Porsch, L; Raymond, EG; Weaver, MA | 1 |
| Dzuba, IG; Peña, M; Winikoff, B | 1 |
| Gawron, LM; Kiley, JW | 1 |
| Ben-Meir, A; Elami-Suzin, M; Freeman, MD; Laufer, N; Porat, N; Rojansky, N | 1 |
| Langdana, F; Maharaj, D; Searle, L; Tait, J | 1 |
| Chai, J; Ho, PC | 1 |
| Akins, ML; Auchus, RJ; Ehinger, N; House, M; Mahendroo, M; McIntire, D; Milne, GL; Paria, BC; Reese, J; Socrate, S; Timmons, BC | 1 |
| Huang, L; Qian, Z; Zhuang, Y | 1 |
| Chaudhuri, P; Das, C; Mandal, A; Mazumdar, A | 1 |
| Andreeva, A; Marinov, B | 1 |
| Chernev, A; Chernev, T; Manueljan, M | 1 |
| Colleselli, V; D'Costa, E; Mangesius, S; Schreiber, CA; Seeber, BE; Wildt, L | 1 |
| Edwards, P; Free, C; Le, HT; Ngo, TD; Nguyen, TH; Nguyen, YB; Pham, KH | 1 |
| Fox, MC; Krajewski, CM | 1 |
| Diop, A; Okonofua, F; Shittu, O; Shochet, T; Winikoff, B | 1 |
| Davis, A; Shimoni, N; Westhoff, C | 1 |
| Anserini, P; Calanni, L; Ferrero, S; Gianola, G; Morotti, M; Venturini, PL | 1 |
| Begum, F; Chaudhury, P; Dissanayake, M; Tank, J; Yasmin, H; Zaidi, S | 1 |
| Bjørge, L; Engeland, A; Iversen, OE; Løkeland, M; Økland, I | 1 |
| Dickinson, JE; Doherty, DA; Jennings, BG | 1 |
| Goldberg, AB | 1 |
| Agostini, A; Campagna, J; Casetta, A; Doucet-Populaire, F; Gendron, N; Joubrel, C; Kernéis, S; Nedellec, S; Poyart, C; Raymond, J | 1 |
| Bousiéguez, M; Dzuba, IG; Martínez, ML; Mendoza, LJ; Peña, M; Polanco, RR; Smith, PS; Villalón, AE; Winikoff, B | 1 |
| Goldthwaite, LM; Teal, SB | 1 |
| Aliyeva, F; Chong, E; Louie, KS; Rzayeva, G; Tsereteli, T; Winikoff, B | 1 |
| Heikinheimo, O; Kalso, E; Mentula, M | 1 |
| Bertelsen, CB; Bor, P | 1 |
| Bryant, AG; Regan, E; Stuart, G | 1 |
| Essén, B; Gemzell-Danielsson, K; Iyengar, K; Iyengar, S; Klingberg-Allvin, M; Paul, M | 1 |
| Bombas, T; Cameron, S; Fiala, C; Gemzell-Danielsson, K; Parachini, M; Saya, L | 1 |
| Chen, DJ; Chen, WL; Li, CL; Liu, MX; Song, LP; Wang, Y; Zhang, ZF | 1 |
| Bouschbacher, L; Collin, P; de Malartic, CM; Maatouk, A; Morel, O; Welter, E | 1 |
| Coppus, SF; de Heus, R; Snijders, MP; van den Bent, JM; van den Berg, J; Vandenbussche, FP | 1 |
| Bettahar, K; Nisand, I | 1 |
| Blumenthal, PD; Hopkins, FW; Hugin, M; Shaw, JG; Shaw, KA; Velasquez, G | 1 |
| Platais, I | 1 |
| Cleland, K; Gatter, M; Nucatola, DL | 1 |
| Borgatta, L; Edelman, A; Mark, AG | 1 |
| Chen, WL; Jin, L; Li, L; Liu, XY; Peng, P | 1 |
| Cockroft, M; Delvaux, T; Ith, L; Petitet, PH | 1 |
| Avagyan, G; Chong, E; Louie, KS; Tsereteli, T; Vardanyan, S; Winikoff, B | 1 |
| Aranguré Peraza, AG; Bousiéguez, M; Dzuba, IG; García Martinez, ML; Peña, M; Sanhueza Smith, P; Shochet, T; Winikoff, B | 1 |
| Lama, K; Puri, M; Shrestha, P; Tamang, A | 1 |
| Bartz, D; Fortin, J; Goldberg, AB; Maurer, R; Pocius, KD | 1 |
| Acharya, R; Filippi, V; Powell-Jackson, T; Ronsmans, C | 1 |
| Au, HK; Chien, LW; Liu, CF; Tzeng, CR | 1 |
| Almeida, H; Gaio, AR; Guedes-Martins, L; Macedo, F; Reynolds, A; Saraiva, JP | 1 |
| Chelli, H; Dabash, R; Hajri, S; Raghavan, S; Shochet, T; Winikoff, B | 1 |
| Bornstein, J; Kais, M; Masri, I; Odeh, M; Tendler, R | 1 |
| Aggarwal, D; Kapoor, G; Salhan, S; Sarda, N | 1 |
| Chong, E; Gold, M | 1 |
| Goldstone, P; Grossman, D | 1 |
| Harvey, P | 1 |
| Abbas, D; Chong, E; Raymond, EG | 1 |
| Grossman, D; Raymond, EG; Wiebe, E; Winikoff, B | 1 |
| Dzuba, IG; Grossman, D; Schreiber, CA | 1 |
| Castle, J; Chong, E; Dean, G; Frye, LJ; Kuehl, L; Winikoff, B | 1 |
| Blanchard, K; de Menezes, ID; Devjee, J; Fetters, T; Lince-Deroche, N; Moodley, J; Nkonko, E; Sudhinaraset, M; Trueman, K | 1 |
| Bednarek, PH; Chen, BA; Dean, G; Drey, EA; Dutton, C; Fitzmaurice, GM; Fortin, JA; Goldberg, AB; Lichtenberg, ES; Maurer, R; McKetta, S; Winikoff, B | 1 |
| Barnard, S; Kim, C; Ngo, TD; Park, MH | 1 |
| Ali, RF; Anderson, NC; Dehlendorf, CE; Fox, EE; Lichtenberg, ES; Reed, RD | 1 |
| Dalton, VK; Wallett, S | 1 |
| Chen, MJ; Creinin, MD | 2 |
| Creinin, MD; Monmaney, JA; Reeves, MF | 1 |
| Chang, Q; Di, W; Dong, B; Huang, Z; Jing, X; Li, Y; Qian, J; Ren, M; Shen, H; Shi, H; Song, W; Wu, S; Yao, C; Zheng, S | 1 |
| Chen, YP; Tsui, KH; Wang, PH | 1 |
| Chen, DJ; Deng, YF; Li, CL; Liu, KJ; Mo, XT; Song, LP | 1 |
| Burke, AE; Whaley, NS | 1 |
| Chaudhuri, P; Datta, S | 1 |
| Bardy, F; David, P; Dunbavand, A; Opatowski, M; Saurel-Cubizolles, MJ | 1 |
| Coppus, SFPJ; Gordon, BBM; Snijders, MPML; van den Berg, J; Vandenbussche, FPHA | 1 |
| Blumenthal, PD | 1 |
| Ho, PC; Lo, SS | 1 |
| Biswas, K; Griffin, R; Marlow, HM; Menzel, J | 1 |
| Boubli, L; Bretelle, F; Chau, C; Couteau, C; D'Ercole, C; Guidicelli, B | 1 |
| Abreu, P; Alfirevic, Z; Navaratnam, K; Sharp, A | 1 |
| Jiang, Q; Liu, F; Lv, YE; Yang, L; Zheng, Y | 1 |
| Frank, K; Gerychová, R; Huser, M; Janků, P; Ventruba, P | 1 |
| Feng, W; Han, W; Li, J; Liu, W; Lu, Y; Lye, SJ; Ma, C; Sui, Y; Zhao, N | 1 |
| Demars, HH; Hassoun, D; Hiên, H; Périn, I | 1 |
| Andreeva, A; Dimitrov, J; Marinov, B | 1 |
| Geller, S; Park, J; Robinson, N; Turner, J; Wessels, U | 1 |
| Cagnacci, A; Di Carlo, C; Ferrara, C; Giampaolino, P; Nappi, C; Savoia, F; Sglavo, G; Tommaselli, GA | 1 |
| Casey, FE; Moreno-Ruiz, NL; Perritt, JD; Reeves, MF; Ye, PP | 1 |
| Candelas, JA; Domínguez, A; Douthwaite, M; Eckhardt, C; Ngo, TD; Reichwein, B | 1 |
| Blum, J; Blumenthal, PD; Martin, R; Nga, NT; Ngoc, NT; Sheldon, WR; Van Thanh, L; Winikoff, B | 1 |
| Hou, MY | 1 |
| Cansino, C; Chen, MJ; Creinin, MD; Hou, MY; Rounds, KM | 1 |
| Chaumont, A; El-Haddad, J; Foster, AM; LaRoche, KJ; Vogel, KI | 1 |
| Ephrem-Duron, J; Gallot, D; Laurichesse-Delmas, H; Pereira, B; Stadler, A | 1 |
| Agostini, A; Auquier, P; Baumstarck, K; Cohen-Solal, E; Maruani, J; Ohannessian, A | 1 |
| Rosenthal, DL | 1 |
| Grebennikova, G; Lotarevich, T; Platais, I; Tsereteli, T; Winikoff, B | 1 |
| Arnott, G; El-Haddad, J; Foster, AM; Sheinfeld, L | 1 |
| Bokhua, Z; Chong, E; Louie, K; Tsereteli, T; Winikoff, B | 1 |
| Bragg, B; Chawla, K; Hladky, K; Mark, K | 1 |
| Chelli, H; Dabash, R; Hajri, S; Haleb, D; Hassairi, AE; Koenig, L; Labassi, H; Sfar, E; Shochet, T; Temimi, F; Winikoff, B | 1 |
| Immonen, E; Nissi, R; Santala, M; Talvensaari-Mattila, A | 1 |
| Ben-Meir, A; Elami-Suzin, M; Freeman, MD; Porat, N; Rojansky, N; Winograd, O | 1 |
| Bartosik, T; Brunner, C; Ciresa-Koenig, A; Colleselli, V; Marth, C; Nell, T; Seeber, B; Wildt, L | 1 |
| Combellick, SL; Johns, NE; Keder, LM; Kohn, JE; Roberts, SC; Upadhyay, UD | 1 |
| He, FF; Jiang, WX; Shen, Q; Shen, ZJ; Tao, XJ; Zhao, CC; Zhu, XQ | 1 |
| Bartz, D; Fortin, J; Goldberg, AB; Maurer, R; Pocius, KD; Stenquist, A | 1 |
| He, H; Li, CL; Liao, YM; Mo, XT; Song, LP; Tang, SY; Zhou, LJGY | 1 |
| Lerma, K; Shaw, KA | 2 |
| Dragoman, MV; Dung, DL; Grossman, D; Habib, N; Huong, NM; Kapp, N; Tamang, A | 1 |
| Abbas, DF; Blum, J; Chi, HT; Martin, R; Nga, NT; Ngoc, NT; Winikoff, B | 1 |
| Qureshi, S; Sankhwar, PL; Singh, N; Singh, U; Verma, ML | 1 |
| Abrahamyan, R; Avagyan, G; Chong, E; Louie, KS; Tsereteli, T; Winikoff, B | 1 |
| Akerkar, R; Bjørge, L; Bjørge, T; Iversen, OE; Løkeland, M | 1 |
| Blum, J; Blumenthal, PD; Bracken, H; Dabash, R; Ngoc, NTN; Platais, I; Raymond, EG; Sheldon, WR; Shochet, T; Weaver, MA; Winikoff, B | 1 |
| Blumenthal, PD; Long, D; Madan, Y; Mundy, G; Sotheary, K | 1 |
| Goldstone, P; Hawtin, K; Walker, C | 1 |
| Blumenthal, PD; Jones, RK; Mark, A; Nichols, MD; Reeves, MF; Saporta, VA | 1 |
| Brahmi, D; Castleman, L; Grossman, D; Jackson, E; Kapp, N | 1 |
| Vogel, L | 1 |
| Cameron, S; Glasier, A; Harden, J; Lawton, J; Purcell, C | 1 |
| Aiken, ARA; Digol, I; Gomperts, R; Trussell, J | 1 |
| Bateson, D; Black, KI | 1 |
| Beal, MW; Eagen-Torkko, MK; Simmonds, KE | 1 |
| Haverinen, A; Heikinheimo, O; Jahangiri, R; Männistö, J; Mentula, M; Niinimäki, M | 1 |
| Heikinheimo, O; Korjamo, R; Mentula, M | 1 |
| Church, K; Dijkerman, S; Footman, K; Nuremowla, S; Reiss, K; Scott, R; Taleb, F | 1 |
| Chen, MJ; Kendall, PD | 1 |
| Blumenthal, PD; Hopkins, FW; Hugin, M; Lerma, K; Scrivner, KJ; Shaw, JG; Shaw, KA | 1 |
| Ho, PC | 1 |
| Baldwin, MK; Kapp, N; Rodriguez, MI | 1 |
| Aiken, ARA; Gomperts, R; Guthrie, KA; Schellekens, M; Trussell, J | 1 |
| Guilbert, E; Jones, HE; Lichtenberg, ES; Norman, WV; O'Connell White, K; Paul, M | 1 |
| Aiken, ARA | 1 |
| Coeytaux, F; Murtagh, C; Raymond, EG; Wells, E; Winikoff, B | 1 |
| Agostini, A; David, P; Pouriel, M; Rondeau, V | 1 |
| Alam, A; Bracken, H; Das, TR; Lotarevich, T; Reichenbach, L | 1 |
| Boobekova, A; Davletova, A; Johnson, BR; Kazakbaeva, C; Kondrateva, Y; Landoulsi, S; Lazdane, G; Maksutova, E; Monolbaev, K; Seuc Jo, AH | 1 |
| Dunford, A; Fyfe, R | 1 |
| Boraas, C; Bousieguez, M; Comendant, R; Gillespie, G; Grant, M; Hodorogea, S; Platais, I; Raymond, EG; Sagaidac, I; Sanhueza, P; Tan, YL; Van Pratt, E; Weaver, MA; Winikoff, B | 1 |
| Ahmed, A; Ahmmed, F; Al Haque, N; Alam, A; Huda, FA; Karim, F; Mahmood, HR; Sarker, BK | 1 |
| Berer, M; Hoggart, L | 1 |
| Benavides, E; Frapp, S; Grant, M; Hannum, C; Raymond, EG; Reis, M; Sacks, DN; Tan, YL; Weaver, MA | 1 |
| Blum, M; Darney, PD; Grossman, D; Harper, CC; Maharjan, D; Puri, M; Regmi, K; Rocca, CH; Shrestha, P | 1 |
| Aiken, ARA; Lohr, PA; Scott, JG; Starling, JE | 1 |
| Bracken, H; Raymond, EG; Shochet, T | 1 |
| Bharti, N; Dewan, A; Dewan, R; Mittal, A | 1 |
| Brooks, M; Dunn, S | 1 |
| Atrio, J; Barnhart, KT; Creinin, MD; Ratcliffe, SJ; Schreiber, CA; Sonalkar, S | 1 |
| Blanchard, K; Constant, D; Grossman, D; Harries, J; Kluge, J; Lince-Deroche, N; Sinanovic, E | 1 |
| Li, CL; Mo, XT; Song, LP; Tang, SY; Zhou, LJ | 1 |
| Abbas, D; Gosavi, A; Koh, D; Singh, K; Tan, KH; Tan, YL; Winikoff, B | 1 |
| Anger, H; Bousiéguez, M; Coutiño, D; Dabash, R; Peña, M; Sanhueza, P; Winikoff, B | 1 |
| Blanchard, K | 1 |
| Lord, J | 1 |
| Amico, JR; Cheng, TL; Godfrey, EM | 1 |
| Aryal, S; Sharma, B; Shrestha, D | 1 |
| Ganatra, B; Kennedy, CE; Narasimhan, M; Saleem, HT | 1 |
| Abele, H; Breisch, J; Hoopmann, M; Kagan, KO; Prodan, N; Wagner, P | 1 |
| Gallinand, AC; Laviolle, B; Lavoué, V; Le Lous, M; Nyangoh Timoh, K; Peltier, L | 1 |
| Abbas, D; Blum, J; Dragoman, M; Louie, K; Platais, I; Shochet, T; Tsereteli, T; Winikoff, B | 1 |
| Blum, M; Cohen, R; Puri, M; Rocca, CH; Samari, G | 1 |
| H Al Wattar, B; Khan, KS; Murugesu, N; Tobias, A; Zamora, J | 1 |
| Friedrich, S; Gerds, TA; Lidegaard, O; Meaidi, A | 1 |
| Kovač, V; Reljič, M; Serdinšek, T | 1 |
| Hardy-Fairbanks, AJ; Kerestes, CA; Stockdale, CK; Zimmerman, MB | 1 |
| Ralph, JA; Shulman, LP | 1 |
| Dunn, S; Genkin, I; Hum, S; Warden, S | 1 |
| Diamond-Smith, N; Percher, J; Saxena, M; Srivastava, A | 1 |
| Creinin, MD; Hsia, JK; Lohr, PA; Taylor, J | 1 |
| Baldwin, M; Bednarek, P; Castillo, PW; Chong, E; Coplon, L; Fontanilla, T; Kaneshiro, B; Keady, M; Lotarevich, T; Mary, M; Mathieu, N; Platais, I; Priegue, E; Raymond, E; Schnyer, A; Tschann, M; Winikoff, B | 1 |
| Hickey, M; Kim, BV; Lemmers, M; Mol, BWJ; Neilson, JP; Vazquez, JC; Verschoor, MA | 1 |
| Coppus, SF; Hamel, CC; Snijders, MP; van den Berg, J; Vandenbussche, FP | 2 |
| Blumenthal, PD; Lerma, K | 1 |
| Cleeve, A; Endler, M; Gemzell-Danielsson, K | 1 |
| Ho, PC; Lui, MW | 1 |
| Abdullahi, ZG; Bello, N; Igashi, JB; Koledade, AK; Maikudi, HA; Mohammed, U; Shittu, OS | 1 |
| Agostini, A; Bombas, T; Cameron, S; Fiala, C; Gemzell Danielsson, K; Lertxundi, R; Lubusky, M; Parachini, M; Saya, L; Trumbic, B | 1 |
| Abbas, DF; Blum, J; Dragoman, M; Karki, A; Karki, C; Sharma, J; Shochet, T; Shrestha, A; Tamang, A; Tuladhar, H; Winikoff, B | 1 |
| Cleeve, A; Fønhus, MS; Lavelanet, A | 1 |
| Aburto-Arciniega, MB; Arce Cedeño, A; Bonifaz Alfonzo, L; Díaz Olavarrieta, C; Fajardo Dolci, GE; Guevara-Guzmán, R; Phillips, VJ; Sanhueza-Smith, P; Villa, AR | 1 |
| Barinov, SV; Kadcyna, TV; Lazareva, OV; Medyannikova, IV; Shamina, IV; Shkabarnya, LL; Tirskaya, YI | 1 |
| Babich, DA; Baev, OR; Prikhodko, AM; Sukhikh, GT; Tysyachniy, OV | 1 |
| Du, X; Duan, J; Huang, YM; Wang, Y; Yang, Y | 1 |
| Church, K; Dijkerman, S; Keenan, K; Mitu, SA; Ngo, TD; Nuremowla, S; Reiss, K | 1 |
| Bessenaar, T; Eckersberger, E; Griffin, R; Kapp, N; Methazia, J | 1 |
| Cahill, EP; Conti, J | 1 |
| Cameron, S; Hasler, E; Lohr, PA; Schmidt-Hansen, M | 1 |
| Bertholdt, C; David, MG; Gabriel, P; Morel, O; Perdriolle-Galet, E | 1 |
| Altman, D; Ehrnstén, L; Kopp Kallner, H; Ljungblad, A | 1 |
| Bergeson, K; Kline, RJ; Prasad, S | 1 |
| Diedrich, JT; Drey, EA; Newmann, SJ | 1 |
| Chong, E; Dzuba, IG; Hannum, C; Lichtenberg, ES; Lugo Hernández, EM; Ngoc, NTN; Patel, A; Rzayeva, G; Sanhueza Smith, P; Tsertsvadze, G; Winikoff, B | 1 |
| Blum, J; Frye, LJ; Kilfedder, C; Winikoff, B | 1 |
| Foster, AM; Grossman, D; Mark, A; Prager, SW; Winikoff, B | 1 |
| Cameron, S; Hasler, E; Lord, J; Schmidt-Hansen, M | 1 |
| Aiken, ARA; Beasley, A; Brooks, IHM; Dermish, AI; Goyal, V; Kumar, B; Potter, JE; Schutt-Ainé, A; Wallace, R | 1 |
| Bousieguez, M; Bracken, H; Ha, DQ; Linh, NTH; Ngoc, NTN; Ortiz, MA; Paredes, NR; Quyet, VB; Winikoff, B | 1 |
| Gambir, K; Ganatra, B; Kim, C; Necastro, KA; Ngo, TD | 1 |
| Grossman, D; Harris, LH | 1 |
| Atrio, J; Chen, M; Harvie, HS; Koelper, N; Loza-Avalos, SE; Nagendra, D; Schreiber, CA; Sonalkar, S | 1 |
| Foster, AM; LaRoche, KJ | 1 |
| Atrio, JM; Creinin, MD; Koelper, N; McAllister, A; Sammel, MD; Schreiber, CA; Sonalkar, S | 1 |
| Atrio, JM; Coplon, L; Creinin, MD; Dean, G; Gold, M; Grossman, D; Mark, A; Perritt, J; Raymond, EG; Taylor, D; Upadhyay, UD | 1 |
| Doctoroff, J; Foster, AM; Mark, A; Yalahow, A | 1 |
| Alam, B; Kaler, A; Mumtaz, Z | 1 |
| Farez, R; Heinlein, M; Jacques, L; Kaljo, K; Nugent, M; Pan, A; Ralph, J | 1 |
| Bullard, KA; Cisternas, C; Gerdts, C; Grosso, B; Moseson, H; Vera, V | 1 |
| Grossman, D; Landau, C; Raifman, S; Sella, S; Wingo, E | 1 |
| Beaman, J; Prifti, C; Schwarz, EB; Sobota, M | 1 |
| Bousiéguez, M; Castañeda Vivar, JJ; Castillo, PW; Dzuba, IG; Lugo Hernández, EM; Sanhueza Smith, P | 1 |
| Parsons, JA | 1 |
| Jasmin Friedrich, S; Lidegaard, Ø; Meaidi, A | 1 |
| Blumenthal, PD; Henkel, A; Lerma, K; Shaw, KA | 1 |
| Abubeker, FA; Kim, C; Lavelanet, A; Rodriguez, MI | 1 |
| Barnhart, K | 1 |
| Ferguson, I; Scott, H | 1 |
| Berkley, HH; Greene, HL; Wittenberger, MD | 1 |
| Agostini, A; Frantz, S; Herman-Demars, H; Quaranta, LM; Sicot, M; Zinovieva, E | 1 |
| Bajracharya, N; Bharati, S; Bhattachan, K; Dangal, G; Karki, A; Poudel, R; Pradhan, H; Shrestha, R; Tiwari, K | 1 |
| Cameron, S; Hasler, E; Lohr, PA; Nevill, M; Pandey, A; Schmidt-Hansen, M; Taylor, P | 1 |
| Egwuatu, I; Filippa, S; Gerdts, C; Grosso, B; Jayaweera, R; Keefe-Oates, B; Kristianingrum, I; Moseson, H; Motana, R; Nmezi, S; Raifman, S; Zurbriggen, R | 1 |
| Allaouidine, C; Chinery, L; Gülmezoglu, AM; Larson, M; Tomazzini, A | 1 |
| Sultana, N | 1 |
| Dragoman, M; Goldman, AR; Hintermeister, A; Porsch, L | 1 |
| Acharya, R; RamaRao, S; Shukla, A; Vázquez-Quesada, L; Vieitez, I | 1 |
| Chen, M; Song, L; Wei, T; Wu, L; Xiong, W; Yan, A; Zeng, M; Zhang, J; Zu, Q | 1 |
| Cameron, S; Fletcher, J; Hasler, E; Lord, J; O'Shea, LE | 1 |
| Creinin, MD; Perriera, L | 1 |
| Cameron, S; Hasler, E; Lohr, PA; Lord, J; O'Shea, LE | 1 |
| Bessenaar, T; Dragoman, MV; Duong, LD; Gautam, J; Grossman, D; Gulmezoglu, M; Habib, N; Hong, M; Kapp, N; Nguyen, MH; Tamang, A; Yoko, JL | 1 |
| Flynn, AN; Koelper, N; McAllister, A; Roe, AH; Sammel, MD; Schreiber, CA | 1 |
| Anger, HA; Baldwin, MK; Banks, J; Bednarek, P; Boraas, C; Chong, E; Coplon, L; Grant, M; Haskell, S; Kaneshiro, B; Platais, I; Raymond, EG; Shochet, T; Tocce, K | 1 |
| Bagga, R; Bharati, J; Choudhary, N; Jain, S; Rajkumar Kopp, C; Saha, PK; Sharma, B; Singla, R | 1 |
| Kleiverda, G; Leusink, P | 1 |
| Aqtar, F; Averbach, S; Crouthamel, B; Hurst, S; Paul, D; Pearson, E; Silverman, J; Tilford, S | 1 |
| Anger, HA; Baldwin, MK; Banks, J; Bednarek, PH; Boraas, CM; Chong, E; Coplon, L; Grant, MS; Haskell, S; Platais, I; Priegue, E; Raidoo, S; Raymond, E; Shochet, T; Soon, R; Thompson, F; Tocce, K; Winikoff, B | 1 |
| Bowen, E; Kaneshiro, B; Kerestes, C; Lacar, L; Murayama, S; Natavio, M; Platais, I; Raidoo, S; Seamon, E; Soon, R; Stowers, P; Tyson, J | 1 |
| Glaser, K; Whitehair, J | 1 |
| Allanson, ER; Copson, S; Criddle, S; Dickinson, JE; Doherty, DA; Jennings, B; Spilsbury, K; Wong, AM | 1 |
| Early, J; Macnaughton, H; Nothnagle, M | 1 |
| Flynn, AN; Jiang, E; Koelper, N; Martin, B; McAllister, A; Roe, AH; Schreiber, CA | 1 |
| Aultman, K; Beran, BD; Cirucci, CA; Harrison, DJ; Lockwood, MD; Seiler, S | 1 |
| Biggs, MA; Grossman, D; Raifman, S; Ralph, L | 1 |
| Agostini, A; Baumstarck, K; Cardinale, C; Fabre, C; Hamdaoui, N | 1 |
| Ahmed, A; Beeson, LE; Bender-Atik, R; Bhatia, K; Bottomley, C; Brewin, J; Cheed, V; Cheong, Y; Choudhary, M; Chu, JJ; Coomarasamy, A; Debs, S; Devall, AJ; Gallos, ID; Gupta, P; Hamilton, J; Hardy, P; Hassan, I; Hinshaw, K; Hodge, FS; Horne, AW; Izzat, F; Jeve, Y; Jones, LL; Kumar, CS; La Fontaine Papadopoulos, JH; Naftalin, J; Nunes, N; Okeke Ogwulu, CB; Oliver, A; Pringle, S; Quenby, S; Roberts, TE; Ross, J; Shahid, A; Small, R; Underwood, M; Watkins, L; Williams, EV; Yongzhong, S | 1 |
| Blaylock, R; Chang, JJ; Lohr, PA; Meurice, ME; Whitehouse, KC | 1 |
| Donovan, MK; Ghorashi, AR; Ma, J; Rikelman, J; Singh, D; Thompson, A | 1 |
| Blumenthal, PD; Fok, WK; Lerma, K; Shaw, KA | 1 |
| Aiken, ARA; Gomperts, R; Starling, JE | 1 |
| Beeson, LE; Coomarasamy, A; Devall, AJ; Do, V; Gallos, ID; Ghosh, J; Gülmezoglu, AM; Jeffery, HC; Lavelanet, A; Papadopoulou, A; Price, MJ; Tobias, A; Tunçalp, Ö | 1 |
| Boydell, N; Cameron, ST; Harden, J; Reynolds-Wright, JJ | 1 |
| Chen, S; Hu, Q; Li, C; Li, J; Luo, L; Yang, X; Zhang, X | 1 |
| Baker, CC; Chen, MJ; Creinin, MD; Hou, MY; Mastey, N; Matulich, MC; Melo, J; Uhm, S; Wilson, SF | 1 |
| Lama, L; Pokhrel, M; Sharma, J; Tiwari, S | 1 |
| Hu, S; Yu, Q | 1 |
| Benson, LS; Lokken, EM; Micks, EA; Shay, RL | 1 |
| Arena, A; Bachrach, L; Beaman, J; Biggs, MA; Gold, M; Grossman, D; Hannum, C; Ho, S; Morris, N; Raifman, S; Schwarz, EB | 1 |
| Chen, X; Li, F; Shi, B; Shou, Y; Zhu, R | 1 |
| Boesen, MP; Brinch, S; Hansen, P; Krogsgaard, MR; Larvad, P | 1 |
| Kallfa, E; Lauszus, FF; Ravn, P | 1 |
| Enzelsberger, SH; Hermann, P; Oppelt, P; Shebl, O; Trautner, PS; Wagner, H; Wetzlmair, D | 1 |
| Cameron, S; Evans, E; Johnstone, A; McCabe, K; Reynolds-Wright, JJ | 1 |
| Durocher, J; Frye, LJ; Kilfedder, C; Srinivasan, K; Winikoff, B | 1 |
| Bercu, C; Carbone, S; Egwuatu, I; Gerdts, C; Grosso, B; Jayaweera, R; Kristianingrum, IA; Moseson, H; Motana, R; Nmezi, S; Zurbriggen, R | 1 |
| Ahmed, A; Beeson, L; Bender-Atik, R; Bhatia, K; Bottomley, C; Brewin, J; Cheed, V; Cheong, Y; Choudhary, M; Chu, J; Coomarasamy, A; Deb, S; Devall, A; Gallos, I; Gupta, P; Hamilton, J; Hardy, P; Hassan, I; Hinshaw, K; Hodge, F; Horne, A; Izzat, F; Jeve, Y; Jones, L; Kumar, C; Naftalin, J; Nunes, N; Ogwulu, CO; Oliver, A; Papadopoulos, JF; Pringle, S; Quenby, S; Roberts, T; Ross, J; Shahid, A; Small, R; Sun, Y; Underwood, M; Watkins, L; Williams, E | 1 |
| Biggs, MA; Ehrenreich, K; Grossman, D | 1 |
| Mullock, A; Parsons, JA; Romanis, EC | 1 |
| Barar, R; Biggs, MA; Blanchard, K; Ehrenreich, K; Grossman, D; Kapp, N; Moayedi, G; Morris, N; Perritt, J; Ralph, LJ; Raymond, EG; White, K | 1 |
| Rubin, R | 1 |
| Bergen, S; Chavkin, W; Dragoman, M; Fofie, C | 1 |
| Foster, AM; LaRoche, KJ; Persaud, M; Wylie, A | 1 |
| Aslam, M; Foster, AM; Messier, K; Shabir, N | 1 |
| Diao, WY; Du, L; Du, YH; Gemzell-Danielsson, K; Ho, PC; Li, RHW; Zhang, L | 1 |
| Boucoiran, I; Ferreira, E; St-Pierre, ÉR; Vlad, S | 1 |
| Barrett, J; Ennis, M; Guilbert, E; Renner, R; Roy, G | 1 |
| Lohr, PA; Shochet, T; Whitehouse, KC | 1 |
| Davis, J; Fontanilla, T; Friedlander, EB; Horiuchi, W; Kaneshiro, B; Raidoo, S; Salcedo, J; Soon, R; Tschann, M | 1 |
| Carson, A; Dunn, S; Ennis, M; Guilbert, E; Kean, L; Martin-Misener, R; Norman, WV; Pymar, H; Renner, R | 1 |
| Cameron, S; Reynolds-Wright, J | 1 |
| Cerrillos, L; Diaz-Acedo, R; Fobelo-Lozano, MJ; Garcia-Jimenez, R; Ostos, R; Valero, I; Weber-Fernandez, AM | 1 |
| Cameron, S; French, RS; Lewandowska, M; Lohr, PA; Meiksin, R; Palmer, MJ; Reiter, J; Salaria, N; Scott, RH; Wellings, K | 1 |
| Braun, J; Franke, JF; Hammer, K; Kerschke, L; Klockenbusch, W; Köster, HA; Möllers, M; Möllmann, U; Oelmeier, K; Schmitz, R | 1 |
| Cameron, S; Morroni, C; Reynolds-Wright, JJ; Woldetsadik, MA | 1 |
| Cottrill, A; Dethier, D; Fortin, J; Fulcher, IR; Gilbert, A; Goldberg, AB; Hofer, RK; Janiak, E; Roncari, D | 1 |
| Cabedo-Ferreiro, R; Falguera-Puig, G; Gómez-Masvidal, M; Manresa-Domínguez, JM; Montero-Pons, L; Reyes-Lacalle, A; Vicente-Hernández, MM | 1 |
| Biggs, MA; Blanchard, K; Bustamante, CK; Choimorrow, SY; Ehrenreich, K; Grossman, D; Hauser, D; Hernandez, Y; Kapp, N; Kromenaker, T; Moayedi, G; Morris, N; Perritt, JB; Ralph, L; Raymond, EG; Valladares, ES; White, K | 1 |
| Abernathy, A; Flynn, AN; Koelper, NC; McAllister, A; Roe, AH; Sammel, MD; Schreiber, CA; Sonalkar, S | 1 |
| Huang, H; Li, J; Liu, H; Lu, J; Wang, R; Yang, Y | 1 |
| Barker, E; Latta, K; Laursen, L; Testani, E; York, SL | 1 |
| Fitzgerald, K; Laursen, L; Whitaker, AK; Young, D | 1 |
| Gutman, SM; Harvie, HS; Koelper, NC; Loza-Avalos, SE; Nagendra, D; Schreiber, CA; Sonalkar, S | 1 |
| Chu, Z; Han, H; Jia, L; Li, J; Tian, F; Yan, P; Zhang, J; Zhang, Y | 1 |
| Heikinheimo, O; Kemppainen, V; Mentula, M; Palkama, V | 1 |
| Beestrum, M; Dungan, J; Kiley, J; Nosal, C; Turner, A | 1 |
| Du, S; Li, R; Long, Q; Tang, F; Wu, S; Zhao, Y | 1 |
| Mazer-Amirshahi, M; Ye, P | 1 |
| Constant, D; Endler, M; Gemzell Danielsson, K; Gomperts, R; Grossman, D; Petro, G; Weinryb, M | 1 |
| Cameron, ST; Morroni, C; Reynolds-Wright, JJ; Woldetsadik, MA | 1 |
| Huang, Q; Li, LL; Peng, DY; Qi, JJ; Yao, M | 1 |
| Bettahar, K; Deruelle, P; Koch, A | 1 |
| Choobun, T; Maneeon, R | 1 |
| Munro, S; Norman, WV; Soon, JA; Zusman, EZ | 1 |
| An, J; Chen, R; Lu, Y; Su, R; Wang, W | 1 |
| Biggs, MA; Grossman, D; Serrano, S; Valladares, ES | 1 |
| Cameron, S; Reynolds-Wright, JJ; Tai, NQR | 1 |
| Cirucci, C; Francis, C; Harrison, D | 1 |
| Arnalsteen, C; Bettahar, K; Deshaies, A; Hauss, AS; Jochum, F; Kiehl, A; Koch, A; Martel, C | 1 |
| Arena, A; Casadio, P; Degli Esposti, E; Lenzi, J; Lenzi, M; Moro, E; Perrone, A; Seracchioli, R; Zanello, M | 1 |
| Frye, LJ; Gawron, LM; Kaiser, JE; Sexsmith, CD; Shochet, T; Turok, D; Winikoff, B | 1 |
| Gong, Y; Hu, YF; Huang, GY; Li, W; Sheng, F; Wu, MY; Yang, Y; Zhang, LL; Zhang, P; Zou, L | 1 |
| Liu, N; Ray, JG | 1 |
| Boerma, C; Brandell, K; Cameron, S; Gemzell-Danielsson, K; Gibson, G; Heikinheimo, O; Hognert, H; Reynolds-Wright, JJ; Tuladhar, H | 1 |
| Fortin, J; Gelfand, D; Gilbert, AL; Goldberg, AB; Roncari, D | 1 |
| Cohen, D; Golden, L | 1 |
| Baker, CN | 1 |
| Ganatra, B; Grossman, A; Lavelanet, A; Prata, N; Rehnström Loi, U; Williams, N | 1 |
| Dethier, D; Kahili-Heede, M; Kaneshiro, B; Pearlman Shapiro, M | 1 |
| Boraas, CM; Coplon, L; Gold, M; Kaneshiro, B; Koenig, LR; Raymond, EG; Upadhyay, UD; Winikoff, B | 1 |
| Dunn, S; Guilbert, ER; Munro, SB; Norman, WV | 1 |
| Mamatsashvili, L; Platais, I; Tsereteli, N; Tsereteli, T; Tsertsvadze, G | 1 |
| Dickinson, JE; Doherty, DA | 2 |
| Beasley, A; Brandi, K; Castle, J; Creinin, MD; Gerdts, C; Gil, L; Grant, M; Grossman, D; Lockley, A; Mark, A; Perritt, J; Raymond, EG; Shochet, T; Truan, D; Upadhyay, UD | 1 |
| Eckersberger, E; Kapp, N; Mao, B; Menzel, J; Pearson, E; Rathavy, T; Saphonn, V | 1 |
| Burns, MM; Fay, KE; Feng, C | 1 |
| Gemzell-Danielsson, K; Maltzman, LL; Marions, L; Podolskyi, V | 1 |
| Afolabi, K; Asmani, C; Bhattarai, B; Chanza, H; Conneh-Duworko, MJ; Dhakal, NP; Dlamini-Nqeketo, S; Elamin, H; Ganatra, B; Grossman, A; Hailu, BG; Kabuteni, TJ; Läser, L; Lavelanet, A; Moses, F; Ojo, OA; Ouedraogo, L; Phiri, H; Prata, N; Rahman, MM; Rehnström Loi, U; Tehoungue, BZ; Williams, N; Zulu, T | 1 |
| Tanne, JH | 1 |
| Anger, HA; Raymond, EG | 1 |
| Gluck, AR | 1 |
| Gudu, W; Shimeles, T; Sium, AF | 1 |
| Boyd, K; Grant, M; Koenig, LR; Raymond, EG; Shochet, T; Upadhyay, U; Weaver, MA | 1 |
| Blair, R; Costescu, D; Davis, R; Guarna, G; Kotait, M; Vu, N; Yakoub, D | 1 |
| Fortin, J; Goldberg, AB; Hoe, E; Janiak, E; Neill, S | 1 |
| Bercu, C; Egwuatu, I; Gerdts, C; Grosso, B; Jayaweera, R; Kristianingrum, IA; Moseson, H; Motana, R; Nmezi, S; Zurbriggen, R | 1 |
| Boos, EW; Dusetzina, SB; Horta, M; Leech, AA; Thompson, I | 1 |
| Raymond, EG; Shochet, T; Weaver, MA | 1 |
| Baker, CC; Creinin, MD; Flynn, AN; Han, G; Wu, BT | 1 |
| Chen, Y; Xu, Y; Yang, P; Zhang, L | 1 |
| Bettencourt-Silva, B; Brás, F; Cunha, AI; Furtado, JM; Lopes-Guerra, C; Miguelote, R; Miranda, C; Rego, MT; Sousa-Santos, R | 1 |
| Fraz, F; Liu, SM; Shaw, KA | 1 |
| Gemzell-Danielsson, K; Gomperts, R; Marions, L; Podolskyi, V | 1 |
| Kopp Kallner, H | 1 |
| Bercu, C; Egwuatu, I; Gerdts, C; Grosso, B; Jayaweera, R; Kristianingrum, IA; Moseson, H; Nmezi, S; Zurbriggen, R | 1 |
124 review(s) available for mifepristone and misoprostol
| Article | Year |
|---|---|
Clinical uses of mifepristone (MFP).
Topics: Abortion, Induced; Animals; Cervix Uteri; Clinical Trials as Topic; Contraceptives, Postcoital; Endometriosis; Female; Humans; Hydrocortisone; Labor, Induced; Mifepristone; Misoprostol; Neoplasms; Pregnancy | 1995 |
The use of progesterone antagonists in combination with prostaglandin for termination of pregnancy.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Alprostadil; Cervix Uteri; Clinical Trials as Topic; Dinoprostone; Drug Synergism; Female; Humans; Laminaria; Mifepristone; Misoprostol; Multicenter Studies as Topic; Myometrium; Pregnancy; Pregnancy Trimester, First; Pregnancy Trimester, Second; Progesterone; Randomized Controlled Trials as Topic; Uterine Contraction | 1994 |
[Mifepristone and misoprostol in therapeutic abortions].
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Therapeutic; Adult; Drug Costs; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Prospective Studies; Time Factors; Treatment Outcome | 1996 |
Medical options for early pregnancy termination.
Topics: Abortifacient Agents; Abortion, Induced; Algorithms; Decision Trees; Drug Therapy, Combination; Female; Humans; Methotrexate; Mifepristone; Misoprostol; Pregnancy; Time Factors; Treatment Outcome | 1997 |
[Cervical ripening].
Topics: Cervix Uteri; Dinoprostone; Female; Humans; Labor, Induced; Mifepristone; Misoprostol; Oxytocics | 1997 |
[Trends since 1989, in France, of induced abortions by mifepristone (RU486) combined with a prostaglandin analogue].
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Drug Administration Schedule; Drug Therapy, Combination; Female; France; Humans; Mifepristone; Misoprostol; Patient Acceptance of Health Care | 1997 |
[Voluntary abortion: new perspectives in local anesthesia].
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Anesthesia, Local; Humans; Mifepristone; Misoprostol | 1998 |
Modern management of miscarriage: is there a place for non-surgical treatment?
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Incomplete; Abortion, Missed; Abortion, Spontaneous; Dilatation and Curettage; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 1998 |
Methods of abortion in Europe during the first trimester of pregnancy.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Alprostadil; Anesthetics; Dilatation and Curettage; Europe; Female; Humans; Mifepristone; Misoprostol; Patient Acceptance of Health Care; Pregnancy; Pregnancy Trimester, First | 1997 |
Induction of labour: new horizons.
Topics: Abortifacient Agents; Administration, Oral; Cervical Ripening; Female; Gels; Humans; Labor, Induced; Mifepristone; Misoprostol; Oxytocin; Pessaries; Pregnancy; Prostaglandins; Relaxin | 1998 |
Use of misoprostol in first and second trimester abortion: a review.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Pregnancy Trimester, Second | 1999 |
Abortion with mifepristone and misoprostol: regimens, efficacy, acceptability and future directions.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Female; Forecasting; Humans; Mifepristone; Misoprostol; Patient Acceptance of Health Care; Pregnancy; Treatment Outcome | 2000 |
Misoprostol and pregnancy.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Incomplete; Abortion, Induced; Abortion, Missed; Cervical Ripening; Drug Therapy, Combination; Empirical Research; Female; Government Regulation; Humans; Labor, Induced; Methotrexate; Mifepristone; Misoprostol; Mobius Syndrome; Oxytocics; Postpartum Hemorrhage; Pregnancy; Pregnant Women | 2001 |
The mifepristone-misoprostol regimen for early medical abortion.
Topics: Abortifacient Agents; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Pregnancy Trimester, First; Self Administration | 2001 |
Options for early therapeutic abortion: a comparative review.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Therapeutic; Alprostadil; Drug Therapy, Combination; Female; Humans; Methotrexate; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Pregnancy, Ectopic; Randomized Controlled Trials as Topic; Treatment Outcome; Vacuum Curettage | 2002 |
[Spontaneous abortions of first trimester pregnancy: is uterine aspiration still in line?].
Topics: Abortifacient Agents; Abortion, Spontaneous; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Prostaglandins; Vacuum Extraction, Obstetrical | 2002 |
Pharmacoeconomics of medical abortion: a review of cost in the United States, Europe and Asia.
Topics: Abortion, Induced; Adolescent; Adult; Asia; Costs and Cost Analysis; Economics, Pharmaceutical; Europe; Female; Humans; Methotrexate; Mifepristone; Misoprostol; Pregnancy; United States | 2003 |
Methods for cervical ripening and induction of labor.
Topics: Cervical Ripening; Cervix Uteri; Dinoprostone; Female; Hormone Antagonists; Humans; Labor, Induced; Mifepristone; Misoprostol; Oxytocics; Pregnancy; Randomized Controlled Trials as Topic; Uterine Contraction | 2003 |
Prostaglandins for first-trimester termination.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Alprostadil; Cervical Ripening; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Pregnancy Tests; Pregnancy Trimester, First; Prostaglandins, Synthetic; Self Administration | 2003 |
Current medical abortion care.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Contraceptives, Postcoital, Synthetic; Female; Humans; Mifepristone; Misoprostol; Patient Acceptance of Health Care; Patient Education as Topic; Pregnancy; Sexual Behavior; Treatment Outcome; United States; Women's Health | 2003 |
Differences in efficacy, differences in providers: results from a hazard analysis of medical abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Oral; Age Factors; Educational Status; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pregnancy; Proportional Hazards Models; Risk Factors; Socioeconomic Factors; Treatment Outcome | 2004 |
Medical methods for first trimester abortion.
Topics: Abortifacient Agents; Abortion, Incomplete; Abortion, Induced; Drug Therapy, Combination; Female; Humans; Methotrexate; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Prostaglandins; Tamoxifen | 2004 |
[Side effect of mifepristone in combination with misoprostol for medical abortion].
Topics: Abortifacient Agents; Abortion, Induced; Female; Humans; Mifepristone; Misoprostol | 2004 |
Induced abortion: an overview for internists.
Topics: Abortifacient Agents; Abortion, Induced; Adult; Costs and Cost Analysis; Female; Humans; Internal Medicine; Methotrexate; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Referral and Consultation; Socioeconomic Factors; United States | 2004 |
Medical methods for first trimester abortion.
Topics: Abortifacient Agents; Abortion, Incomplete; Abortion, Induced; Drug Therapy, Combination; Female; Humans; Methotrexate; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Prostaglandins; Randomized Controlled Trials as Topic; Tamoxifen | 2004 |
Medical methods for first-trimester abortion.
Topics: Abortifacient Agents; Abortion, Induced; Alprostadil; Female; Humans; Methotrexate; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Prostaglandins; Tamoxifen; Treatment Outcome | 2004 |
Medical termination of pregnancy in the early first trimester.
Topics: Abortifacient Agents; Abortion, Induced; Antimetabolites; Dilatation and Curettage; Female; Humans; Methotrexate; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Prostaglandins | 2005 |
[Study on Meta analysis regarding the acceptability of medical abortion compared with surgical abortion].
Topics: Abortifacient Agents; Abortion, Induced; Choice Behavior; Controlled Clinical Trials as Topic; Female; Humans; Mifepristone; Misoprostol; Pain; Patient Satisfaction; Pregnancy; Pregnancy, Unwanted | 2006 |
Mifepristone dose in the regimen with misoprostol for medical abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Dose-Response Relationship, Drug; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 2006 |
Studies on uterine contractility following mifepristone and various routes of misoprostol.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Administration, Sublingual; Delayed-Action Preparations; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Time Factors; Uterine Contraction | 2006 |
A systematic review of more than one dose of misoprostol after mifepristone for abortion up to 10 weeks of gestation.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Female; Gestational Age; Humans; MEDLINE; Mifepristone; Misoprostol; Pregnancy; Randomized Controlled Trials as Topic; Treatment Outcome | 2006 |
Evidence for shortening the time interval of prostaglandin after mifepristone for medical abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Female; Humans; MEDLINE; Mifepristone; Misoprostol; Pregnancy; Prostaglandins; Randomized Controlled Trials as Topic; Time Factors | 2006 |
Mifepristone and misoprostol sequential regimen side effects, complications and safety.
Topics: Abortifacient Agents; Abortion, Induced; Animals; Clinical Trials as Topic; Female; Humans; Mifepristone; Misoprostol; Pelvic Infection; Pregnancy; Uterine Hemorrhage | 2006 |
Review of medical abortion using mifepristone in combination with a prostaglandin analogue.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Sublingual; Analgesia, Obstetrical; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Prostaglandins; Time Factors; Uterine Contraction; Uterine Hemorrhage; World Health Organization | 2006 |
Medical treatment for early fetal death (less than 24 weeks).
Topics: Abortifacient Agents; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Female; Fetal Death; Humans; Mifepristone; Misoprostol; Pregnancy; Randomized Controlled Trials as Topic; Ultrasonography, Prenatal | 2006 |
The use of misoprostol for early pregnancy failure.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Incomplete; Abortion, Spontaneous; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Ultrasonography, Prenatal | 2006 |
Contemporary management of early pregnancy failure.
Topics: Abortifacient Agents; Abortion, Missed; Combined Modality Therapy; Dilatation and Curettage; Female; Humans; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Pregnancy Outcome; Pregnancy Trimester, First; Vacuum Extraction, Obstetrical | 2007 |
Overcoming the challenging cervix: techniques to access the uterine cavity.
Topics: Cervix Uteri; Constriction, Pathologic; Dilatation; Female; Gynecologic Surgical Procedures; Humans; Laminaria; Mifepristone; Misoprostol; Oxytocics; Ultrasonography; Uterine Cervical Diseases | 2008 |
Surgical versus medical methods for second trimester induced abortion.
Topics: Abortifacient Agents; Abortion, Induced; Dilatation and Curettage; Dinoprost; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Randomized Controlled Trials as Topic | 2008 |
A review of developments in medical termination of pregnancy.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Attitude to Health; Choice Behavior; Drug Administration Schedule; Evidence-Based Medicine; Female; Health Services Needs and Demand; Humans; Mifepristone; Misoprostol; Nurse's Role; Nursing Research; Practice Guidelines as Topic; Pregnancy; Pregnancy Trimester, First; Pregnancy Trimester, Second; Time Factors; United Kingdom | 2008 |
Second trimester medical abortion with mifepristone-misoprostol and misoprostol alone: a review of methods and management.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second | 2008 |
Complications after second trimester surgical and medical abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Dilatation and Curettage; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second | 2008 |
Medical management of early pregnancy failure: efficacy.
Topics: Abortifacient Agents; Abortion, Spontaneous; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Randomized Controlled Trials as Topic; Treatment Outcome | 2008 |
Rupture of uterus in the first trimester during medical termination of pregnancy for exomphalos using mifepristone/misoprostol.
Topics: Abdominal Pain; Abortifacient Agents, Nonsteroidal; Abortion, Therapeutic; Administration, Intravaginal; Administration, Oral; Adult; Drug Therapy, Combination; Female; Fetal Diseases; Hernia, Umbilical; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Ultrasonography; Uterine Rupture | 2008 |
Medication abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Counseling; Dilatation and Curettage; Drug Approval; Female; Global Health; Humans; Mifepristone; Misoprostol; Patient Acceptance of Health Care; Patient Selection; Pregnancy | 2009 |
Second-trimester induction of labor.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Administration, Intravaginal; Dilatation; Drug Therapy, Combination; Female; Gynecologic Surgical Procedures; Humans; Maternal Mortality; Mifepristone; Misoprostol; Pain, Postoperative; Pregnancy; Pregnancy Trimester, Second | 2009 |
Meta-analysis of 200 or 600 mg mifepristone in association with two prostaglandins for termination of early pregnancy.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Alprostadil; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Outcome Assessment, Health Care; Pregnancy; Randomized Controlled Trials as Topic | 2009 |
Cervical preparation for first trimester surgical abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Alprostadil; Cervical Ripening; Dinoprost; Dinoprostone; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First | 2010 |
Flexible mifepristone and misoprostol administration interval for first-trimester medical termination.
Topics: Abortifacient Agents; Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Meta-Analysis as Topic; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
Medical and surgical options for induced abortion in first trimester.
Topics: Abortifacient Agents; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Anesthesia, Obstetrical; Female; Humans; Mifepristone; Misoprostol; Patient Preference; Pregnancy; Pregnancy Trimester, First; Vacuum Curettage | 2010 |
Cervical preparation for second trimester dilation and evacuation.
Topics: Abortifacient Agents; Abortion, Induced; Cervix Uteri; Extraction, Obstetrical; Female; Humans; Labor Stage, First; Laminaria; Mifepristone; Misoprostol; Osmosis; Polymers; Pregnancy; Pregnancy Trimester, Second; Preoperative Care; Prostaglandins | 2010 |
Medical methods for mid-trimester termination of pregnancy.
Topics: Abortifacient Agents; Abortion, Induced; Administration, Intravaginal; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Prostaglandins A; Randomized Controlled Trials as Topic | 2011 |
Expanding medical abortion: can medical abortion be effectively provided without the routine use of ultrasound?
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Ultrasonography, Prenatal | 2011 |
Introduction and provision of medical abortion: a tale of two countries in which technology is necessary but not sufficient.
Topics: Abortion, Induced; Female; France; Humans; Mifepristone; Misoprostol; Pregnancy; United States | 2011 |
Comparative effectiveness, safety and acceptability of medical abortion at home and in a clinic: a systematic review.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Ambulatory Care Facilities; Comparative Effectiveness Research; Drug Therapy, Combination; Female; Home Care Services; Humans; Middle Aged; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Prospective Studies; Young Adult | 2011 |
Mifepristone in combination with prostaglandins for termination of 10-16 weeks' gestation: a systematic review.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Alprostadil; Carboprost; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Pregnancy Trimester, Second; Prostaglandins; Randomized Controlled Trials as Topic | 2011 |
Does cervical preparation before outpatient hysteroscopy reduce women's pain experience? A systematic review.
Topics: Ambulatory Care; Dilatation; Female; Hormone Antagonists; Humans; Hysteroscopy; Mifepristone; Misoprostol; Pain; Premedication | 2011 |
Termination of second-trimester pregnancy by mifepristone combined with misoprostol versus intra-amniotic injection of ethacridine lactate (Rivanol®): a systematic review of Chinese trials.
Topics: Abortifacient Agents; Abortion, Induced; China; Ethacridine; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Randomized Controlled Trials as Topic | 2011 |
Medical methods for first trimester abortion.
Topics: Abortifacient Agents; Abortion, Incomplete; Abortion, Induced; Drug Therapy, Combination; Female; Humans; Methotrexate; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Prostaglandins; Randomized Controlled Trials as Topic; Tamoxifen | 2011 |
First-trimester medical abortion with mifepristone 200 mg and misoprostol: a systematic review.
Topics: Abortifacient Agents; Abortion, Induced; Drug Therapy, Combination; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Treatment Failure | 2013 |
A review of evidence for safe abortion care.
Topics: Abortifacient Agents; Abortion, Induced; Analgesia, Obstetrical; Antibiotic Prophylaxis; Female; Gestational Age; Humans; Maternal Death; Mifepristone; Misoprostol; Pregnancy; Treatment Outcome; Ultrasonography, Prenatal; Vacuum Curettage; World Health Organization | 2013 |
Medical methods for cervical ripening before the removal of intrauterine devices in postmenopausal women: a systematic review.
Topics: Abortifacient Agents; Cervical Ripening; Device Removal; Estradiol; Female; Humans; Intrauterine Devices; Mifepristone; Misoprostol; Postmenopause; Pregnancy; Randomized Controlled Trials as Topic | 2013 |
Interruption of nonviable pregnancies of 24-28 weeks' gestation using medical methods: release date June 2013 SFP guideline #20133.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Female; Fetal Death; Gestational Age; Humans; Labor, Induced; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second | 2013 |
Mifepristone-misoprostol dosing interval and effect on induction abortion times: a systematic review.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Drug Administration Schedule; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second | 2013 |
Controversies in family planning: pregnancy termination in women with uterine anatomic abnormalities.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adult; Family Planning Services; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Uterus | 2014 |
[Advantages by medical abortions at home in the first trimester].
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Denmark; Female; Humans; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Pregnancy Trimester, First; Self Administration | 2014 |
An overview of medical abortion for clinical practice.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Aftercare; Chorionic Gonadotropin; Counseling; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pain; Pregnancy; Ultrasonography, Prenatal | 2014 |
Pain during medical abortion, the impact of the regimen: a neglected issue? A review.
Topics: Abortion, Induced; Adult; Analgesics; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pain; Pain Management; Pain Measurement; Pregnancy; Prospective Studies | 2014 |
Second-trimester postabortion care for ruptured membranes, fetal demise, and incomplete abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Incomplete; Aftercare; Cohort Studies; Female; Fetal Death; Fetal Membranes, Premature Rupture; Humans; Mifepristone; Misoprostol; Oxytocics; Oxytocin; Pregnancy; Pregnancy Trimester, Second; Randomized Controlled Trials as Topic | 2015 |
Outpatient medical abortion is safe and effective through 70 days gestation.
Topics: Abortifacient Agents; Abortion, Induced; Ambulatory Care; Female; Gestational Age; Humans; Menstruation; Mifepristone; Misoprostol; Pregnancy; Time Factors; United States | 2015 |
Doctors or mid-level providers for abortion.
Topics: Abortifacient Agents; Abortion, Legal; Abortion, Therapeutic; Allied Health Personnel; Clinical Competence; Cohort Studies; Female; Humans; Midwifery; Mifepristone; Misoprostol; Nurses; Nursing Assistants; Observational Studies as Topic; Physician Assistants; Physicians; Pregnancy; Pregnancy Trimester, First; Randomized Controlled Trials as Topic; Vacuum Curettage | 2015 |
Mifepristone With Buccal Misoprostol for Medical Abortion: A Systematic Review.
Topics: Abortifacient Agents; Abortion, Induced; Administration, Buccal; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First | 2015 |
Update on medical abortion: simplifying the process for women.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adult; Directive Counseling; Female; Humans; Mifepristone; Misoprostol; Pregnancy; United States; Women's Health | 2015 |
The added value of mifepristone to non-surgical treatment regimens for uterine evacuation in case of early pregnancy failure: a systematic review of the literature.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Spontaneous; Clinical Protocols; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First | 2015 |
Update on second-trimester surgical abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Observational Studies as Topic; Osmosis; Pregnancy; Pregnancy Trimester, Second; Retrospective Studies | 2016 |
A research agenda for moving early medical pregnancy termination over the counter.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Drug Approval; Drug Therapy, Combination; Female; Health Knowledge, Attitudes, Practice; Humans; Mifepristone; Misoprostol; Nonprescription Drugs; Pregnancy; Pregnancy Trimester, First; United States; United States Food and Drug Administration | 2017 |
Development of medical termination of pregnancy: a review.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Prostaglandins; Treatment Outcome | 2017 |
Update on second trimester medical abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Oral; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Operative Time; Pregnancy; Pregnancy Trimester, Second; Randomized Controlled Trials as Topic | 2017 |
Efficacy of medical abortion prior to 6 gestational weeks: a systematic review.
Topics: Abortifacient Agents; Abortion, Induced; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Observational Studies as Topic; Pregnancy; Pregnancy Trimester, First; Prospective Studies; Randomized Controlled Trials as Topic; Treatment Outcome | 2018 |
Low-sensitivity urine pregnancy testing to assess medical abortion outcome: A systematic review.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Tests; Treatment Failure | 2018 |
Providing Abortion Services in the Primary Care Setting.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Communication; Counseling; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Primary Health Care; Women's Health | 2018 |
Medical and surgical abortion for women living with HIV.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Oral; Administration, Sublingual; Adult; Drug Administration Schedule; Female; HIV Long-Term Survivors; Humans; Mifepristone; Misoprostol; Prospective Studies | 2018 |
Management of first-trimester miscarriage: a systematic review and network meta-analysis.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Spontaneous; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Network Meta-Analysis; Pregnancy; Pregnancy Trimester, First; Vacuum Curettage | 2019 |
Adjunctive Agents for Cervical Preparation in Second Trimester Surgical Abortion.
Topics: Abortifacient Agents, Nonsteroidal; Adult; Cervix Uteri; Dilatation; Extraction, Obstetrical; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Preoperative Care | 2019 |
Medical treatment for early fetal death (less than 24 weeks).
Topics: Delivery, Obstetric; Female; Fetal Death; Humans; Mifepristone; Misoprostol; Oxytocics; Pregnancy; Pregnancy Trimester, First; Randomized Controlled Trials as Topic | 2019 |
Current and potential methods for second trimester abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Dilatation; Female; Humans; Mifepristone; Misoprostol; Pain, Postoperative; Pregnancy; Pregnancy Trimester, Second | 2020 |
Online access to abortion medications: a review of utilization and clinical outcomes.
Topics: Abortifacient Agents; Abortion, Induced; Female; Health Services Accessibility; Humans; Internet; Maternal Mortality; Mifepristone; Misoprostol; Pregnancy; Quality of Health Care; Telemedicine | 2020 |
First trimester termination of pregnancy.
Topics: Abortifacient Agents; Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Pain Management; Pregnancy; Pregnancy Trimester, First; Vacuum Extraction, Obstetrical | 2020 |
Management of pain associated with up-to-9-weeks medical termination of pregnancy (MToP) using mifepristone-misoprostol regimens: expert consensus based on a systematic literature review.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Anti-Inflammatory Agents, Non-Steroidal; Consensus; Female; Humans; Ibuprofen; Mifepristone; Misoprostol; Pain Management; Pain Measurement; Pregnancy; Pregnancy Trimester, First | 2020 |
A systematic review of the effectiveness, safety, and acceptability of medical management of intrauterine fetal death at 14-28 weeks of gestation.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Dose-Response Relationship, Drug; Female; Fetal Death; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Randomized Controlled Trials as Topic | 2019 |
Reconceptualizing safe abortion and abortion services in the age of abortion pills: A discussion paper.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Contraception; Delivery of Health Care; Female; Health Personnel; Humans; Mifepristone; Misoprostol; Pregnancy; Women's Health Services | 2020 |
Twelve years after abortion decriminalization in Mexico City: Can we still remain an island of liberties?
Topics: Abortion, Induced; Abortion, Legal; Adolescent; Contraception, Postcoital; Female; Health Policy; Health Services Accessibility; Humans; Mexico; Mifepristone; Misoprostol; Pregnancy; Reproductive Rights; Vacuum Curettage; Women's Rights | 2020 |
Self-managed abortion.
Topics: Abortion, Induced; Abortion, Legal; Female; Health Policy; Health Services Accessibility; Humans; Internet; Mifepristone; Misoprostol; Patient Safety; Pregnancy; Self-Management; Telemedicine; United States | 2019 |
Follow-up strategies to confirm the success of medical abortion of pregnancies up to 10 weeks' gestation: a systematic review with meta-analyses.
Topics: Abortifacient Agents; Abortion, Induced; Ambulatory Care; Diagnostic Self Evaluation; Female; Humans; Mifepristone; Misoprostol; Patient Compliance; Patient Preference; Patient Satisfaction; Pregnancy; Pregnancy Tests; Pregnancy Trimester, First; Surveys and Questionnaires; Telephone; Text Messaging; Treatment Outcome; Ultrasonography | 2020 |
Society of Family Planning clinical recommendations: Cervical preparation for dilation and evacuation at 20-24 weeks' gestation.
Topics: Abortifacient Agents; Abortion, Induced; Cervix Uteri; Extraction, Obstetrical; Family Planning Services; Female; Humans; Labor Stage, First; Laminaria; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Preoperative Care; Societies, Medical | 2020 |
Simultaneous compared to interval administration of mifepristone and misoprostol for medical abortion up to 10
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pregnancy | 2020 |
Self-administered versus provider-administered medical abortion.
Topics: Abortifacient Agents; Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Patient Safety; Pregnancy; Pregnancy Trimester, First; Randomized Controlled Trials as Topic | 2020 |
Complications of Unsafe and Self-Managed Abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Abortion, Spontaneous; Adult; Diagnosis, Differential; Female; Health Policy; Humans; Mifepristone; Misoprostol; Pregnancy; Self-Management; United States | 2020 |
Trends in medication abortion provision before and after the introduction of mifepristone: A study of the National Abortion Federation's Canadian member services.
Topics: Abortion, Induced; Abortion, Spontaneous; Canada; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 2020 |
Women's voices and medical abortions: A review of the literature.
Topics: Abortifacient Agents; Abortion, Induced; Female; Health Services Accessibility; Humans; Mifepristone; Misoprostol; Patient Preference; Pregnancy; Pregnant Women; Qualitative Research | 2020 |
Medication to Manage Abortion and Miscarriage.
Topics: Abortion, Induced; Abortion, Spontaneous; Female; Gestational Age; Humans; Middle Aged; Mifepristone; Misoprostol; Pregnancy | 2020 |
Medical termination for pregnancy in early first trimester (≤ 63 days) using combination of mifepristone and misoprostol or misoprostol alone: a systematic review.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First | 2020 |
Systematic Review of the Effectiveness, Safety, and Acceptability of Mifepristone and Misoprostol for Medical Abortion in Low- and Middle-Income Countries.
Topics: Abortifacient Agents; Abortifacient Agents, Nonsteroidal; Abortion, Induced; Developing Countries; Female; Humans; Mifepristone; Misoprostol; Patient Acceptance of Health Care; Pregnancy; Treatment Outcome | 2020 |
Expulsion at home for early medical abortion: A systematic review with meta-analyses.
Topics: Abortifacient Agents; Abortion, Induced; Female; Gestational Age; Home Care Services; Humans; Mifepristone; Misoprostol; Pregnancy | 2021 |
Different dosing intervals of mifepristone-misoprostol for second-trimester termination of pregnancy: A meta-analysis and systematic review.
Topics: Abortifacient Agents; Abortifacient Agents, Nonsteroidal; Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Randomized Controlled Trials as Topic | 2021 |
Cervical priming before surgical abortion up to 13
Topics: Abortion, Induced; Cervix Uteri; England; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Randomized Controlled Trials as Topic | 2020 |
Cervical priming before surgical abortion between 14 and 24 weeks: a systematic review and meta-analyses for the National Institute for Health and Care Excellence-new clinical guidelines for England.
Topics: Abortion, Induced; Cervix Uteri; England; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 2021 |
Methods for managing miscarriage: a network meta-analysis.
Topics: Abortion, Incomplete; Abortion, Missed; Abortion, Spontaneous; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Network Meta-Analysis; Oxytocics; Placebos; Pregnancy; Pregnancy Trimester, First; Randomized Controlled Trials as Topic; Suction; Vacuum Curettage; Watchful Waiting | 2021 |
Medical Induction for Mid trimester Abortion: A Hospital-based Descriptive Cross-sectional Study.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Cross-Sectional Studies; Female; Hospitals; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second | 2020 |
[Clinical and diagnostic-imaging findings in patellofemoral instability].
Topics: Abortion, Induced; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Research Design | 2021 |
[Control of the level of human chorionic gonadotropin in urine compared to the level of serum after medically provoked abortion is a safe alternative].
Topics: Abortion, Induced; Abortion, Spontaneous; Chorionic Gonadotropin; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 2021 |
Community-based distribution of misoprostol for early abortion: Outcomes from a program in Sindh, Pakistan.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Delivery of Health Care; Female; Humans; Mifepristone; Misoprostol; Pakistan; Pregnancy | 2022 |
Pain management for medical abortion before 14 weeks' gestation.
Topics: Abortion, Induced; Abortion, Spontaneous; Acetaminophen; Female; Humans; Ibuprofen; Mifepristone; Misoprostol; Pain; Pain Management; Pregabalin; Pregnancy | 2022 |
Comparison of vaginal and buccal misoprostol after mifepristone for medication abortion through 70 days of gestation: A retrospective chart review.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Abortion, Spontaneous; Administration, Intravaginal; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Prospective Studies; Retrospective Studies | 2022 |
Labour induction for termination of pregnancy with severe fetal anomalies after 24 weeks' gestation: a case series and systematic review of the literature.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Female; Gestational Age; Humans; Infant; Labor, Induced; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Retrospective Studies | 2022 |
Toxicity of abortifacients: A review for physicians in the post roe era.
Topics: Abortifacient Agents; Abortion, Induced; Female; Humans; Methotrexate; Mifepristone; Misoprostol; Physicians; Pregnancy; United States | 2022 |
Pain management for medical abortion before 14 weeks' gestation: A systematic review.
Topics: Female; Humans; Ibuprofen; Mifepristone; Misoprostol; Observational Studies as Topic; Pain; Pain Management; Pregnancy | 2022 |
[Medical strategy for abortions between 14 and 16 weeks of gestation].
Topics: Abortion, Induced; Administration, Intravaginal; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pregnancy | 2022 |
Medical Abortion before Confirmed Intrauterine Pregnancy: A Systematic Review.
Topics: Abortion, Induced; Abortion, Spontaneous; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy, Ectopic | 2022 |
No-Test Medication Abortion: A Systematic Review.
Topics: Abortifacient Agents; Abortion, Induced; Female; Humans; Infant; Mifepristone; Misoprostol; Pregnancy; Pregnancy, Ectopic | 2023 |
Toxicities of herbal abortifacients.
Topics: Abortifacient Agents; Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 2023 |
Effectiveness and safety of misoprostol-only for first-trimester medication abortion: An updated systematic review and meta-analysis.
Topics: Abortifacient Agents; Abortifacient Agents, Nonsteroidal; Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First | 2023 |
Early pregnancy loss medical management in clinical practice.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Abortion, Spontaneous; Cicatrix; Female; Humans; Mifepristone; Misoprostol; Multicenter Studies as Topic; Pregnancy; Pregnancy, Ectopic; Retrospective Studies | 2023 |
Cervical preparation for second-trimester procedural abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second | 2023 |
215 trial(s) available for mifepristone and misoprostol
| Article | Year |
|---|---|
What do women want during medical abortion?
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Acetaminophen; Administration, Oral; Adolescent; Adult; Alprostadil; Bias; Codeine; Female; Heroin; Humans; Mifepristone; Misoprostol; Pain; Patient Satisfaction; Pessaries; Pregnancy | 1992 |
Uterine contractility and induction of abortion in early pregnancy by misoprostol and mifepristone.
Topics: Abortion, Therapeutic; Administration, Oral; Adolescent; Adult; Female; Humans; Mifepristone; Misoprostol; Monitoring, Physiologic; Pregnancy; Pregnancy Trimester, First; Tablets; Time Factors; Uterine Contraction | 1991 |
[Contraceptive activity of RU486 and oral active prostaglandin combination].
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Legal; Administration, Oral; Adult; Alprostadil; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 1991 |
Randomized trial of misoprostol and cervagem in combination with a reduced dose of mifepristone for induction of abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Oral; Adult; Alprostadil; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pessaries; Pregnancy; Treatment Outcome | 1995 |
Termination of early pregnancy by two regimens of mifepristone with misoprostol and mifepristone with PG05--a multicentre randomized clinical trial in China.
Topics: Abdominal Pain; Abortion, Induced; Administration, Oral; Adolescent; Adult; China; Diarrhea; Dinoprost; Dose-Response Relationship, Drug; Female; Humans; Mifepristone; Misoprostol; Pessaries; Pregnancy; Pregnancy Trimester, First; Uterine Hemorrhage | 1994 |
Methotrexate and misoprostol for abortion at 57-63 days gestation.
Topics: Abortion, Induced; Acetaminophen; Administration, Oral; Adult; Chorionic Gonadotropin; Codeine; Colic; Drug Therapy, Combination; Female; Humans; Ibuprofen; Injections, Intramuscular; Methotrexate; Mifepristone; Misoprostol; Pilot Projects; Pregnancy; Pregnancy Trimester, First; Time Factors | 1994 |
[Termination of early pregnancy by two regimens of mifepristone with misoprostol: a multicentre clinical trial].
Topics: Abortion, Induced; Adolescent; Adult; Carboprost; Drug Synergism; Female; Humans; Mifepristone; Misoprostol; Pessaries; Pregnancy; Pregnancy Trimester, First | 1994 |
[The pathological investigations on termination of early pregnancy with mifepristone].
Topics: Abortion, Induced; Adult; Chorionic Villi; Decidua; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First | 1995 |
Induction of abortion in the second trimester by a combination of misoprostol and mifepristone: a randomized comparison between two misoprostol regimens.
Topics: Abortion, Induced; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Time Factors | 1995 |
Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol.
Topics: Abortion, Induced; Administration, Intravaginal; Administration, Oral; Adult; Confidence Intervals; Diarrhea; Female; Follow-Up Studies; Humans; Mifepristone; Misoprostol; Pregnancy; Prospective Studies; Vomiting | 1995 |
Early abortion induction by a combination of mifepristone and oral misoprostol: a comparison between two dose regimens of misoprostol and their effect on blood pressure.
Topics: Abortion, Induced; Administration, Oral; Blood Pressure; Drug Combinations; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Treatment Outcome | 1994 |
RU486: the French experience.
Topics: Abdominal Pain; Abortion, Induced; Adult; Alprostadil; Contraindications; Dinoprostone; Female; France; Humans; Hypotension; Mifepristone; Misoprostol; Myocardial Infarction; Pilot Projects; Pregnancy; Uterine Hemorrhage | 1994 |
The effect of dose of mifepristone and gestation on the efficacy of medical abortion with mifepristone and misoprostol.
Topics: Abortion, Induced; Adult; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Treatment Outcome | 1993 |
The abortifacient effect of misoprostol in the second trimester. A randomized comparison with gemeprost in patients pre-treated with mifepristone (RU486).
Topics: Abortifacient Agents, Nonsteroidal; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Alprostadil; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Mifepristone; Misoprostol; Pessaries; Pregnancy; Pregnancy Trimester, Second | 1993 |
[Histological study of uterine cervix during termination of early pregnancy by mifepristone and prostaglandins].
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Carboprost; Cervix Uteri; Drug Synergism; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First | 1995 |
Termination of early pregnancy (up to 63 days of amenorrhea) with mifepristone and increasing doses of misoprostol [corrected].
Topics: Abortifacient Agents; Adolescent; Adult; Amenorrhea; Chorionic Gonadotropin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; France; Hemostatic Techniques; Humans; Incidence; Menstruation-Inducing Agents; Mifepristone; Misoprostol; Pregnancy; Pregnancy, Ectopic; Time Factors; Ultrasonography; Uterine Hemorrhage; Uterus | 1995 |
A comparison of 600 and 200 mg mifepristone prior to second trimester abortion with the prostaglandin misoprostol.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second | 1996 |
Misoprostol is as effective as gemeprost in termination of second trimester pregnancy when combined with mifepristone: a randomised comparative trial.
Topics: Abortifacient Agents; Abortion, Induced; Adult; Alprostadil; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 1996 |
[Mifepristone and misoprostol in therapeutic abortions].
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Therapeutic; Adult; Drug Costs; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Prospective Studies; Time Factors; Treatment Outcome | 1996 |
Oral misoprostol versus mifepristone for cervical dilatation before vacuum aspiration in first trimester nulliparous pregnancy: a double blind prospective randomised study.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Administration, Oral; Adult; Double-Blind Method; Female; Humans; Mifepristone; Misoprostol; Parity; Pregnancy; Pregnancy Trimester, First; Prospective Studies; Tablets; Uterine Hemorrhage; Vacuum Extraction, Obstetrical | 1996 |
Safety, efficacy, and acceptability of medical abortion in China, Cuba, and India: a comparative trial of mifepristone-misoprostol versus surgical abortion.
Topics: Abortifacient Agents; Abortion, Induced; Adult; China; Cuba; Developing Countries; Female; Humans; India; Mifepristone; Misoprostol; Patient Acceptance of Health Care; Patient Participation; Pregnancy; Pregnant Women; Research Design; Risk Assessment; Treatment Failure | 1997 |
Unsuccessful treatment of missed abortion with a combination of an antiprogesterone and a prostaglandin E1 analogue.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Missed; Administration, Oral; Drug Combinations; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Prospective Studies; Treatment Failure | 1997 |
Women's satisfaction with medical abortion with RU486.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion Applicants; Abortion, Induced; Adult; Double-Blind Method; Female; Humans; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy | 1997 |
Vaginal misoprostol compared with oral misoprostol in termination of second-trimester pregnancy.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Adult; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Premedication; Prospective Studies; Time Factors | 1997 |
Early pregnancy termination with mifepristone and misoprostol in the United States.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Drug Therapy, Combination; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Receptors, Progesterone; Treatment Failure; United States; Uterine Hemorrhage | 1998 |
[Evaluation of combination RU 486-laminaria tents-misoprostol-peridural anesthesia in second and third trimester induced abortions].
Topics: Abortifacient Agents; Abortion, Induced; Adolescent; Adult; Analgesia, Epidural; Clinical Protocols; Drug Therapy, Combination; Female; Humans; Laminaria; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Prospective Studies; Time Factors | 1998 |
An effective regimen for early medical abortion: a report of 2000 consecutive cases.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Incomplete; Abortion, Induced; Adolescent; Adult; Analgesia; Female; Gestational Age; Humans; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Retrospective Studies; Treatment Outcome | 1998 |
Blood loss with mifepristone--misoprostol abortion: measures from a trial in China, Cuba and India.
Topics: Abortifacient Agents; Abortion, Therapeutic; Adult; Blood Loss, Surgical; Cuba; Feasibility Studies; Female; Humans; India; Logistic Models; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Software; Uterine Hemorrhage | 1998 |
Medical versus surgical abortion.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Chi-Square Distribution; Cuba; Female; Humans; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Software; Treatment Outcome; Vacuum Curettage | 1998 |
Once-a-month treatment with a combination of mifepristone and the prostaglandin analogue misoprostol.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adult; Drug Administration Schedule; Drug Combinations; Female; Humans; Luteinizing Hormone; Menstrual Cycle; Menstruation-Inducing Agents; Mifepristone; Misoprostol; Pregnancy; Prostaglandins; Treatment Outcome | 1999 |
A randomized double-blind placebo-controlled study to assess the effect of oral contraceptive pills on the outcome of medical abortion with mifepristone and misoprostol.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Abortion, Missed; Adult; Contraceptives, Oral; Double-Blind Method; Female; Hemoglobins; Humans; Mifepristone; Misoprostol; Placebos; Pregnancy; Time Factors; Uterine Hemorrhage | 1999 |
Low-dose mifepristone 200 mg and vaginal misoprostol for abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Drug Therapy, Combination; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Outcome; Prospective Studies; Self Administration; Ultrasonography; United States; United States Food and Drug Administration; Uterus | 1999 |
Early pregnancy termination with intravaginally administered sodium chloride solution-moistened misoprostol tablets: historical comparison with mifepristone and oral misoprostol.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Adult; Cohort Studies; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Sodium Chloride; Tablets; Treatment Outcome | 1999 |
Low-dose mifepristone followed by vaginal misoprostol at 48 hours for abortion up to 63 days.
Topics: Abortifacient Agents; Abortion, Induced; Administration, Intravaginal; Adolescent; Adult; Female; Gestational Age; Humans; Middle Aged; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Pregnancy Trimester, First; Prospective Studies; Surveys and Questionnaires; Treatment Outcome | 2000 |
Bleeding patterns after early abortion with mifepristone and misoprostol or manual vacuum aspiration.
Topics: Abortion, Induced; Adult; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Pregnancy Trimester, First; Prospective Studies; Uterine Hemorrhage; Vacuum Curettage; Vacuum Extraction, Obstetrical | 2000 |
In-depth interviews with medical abortion clients: thoughts on the method and home administration of misoprostol.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Female; Home Care Services; Humans; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Self Medication; Social Support | 2000 |
Early abortion by mifepristone (RU 486) followed by vaginal gel (meteneprost) versus oral (misoprostol) prostaglandin.
Topics: 16,16-Dimethylprostaglandin E2; Abortifacient Agents; Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Adult; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pregnancy; Treatment Outcome | 1999 |
Mifepristone for preinduction cervical ripening beyond 41 weeks' gestation: a randomized controlled trial.
Topics: Adult; Cervical Ripening; Cesarean Section; Double-Blind Method; Female; Humans; Labor, Induced; Mifepristone; Misoprostol; Oxytocics; Oxytocin; Pregnancy; Pregnancy, Prolonged | 2000 |
Randomized comparison of vaginal (200 microg every 3 h) and oral (400 microg every 3 h) misoprostol when combined with mifepristone in termination of second trimester pregnancy.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Diarrhea; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second | 2000 |
Mifepristone versus vaginally administered misoprostol for cervical priming before first-trimester termination of pregnancy: a randomized, controlled study.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Cervix Uteri; Dilatation; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Vagina | 2000 |
Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: A randomized trial.
Topics: Abortifacient Agents; Abortion, Induced; Administration, Intravaginal; Adult; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Prospective Studies; Time Factors | 2000 |
A multicentre randomized comparative clinical trial of 200 mg RU486 (mifepristone) single dose followed by either 5 mg 9-methylene PGE(2) gel (meteneprost) or 600 microg oral PGE(1) (misoprostol) for termination of early pregnancy within 28 days of missed
Topics: 16,16-Dimethylprostaglandin E2; Abortifacient Agents; Abortion, Therapeutic; Adolescent; Adult; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Menstrual Cycle; Mifepristone; Misoprostol; Outcome Assessment, Health Care; Pregnancy | 2000 |
A randomized comparison of mifepristone and self-administered oral or vaginal misoprostol for early abortion.
Topics: Abortifacient Agents; Administration, Intravaginal; Administration, Oral; Adult; Female; Humans; Mifepristone; Misoprostol; Pain Measurement; Patient Acceptance of Health Care; Pregnancy; Prospective Studies; Self Administration; Time Factors; Treatment Outcome | 2000 |
A comparative study of surgical and medical procedures: 932 pregnancy terminations up to 63 days gestation.
Topics: Abortifacient Agents; Abortion, Incomplete; Abortion, Legal; Adolescent; Adult; Female; Humans; Middle Aged; Mifepristone; Misoprostol; Parity; Pregnancy; Retrospective Studies | 2001 |
Termination of early pregnancy in the scarred uterus with mifepristone and misoprostol.
Topics: Abortifacient Agents; Abortion, Therapeutic; Adult; Cesarean Section; Cicatrix; Female; Humans; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Prospective Studies; Uterus | 2001 |
Timing of pain and bleeding after mifepristone-induced abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Drug Administration Schedule; Dysmenorrhea; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Statistics, Nonparametric; Time Factors; Uterine Hemorrhage | 2000 |
Analgesia during at-home use of misoprostol as part of a medical abortion regimen.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Analgesics, Opioid; Female; Gestational Age; Gravidity; Humans; Mifepristone; Misoprostol; Parity; Pregnancy; Regression Analysis; Time Factors | 2000 |
[Termination of 10-16 weeks's gestation with mifepristone plus misoprostol: a multicentre randomized clinical trial].
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Female; Humans; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Pregnancy Trimester, Second | 1999 |
Efficacy of mifepristone followed on the same day by misoprostol for early termination of pregnancy: report of a randomised trial.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Prospective Studies; Treatment Outcome | 2001 |
First trimester abortion with mifepristone and vaginal misoprostol.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Denmark; Female; Humans; Middle Aged; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Pregnancy Trimester, First | 2001 |
Mifepristone and misoprostol for early abortion when no gestational sac is present.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Adult; Chorionic Gonadotropin; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Patient Satisfaction; Pilot Projects; Pregnancy; Pregnancy Trimester, First; Pregnancy, Ectopic; Prospective Studies; Ultrasonography; Uterus | 2001 |
Mifepristone 100 mg in abortion regimens.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 2001 |
Double-blind randomized trial of mifepristone in combination with vaginal gemeprost or misoprostol for induction of abortion up to 63 days gestation.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Adult; Alprostadil; Double-Blind Method; Drug Synergism; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pregnancy; Treatment Outcome | 2001 |
Early pregnancy termination with mifepristone and misoprostol in Norway.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Acetaminophen; Adolescent; Adult; Analgesics, Non-Narcotic; Analgesics, Opioid; Codeine; Female; Humans; Mifepristone; Misoprostol; Norway; Pain Measurement; Patient Satisfaction; Pregnancy; Pregnancy Trimester, First; Treatment Outcome | 2001 |
Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Prospective Studies; Regression Analysis; Treatment Outcome | 2001 |
Mifepristone followed on the same day by vaginal misoprostol for early abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Adult; Dilatation and Curettage; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Time Factors; Ultrasonography | 2001 |
A randomized comparison of medical abortion and surgical vacuum aspiration at 10-13 weeks gestation.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Anesthesia, General; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pain; Patient Satisfaction; Postoperative Complications; Pregnancy; Treatment Outcome; Vacuum Curettage | 2002 |
The effect of contraceptive pills on the measured blood loss in medical termination of pregnancy by mifepristone and misoprostol: a randomized placebo controlled trial.
Topics: Abortifacient Agents; Abortion, Induced; Adult; Contraceptives, Oral; Female; Hemoglobins; Humans; Mifepristone; Misoprostol; Placebos; Pregnancy; Uterine Hemorrhage | 2002 |
[Prevent from bleeding after medical abortion through prolonged application of mifepristone with misoprostol for terminating early pregnancy].
Topics: Abortion, Induced; Female; Humans; Menstruation; Mifepristone; Misoprostol; Time Factors; Uterine Hemorrhage | 2000 |
Tissue-type plasminogen activator and plasminogen activator inhibitor type-1 mRNA and their protein expression levels in human decidua after early pregnancy termination by mifepristone plus misoprostol.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adult; Chromogenic Compounds; Decidua; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression Regulation; Humans; Mifepristone; Misoprostol; Plasminogen Activator Inhibitor 1; Pregnancy; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tissue Plasminogen Activator | 2001 |
Could American women use mifepristone-misoprostol pills safely with less medical supervision?
Topics: Abortion, Induced; Adolescent; Adult; Female; Gestational Age; Humans; Middle Aged; Mifepristone; Misoprostol; Physician's Role; Pregnancy; Pregnancy Tests; Self Administration | 2002 |
Comparison of abortions induced by methotrexate or mifepristone followed by misoprostol.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Female; Hemorrhage; Humans; Methotrexate; Mifepristone; Misoprostol; Pain; Pregnancy | 2002 |
A prospective randomized, double-blinded, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of early pregnancy.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Adult; Double-Blind Method; Drug Synergism; Female; Humans; Mifepristone; Misoprostol; Nausea; Pregnancy; Prospective Studies | 2002 |
Pilot study on the use of sublingual misoprostol with mifepristone in termination of first trimester pregnancy up to 9 weeks gestation.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Oral; Administration, Sublingual; Adult; Drug Synergism; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pilot Projects; Pregnancy; Pregnancy Trimester, First | 2002 |
Mifepristone-misoprostol abortion: a trial in rural and urban Maharashtra, India.
Topics: Abortifacient Agents; Abortion, Induced; Administration, Oral; Adult; Family Planning Services; Female; Humans; India; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Prospective Studies; Rural Health; Urban Health | 2002 |
A prospective randomized study on the measured blood loss in medical termination of early pregnancy by three different misoprostol regimens after pretreatment with mifepristone.
Topics: Abortifacient Agents, Steroidal; Adult; Diarrhea; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Treatment Failure; Uterine Hemorrhage | 2002 |
Randomized trial of oral versus vaginal misoprostol 2 days after mifepristone 200 mg for abortion up to 63 days of pregnancy.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Adult; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pain; Pregnancy; Treatment Outcome; Uterine Hemorrhage | 2002 |
Management of missed abortion: comparison of medical treatment with either mifepristone + misoprostol or misoprostol alone with surgical evacuation. A multi-center trial in Copenhagen county, Denmark.
Topics: Abortifacient Agents; Abortion, Missed; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Chorionic Gonadotropin; Cross-Over Studies; Denmark; Drug Administration Schedule; Female; Gestational Age; Humans; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Prospective Studies; Treatment Outcome | 2002 |
A randomised study of misoprostol and gemeprost in combination with mifepristone for induction of abortion in the second trimester of pregnancy.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Administration, Oral; Alprostadil; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pessaries; Pregnancy; Pregnancy Trimester, First; Pregnancy Trimester, Second; Tablets | 2002 |
Medical termination of missed abortion.
Topics: Abortifacient Agents; Abortion, Missed; Abortion, Therapeutic; Adolescent; Adult; Female; Humans; Mifepristone; Misoprostol; Patient Acceptance of Health Care; Pregnancy; Treatment Outcome; Ultrasonography; Vacuum Curettage | 2002 |
Verifying the effectiveness of medical abortion; ultrasound versus hCG testing.
Topics: Abortifacient Agents; Abortion, Induced; Chorionic Gonadotropin; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Treatment Outcome; Ultrasonography; Uterus | 2003 |
WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. I: Efficacy.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Oral; Adult; Amenorrhea; Double-Blind Method; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Risk Factors; Treatment Outcome | 2003 |
A prospective, randomized, placebo-controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks gestation.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Sublingual; Adult; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Placebos; Pregnancy; Pregnancy Trimester, First; Treatment Outcome | 2003 |
A pilot study of mifepristone in combination with sublingual or vaginal misoprostol for medical termination of pregnancy up to 63 days gestation.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Sublingual; Adult; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pilot Projects; Pregnancy; Treatment Outcome | 2003 |
Luteal phase treatment with mifepristone and misoprostol for fertility regulation.
Topics: Adult; Contraception; Contraceptives, Oral; Contraceptives, Postcoital, Synthetic; Drug Therapy, Combination; Female; Humans; Luteal Phase; Mifepristone; Misoprostol; Pregnancy | 2003 |
Menstrual induction with mifepristone and misoprostol.
Topics: Adult; Contraceptives, Oral; Contraceptives, Postcoital, Synthetic; Drug Interactions; Female; Humans; Menstruation; Menstruation-Inducing Agents; Mifepristone; Misoprostol; Retrospective Studies | 2003 |
Mifepristone and misoprostol versus dilation and evacuation for midtrimester abortion: a pilot randomised controlled trial.
Topics: Abortifacient Agents; Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Adult; Dilatation and Curettage; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Patient Satisfaction; Pilot Projects; Pregnancy; Pregnancy Trimester, Second; Treatment Outcome | 2004 |
[Use of Misoprostol for medical abortion: a trial of the acceptability for home use].
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Female; Home Nursing; Humans; Mifepristone; Misoprostol; Pregnancy; Self Administration; Surveys and Questionnaires | 2004 |
A randomized comparison of misoprostol 6 to 8 hours versus 24 hours after mifepristone for abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Drug Administration Schedule; Follow-Up Studies; Humans; Mifepristone; Misoprostol; Prospective Studies; Time Factors | 2004 |
Medical abortion in combination with laminaria for first-trimester termination of pregnancy.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Female; Humans; Laminaria; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Prospective Studies | 2004 |
WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion.
Topics: Abdominal Pain; Abortifacient Agents, Steroidal; Abortion, Induced; Amenorrhea; Analgesics; Dizziness; Double-Blind Method; Fatigue; Female; Headache; Humans; Mifepristone; Misoprostol; Nausea; Parity; Patient Satisfaction; Perception; Treatment Outcome; Vomiting | 2004 |
Randomized, double-blind, controlled trial of mifepristone in capsule versus tablet form followed by misoprostol for early medical abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Oral; Adult; Capsules; China; Double-Blind Method; Drug Administration Schedule; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pregnancy; Prospective Studies; Tablets; Treatment Outcome | 2004 |
Ability of the clinician and patient to predict the outcome of mifepristone and misoprostol medical abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Patient Participation; Pregnancy; Sensitivity and Specificity; Treatment Outcome; Ultrasonography | 2004 |
Effect of antiprogesterone mifepristone followed by misoprostol on circulating leptin in early pregnancy.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Cohort Studies; Corpus Luteum; Double-Blind Method; Estradiol; Female; Humans; Leptin; Mifepristone; Misoprostol; Monitoring, Physiologic; Pregnancy; Pregnancy Outcome; Pregnancy Trimester, First; Pregnancy, Unwanted; Probability; Progesterone; Radioimmunoassay; Risk Assessment; Treatment Outcome | 2005 |
Multicenter trial of a simplified mifepristone medical abortion regimen.
Topics: Abortion, Therapeutic; Administration, Oral; Adult; Combined Modality Therapy; Dilatation and Curettage; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gestational Age; Humans; Logistic Models; Maternal Age; Mifepristone; Misoprostol; Pregnancy; Pregnancy Outcome; Probability; Prospective Studies; Risk Assessment; Single-Blind Method; Treatment Outcome | 2005 |
Early medical abortion: a new regimen up to 49 days' gestation.
Topics: Abortifacient Agents; Abortion, Induced; Adult; Drug Administration Schedule; Drug Therapy, Combination; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pregnancy; Treatment Outcome | 2005 |
A pilot study of mifepristone and misoprostol administered at the same time for abortion up to 49 days gestation.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Adult; Drug Combinations; Female; Humans; Mifepristone; Misoprostol; Pilot Projects; Pregnancy; Pregnancy Trimester, First; Time Factors | 2005 |
A randomized trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion at 13-20 weeks gestation.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Sublingual; Adult; Analgesics; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Pregnancy Trimester, First; Pregnancy Trimester, Second; Treatment Outcome | 2005 |
[The efficacy and acceptability of mifepristone medical abortion with home administration misoprostol provided by private providers linked with the hospital: a prospective study of 433 patients].
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Female; Gestational Age; Hospitals; Humans; Mifepristone; Misoprostol; Pregnancy; Prospective Studies; Self Administration; Treatment Outcome | 2005 |
A pilot study of mifepristone and misoprostol administered at the same time for abortion in women with gestation from 50 to 63 days.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adult; Female; Gestational Age; Humans; Menstruation-Inducing Agents; Mifepristone; Misoprostol; Pilot Projects; Pregnancy; Time Factors | 2005 |
A prospective randomized comparison of sublingual and oral misoprostol when combined with mifepristone for medical abortion at 12-20 weeks gestation.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Administration, Oral; Administration, Sublingual; Adult; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Prospective Studies | 2005 |
A randomised controlled trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion up to 13 weeks of gestation.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Administration, Sublingual; Adolescent; Adult; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Pregnancy Trimester, First; Treatment Outcome | 2005 |
The effect of non-steroidal anti-inflammatory drugs on medical abortion with mifepristone and misoprostol at 13-22 weeks gestation.
Topics: Abdominal Pain; Abortifacient Agents, Nonsteroidal; Abortion, Induced; Acetaminophen; Administration, Intravaginal; Adult; Anti-Inflammatory Agents, Non-Steroidal; Codeine; Diclofenac; Drug Therapy, Combination; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Parity; Pregnancy; Pregnancy Trimester, Second | 2005 |
Evaluation of the efficacy of mifepristone/misoprostol and methotrexate/misoprostol for medical abortion.
Topics: Abortifacient Agents; Abortion, Induced; Adult; Chi-Square Distribution; Drug Therapy, Combination; Female; Humans; Methotrexate; Mifepristone; Misoprostol; Pregnancy; Prospective Studies; Treatment Outcome | 2005 |
Randomised controlled trial comparing efficacy of same day administration of mifepristone and misoprostol for termination of pregnancy with the standard 36- to 48-hour protocol.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Oral; Adolescent; Adult; Clinical Protocols; Female; Humans; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Treatment Outcome; Uterine Hemorrhage | 2005 |
Comparison or oral versus vaginal misoprostol & continued use of misoprostol after mifepristone for early medical abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Adult; Double-Blind Method; Female; Hemorrhage; Humans; Mifepristone; Misoprostol; Pregnancy; Time Factors | 2005 |
Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Buccal; Administration, Intravaginal; Adolescent; Adult; Chi-Square Distribution; Female; Gestational Age; Humans; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Pregnancy Outcome; Prospective Studies | 2005 |
Preference and acceptability of oral versus vaginal administration of misoprostol in medical abortion with mifepristone.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Oral; Administration, Topical; Analgesics; Female; Humans; Mifepristone; Misoprostol; Nausea; Pain; Patient Acceptance of Health Care; Patient Satisfaction; Pregnancy; Uterine Hemorrhage; Vagina; Vomiting | 2005 |
Home use of two doses of misoprostol after mifepristone for medical abortion: a pilot study in Sweden and France.
Topics: Abortifacient Agents; Abortion, Induced; Adult; Female; France; Humans; Middle Aged; Mifepristone; Misoprostol; Patient Satisfaction; Pilot Projects; Pregnancy; Sweden | 2005 |
Bleeding after medication-induced termination of pregnancy with two dosing schedules of mifepristone and misoprostol.
Topics: Abortifacient Agents; Abortion, Induced; Adult; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Parity; Pregnancy; Time Factors; Uterine Hemorrhage | 2006 |
Regimens of misoprostol with mifepristone for early medical abortion: a randomised trial.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Female; Humans; Mifepristone; Misoprostol; Pain; Patient Satisfaction; Pregnancy; Treatment Outcome; Uterine Hemorrhage | 2006 |
A randomized study comparing efficacy and patient satisfaction in medical or surgical treatment of miscarriage.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Spontaneous; Adult; Female; Humans; Incidence; Infections; Mifepristone; Misoprostol; Pain; Patient Satisfaction; Pregnancy; Pregnancy Trimester, First; Treatment Outcome; Vacuum Curettage | 2006 |
A randomized prospective study of misoprostol or mifepristone followed by misoprostol when needed for the treatment of women with early pregnancy failure.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Abortion, Missed; Adult; Drug Combinations; Female; Hormone Antagonists; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Outcome; Treatment Outcome | 2006 |
Mifepristone and misoprostol for the treatment of early pregnancy failure: a pilot clinical trial.
Topics: Abortifacient Agents; Abortion, Induced; Adolescent; Adult; Female; Fetal Death; Humans; Mifepristone; Misoprostol; Patient Satisfaction; Pilot Projects; Pregnancy; Treatment Outcome | 2006 |
Use of mifepristone and sublingual misoprostol for early medical abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Sublingual; Adolescent; Adult; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First | 2006 |
Concurrent use of mifepristone and misoprostol for early medical abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First | 2006 |
Are two doses of misoprostol after mifepristone for early abortion better than one?
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Amenorrhea; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Treatment Outcome | 2007 |
Predictors of acceptability of medication abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adult; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pain; Parity; Patient Acceptance of Health Care; Pregnancy; Treatment Failure; Uterine Hemorrhage | 2007 |
Vaginal vs. sublingual misoprostol with mifepristone for cervical priming in second-trimester abortion by dilation and evacuation: a randomized clinical trial.
Topics: Abortifacient Agents; Abortion, Induced; Administration, Intravaginal; Administration, Sublingual; Dilatation and Curettage; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Pregnancy Trimester, Second; Prospective Studies; Treatment Outcome | 2007 |
Randomised controlled trial comparing the efficacy of same-day administration of mifepristone and misoprostol for termination of pregnancy with the standard 36 to 48 hour protocol.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Adult; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Treatment Outcome | 2007 |
Mifepristone and misoprostol administered simultaneously versus 24 hours apart for abortion: a randomized controlled trial.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Treatment Outcome | 2007 |
Mifepristone followed in 24 hours to 48 hours by misoprostol for late first-trimester abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Prospective Studies; Treatment Outcome | 2007 |
Oral mifepristone and buccal misoprostol administered simultaneously for abortion: a pilot study.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Buccal; Adolescent; Adult; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Patient Satisfaction; Pilot Projects; Time Factors | 2007 |
Mifepristone versus laminaria: a randomized controlled trial of cervical ripening in midtrimester termination.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Cervical Ripening; Female; Humans; Labor, Induced; Laminaria; Mifepristone; Misoprostol; Pain; Pregnancy; Pregnancy Trimester, Second; Time Factors | 2007 |
Termination of early pregnancy using flexible, low-dose mifepristone-misoprostol regimens.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Therapeutic; Administration, Intravaginal; Adolescent; Adult; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Treatment Outcome | 2007 |
Efficacy of simultaneous use of mifepristone and misoprostol for early abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Abortion, Spontaneous; Adolescent; Adult; Drug Administration Schedule; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Oxytocics; Parity; Pregnancy | 2008 |
Medical abortion outcomes after a second dose of misoprostol for persistent gestational sac.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Adolescent; Adult; Drug Administration Schedule; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Treatment Failure; Ultrasonography; Uterus | 2008 |
Mifepristone and misoprostol versus Dilapan and sulprostone for second trimester termination of pregnancy.
Topics: Abortifacient Agents; Abortion, Induced; Adult; Dinoprostone; Drug Therapy, Combination; Female; Humans; Length of Stay; Mifepristone; Misoprostol; Polymers; Pregnancy; Pregnancy Trimester, Second; Prospective Studies | 2008 |
Two distinct oral routes of misoprostol in mifepristone medical abortion: a randomized controlled trial.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Buccal; Administration, Oral; Drug Therapy, Combination; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pregnancy; Treatment Outcome; Young Adult | 2008 |
A randomized trial to compare two dosing intervals of misoprostol following mifepristone administration in second trimester medical abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Time Factors | 2009 |
Hygroscopic dilator (Dilapan-S) and misoprostol combination for the early first-trimester termination of pregnancy: a pilot study.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Dilatation; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pain; Pilot Projects; Polymers; Pregnancy; Pregnancy Trimester, First; Wettability | 2009 |
Two-pill regimens of misoprostol after mifepristone medical abortion through 63 days' gestational age: a randomized controlled trial of sublingual and oral misoprostol.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Oral; Administration, Sublingual; Adolescent; Adult; Female; Humans; Middle Aged; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Young Adult | 2009 |
Two mifepristone doses and two intervals of misoprostol administration for termination of early pregnancy: a randomised factorial controlled equivalence trial.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Drug Administration Schedule; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Tablets; Treatment Outcome; Treatment Refusal | 2009 |
Mifepristone plus vaginal misoprostol vs vaginal misoprostol alone for medical abortion in gestation 63 days or less in Nepalese women: a quasi-randomized controlled trial.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Prospective Studies | 2009 |
Acceptability and feasibility of medical abortion in Nepal.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Administration, Oral; Adolescent; Adult; Drug Therapy, Combination; Family Planning Services; Female; Hospitals, Teaching; Humans; Middle Aged; Mifepristone; Misoprostol; Nepal; Pregnancy; Prospective Studies; Self Administration; Treatment Outcome; Young Adult | 2009 |
Treating miscarriages: a randomised study of cost-effectiveness in medical or surgical choice.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Spontaneous; Adolescent; Adult; Cost-Benefit Analysis; Female; Hospital Costs; Humans; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Prospective Studies; Young Adult | 2009 |
Sublingual misoprostol for first trimester termination of pregnancy.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Administration, Sublingual; Adult; Female; Hematocrit; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Prospective Studies | 2010 |
Feasibility, efficacy, safety, and acceptability of mifepristone-misoprostol for medical abortion in the Democratic People's Republic of Korea.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Oral; Administration, Sublingual; Adult; Democratic People's Republic of Korea; Drug Therapy, Combination; Feasibility Studies; Female; Humans; Mifepristone; Misoprostol; Patient Satisfaction; Pilot Projects; Pregnancy; Rural Health Services; Urban Health Services | 2010 |
Two medical abortion regimens for late first-trimester termination of pregnancy: a prospective randomized trial.
Topics: Abdominal Pain; Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Prospective Studies; Young Adult | 2010 |
Mifepristone combined with misoprostol versus intra-amniotic injection of ethacridine lactate for the termination of second trimester pregnancy: a prospective, open-label, randomized clinical trial.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Chi-Square Distribution; China; Ethacridine; Female; Humans; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Prospective Studies; Young Adult | 2010 |
Misoprostol dose and route after mifepristone for early medical abortion: a randomised controlled noninferiority trial.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Sublingual; Adult; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Pregnancy Trimester, First; Treatment Outcome | 2010 |
Randomized trial of oral versus sublingual misoprostol 24 h after mifepristone for medical abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Sublingual; Adult; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Prospective Studies; Young Adult | 2011 |
Comparison of two dose regimens of misoprostol for second-trimester pregnancy termination.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Surveys and Questionnaires | 2010 |
One- and two-day mifepristone-misoprostol intervals for second trimester termination of pregnancy between 13 and 16 weeks of gestation.
Topics: Abortifacient Agents; Abortion, Incomplete; Abortion, Induced; Adolescent; Adult; Body Mass Index; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Prospective Studies; Young Adult | 2010 |
Comparing medical versus surgical termination of pregnancy at 13-20 weeks of gestation: a randomised controlled trial.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Aged; Aged, 80 and over; Dilatation and Curettage; Female; Humans; Middle Aged; Mifepristone; Misoprostol; Pain; Patient Satisfaction; Pregnancy; Pregnancy Trimester, First; Pregnancy Trimester, Second; Prospective Studies; Treatment Outcome; Vacuum Extraction, Obstetrical | 2010 |
Comparison of 400 mcg buccal and 400 mcg sublingual misoprostol after mifepristone medical abortion through 63 days' LMP: a randomized controlled trial.
Topics: Abortifacient Agents; Abortion, Induced; Administration, Buccal; Administration, Sublingual; Adolescent; Adult; Female; Humans; Menstrual Cycle; Mifepristone; Misoprostol; Patient Satisfaction; Treatment Outcome | 2010 |
Alternatives to routine ultrasound for eligibility assessment prior to early termination of pregnancy with mifepristone-misoprostol.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Drug Therapy, Combination; Feasibility Studies; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Physical Examination; Pregnancy; Prospective Studies; Self Administration; Ultrasonography, Prenatal | 2011 |
A pilot study on the use of letrozole with either misoprostol or mifepristone for termination of pregnancy up to 63 days.
Topics: Abortifacient Agents; Abortion, Induced; Adolescent; Adult; Estradiol; Female; Humans; Hydrocortisone; Letrozole; Mifepristone; Misoprostol; Nitriles; Pilot Projects; Pregnancy; Pregnancy Trimester, First; Progesterone; Triazoles; Young Adult | 2011 |
Simultaneous administration of mifepristone and misoprostol for early termination of pregnancy: a randomized controlled trial.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Eugenic; Administration, Intravaginal; Administration, Oral; Adult; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy | 2011 |
Can midlevel health-care providers administer early medical abortion as safely and effectively as doctors? A randomised controlled equivalence trial in Nepal.
Topics: Abortifacient Agents; Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Female; Hospitals, District; Hospitals, Rural; Humans; Male; Middle Aged; Mifepristone; Misoprostol; Nepal; Nurse Midwives; Nurse Practitioners; Nurses; Physician Assistants; Physicians; Pregnancy; Pregnancy Trimester, First; Risk Assessment; Therapeutic Equivalency | 2011 |
Comparing two early medical abortion regimens: mifepristone+misoprostol vs. misoprostol alone.
Topics: Abortifacient Agents; Abortion, Induced; Adolescent; Adult; Female; Humans; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Vietnam; Young Adult | 2011 |
Simultaneous use of mifepristone and misoprostol for early pregnancy termination.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Adult; Drug Therapy, Combination; Female; Humans; Middle Aged; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Pregnancy Trimester, First; Treatment Outcome | 2011 |
One- and two-day dosing intervals between mifepristone and misoprostol in second trimester medical termination of pregnancy--a randomized trial.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Time Factors; Treatment Outcome | 2011 |
Ovulation resumption after medical abortion with mifepristone and misoprostol.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Chorionic Gonadotropin; Female; Humans; Mifepristone; Misoprostol; Ovulation; Pregnancy; Progesterone; Prospective Studies; Regression Analysis; Young Adult | 2011 |
Mifepristone and misoprostol compared with misoprostol alone for second-trimester abortion: a randomized controlled trial.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Buccal; Adolescent; Adult; Double-Blind Method; Female; Humans; Mifepristone; Misoprostol; Pain Measurement; Pregnancy; Pregnancy Trimester, Second; Time Factors; Treatment Outcome; Young Adult | 2011 |
Efficacy and safety of mifepristone and buccal misoprostol versus buccal misoprostol alone for medical abortion.
Topics: Abortifacient Agents; Abortion, Induced; Abortion, Legal; Administration, Oral; Adult; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pregnancy; Treatment Outcome; Young Adult | 2012 |
Comparison of mifepristone combination with misoprostol and misoprostol alone in the management of intrauterine death: condensation - misoprostol and mifepristone combination is more effective than misoprostol alone in the management of intrauterine death
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Drug Therapy, Combination; Female; Fetal Death; Gestational Age; Humans; Mifepristone; Misoprostol; Pregnancy; Prospective Studies; Treatment Outcome; Young Adult | 2011 |
Risk factors of surgical evacuation following second-trimester medical termination of pregnancy.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Eugenic; Abortion, Therapeutic; Adolescent; Adult; Dilatation and Curettage; Dose-Response Relationship, Drug; Female; Finland; Follow-Up Studies; Hospitals, University; Humans; Maternal Age; Mifepristone; Misoprostol; Placenta, Retained; Pregnancy; Pregnancy Trimester, Second; Risk Factors; Time Factors; Young Adult | 2012 |
Pre-emptive effect of ibuprofen versus placebo on pain relief and success rates of medical abortion: a double-blind, randomized, controlled study.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Oral; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Chi-Square Distribution; Double-Blind Method; Drug Administration Schedule; Female; Hospitals, University; Humans; Ibuprofen; Israel; Logistic Models; Middle Aged; Mifepristone; Misoprostol; Odds Ratio; Pain; Pain Measurement; Placebos; Pregnancy; Prospective Studies; Surveys and Questionnaires; Time Factors; Treatment Outcome; Young Adult | 2012 |
A randomized controlled trial of different buccal misoprostol doses in mifepristone medical abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Buccal; Adolescent; Adult; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Middle Aged; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Treatment Outcome | 2012 |
Immediate versus delayed medical treatment for first-trimester miscarriage: a randomized trial.
Topics: Abortifacient Agents; Abortion, Spontaneous; Adult; Female; Hemorrhage; Humans; Infections; Mifepristone; Misoprostol; Pain; Pregnancy; Pregnancy Trimester, First; Treatment Outcome; Vacuum Curettage | 2012 |
Comparison of misoprostol-only and combined mifepristone-misoprostol regimens for home-based early medical abortion in Tunisia and Vietnam.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Double-Blind Method; Female; Humans; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Tunisia; Vietnam; Young Adult | 2012 |
Can at-home semi-quantitative pregnancy tests serve as a replacement for clinical follow-up of medical abortion? A US study.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Chorionic Gonadotropin; Cohort Studies; Feasibility Studies; Female; Health Knowledge, Attitudes, Practice; Humans; Lost to Follow-Up; Middle Aged; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Pregnancy Tests; Pregnancy, Unwanted; Self Care; United States; Young Adult | 2012 |
Early medical abortion using low-dose mifepristone followed by buccal misoprostol: a large Australian observational study.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Buccal; Administration, Oral; Adolescent; Adult; Australia; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Young Adult | 2012 |
Extending outpatient medical abortion services through 70 days of gestational age.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Adolescent; Adult; Ambulatory Care Facilities; Drug Therapy, Combination; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Outpatients; Patient Acceptance of Health Care; Pregnancy; Prospective Studies; Time Factors; Treatment Outcome; Young Adult | 2012 |
A randomized clinical trial comparing the short-term side effects of sublingual and buccal routes of misoprostol administration for medical abortions up to 63 days' gestation.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Buccal; Administration, Sublingual; Adult; Double-Blind Method; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pregnancy; Young Adult | 2013 |
Early versus delayed insertion of intrauterine contraception after medical abortion - a randomized controlled trial.
Topics: Abortifacient Agents; Abortion, Induced; Adult; Female; Humans; Intrauterine Device Expulsion; Intrauterine Devices; Mifepristone; Misoprostol; Time Factors; Treatment Outcome | 2012 |
[The lowest dosages of mifepristone and misoprostol to terminate ultra-early pregnancy].
Topics: Abdominal Pain; Abortifacient Agents; Abortion, Induced; Administration, Oral; Adult; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Mifepristone; Misoprostol; Nausea; Patient Satisfaction; Pregnancy; Treatment Outcome; Uterine Hemorrhage; Young Adult | 2012 |
Efficacy and acceptability of early mifepristone-misoprostol medical abortion in Ukraine: results of two clinical trials.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Sublingual; Adult; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Mifepristone; Misoprostol; Patient Acceptance of Health Care; Pregnancy; Prospective Studies; Self Administration; Ukraine; Young Adult | 2013 |
Efficacy of misoprostol administration 24 hours after mifepristone for termination of early pregnancy.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Case-Control Studies; Drug Administration Schedule; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Young Adult | 2011 |
Prophylactic compared with therapeutic ibuprofen analgesia in first-trimester medical abortion: a randomized controlled trial.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Analgesia; Analgesics, Non-Narcotic; Female; Humans; Ibuprofen; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Young Adult | 2013 |
Mifepristone followed by misoprostol or oxytocin for second-trimester abortion: a randomized controlled trial.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Female; Humans; Mifepristone; Misoprostol; Oxytocics; Oxytocin; Pregnancy; Pregnancy Trimester, Second; Prospective Studies; Time Factors; Young Adult | 2013 |
Dosing interval of 24hours versus 48hours between mifepristone and misoprostol administration for mid-trimester termination of pregnancy.
Topics: Abortifacient Agents; Abortion, Induced; Adult; Drug Administration Schedule; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Prospective Studies; Treatment Outcome; Young Adult | 2014 |
Can ultrasound predict IUD expulsion after medical abortion?
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Endometrium; Female; Humans; Intrauterine Device Expulsion; Intrauterine Devices, Copper; Mifepristone; Misoprostol; Predictive Value of Tests; ROC Curve; Time Factors; Ultrasonography; Young Adult | 2014 |
Mifepristone and oral, vaginal, or sublingual misoprostol for second-trimester abortion: a randomized controlled trial.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Administration, Sublingual; Adult; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Time Factors | 2014 |
Efficacy and acceptability of a mifepristone-misoprostol combined regimen for early induced abortion among women in Mexico City.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Female; Humans; Mexico; Middle Aged; Mifepristone; Misoprostol; Patient Acceptance of Health Care; Prospective Studies; Treatment Outcome; Urban Population; Young Adult | 2014 |
Same-day and delayed reports of pain intensity in second-trimester medical termination of pregnancy: a brief report.
Topics: Abortion, Induced; Adult; Female; Humans; Mifepristone; Misoprostol; Pain Measurement; Pain, Postoperative; Pregnancy; Pregnancy Trimester, Second; Prospective Studies | 2014 |
Simplified follow-up after medical abortion using a low-sensitivity urinary pregnancy test and a pictorial instruction sheet in Rajasthan, India--study protocol and intervention adaptation of a randomised control trial.
Topics: Abortifacient Agents; Abortion, Induced; Adolescent; Adult; Aftercare; Female; Home Care Services; Humans; India; Mifepristone; Misoprostol; Patient Education as Topic; Pregnancy; Pregnancy Tests; Young Adult | 2014 |
Effectiveness and Safety of Lower Doses of Mifepristone Combined With Misoprostol for the Termination of Ultra-Early Pregnancy: A Dose-Ranging Randomized Controlled Trial.
Topics: Abortifacient Agents; Abortion, Induced; Administration, Oral; Adult; China; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Time Factors; Treatment Outcome; Young Adult | 2015 |
[Association of mifepristone and misoprostol for the medical management of early pregnancy failure].
Topics: Abortion, Spontaneous; Adult; Drug Therapy, Combination; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Oxytocics; Pregnancy; Pregnancy Trimester, First; Retrospective Studies; Treatment Outcome | 2014 |
Adjunct mifepristone for cervical preparation prior to dilation and evacuation: a randomized trial.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Combined Modality Therapy; Dilatation; Female; Humans; Mifepristone; Misoprostol; Operative Time; Pain, Postoperative; Pregnancy; Pregnancy Trimester, Second; Young Adult | 2015 |
A double-blind randomized controlled trial of mifepristone or placebo before buccal misoprostol for abortion at 14-21 weeks of pregnancy.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Double-Blind Method; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Time Factors; Treatment Outcome; Tunisia; Young Adult | 2015 |
Early versus late misoprostol administration after mifepristone for medical abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Drug Administration Schedule; Female; Fetal Movement; Gestational Age; Humans; Mifepristone; Misoprostol; Outcome Assessment, Health Care; Pregnancy; Prospective Studies; Uterus | 2015 |
Minimal effective dose of mifepristone for medical abortion.
Topics: Abortifacient Agents; Abortion, Induced; Adult; Dose-Response Relationship, Drug; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Prospective Studies; Young Adult | 2014 |
A prospective, non-randomized study of home use of mifepristone for medical abortion in the U.S.
Topics: Abortifacient Agents; Abortion, Induced; Adolescent; Adult; Choice Behavior; Female; Humans; Mifepristone; Misoprostol; Patient Acceptance of Health Care; Pregnancy; Prospective Studies; Self Administration; United States; Young Adult | 2015 |
Cervical Preparation Before Dilation and Evacuation Using Adjunctive Misoprostol or Mifepristone Compared With Overnight Osmotic Dilators Alone: A Randomized Controlled Trial.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adult; Combined Modality Therapy; Dilatation and Curettage; Double-Blind Method; Female; Follow-Up Studies; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Outcome; Pregnancy Trimester, Second; Preoperative Care; Prospective Studies; Risk Assessment; Surgical Instruments; Time Factors; Treatment Outcome; Young Adult | 2015 |
Predictors of uterine evacuation following early medical abortion with mifepristone and misoprostol.
Topics: Abortifacient Agents; Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Incomplete; Abortion, Induced; Adult; Age Factors; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Obesity; Parity; Pregnancy; Suction; Uterus | 2016 |
[Efficacy and safety of mifepristone combined with misoprostol for termination of pregnancy between 8 and 16 weeks of gestation].
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Pregnancy Trimester, Second; Treatment Outcome | 2015 |
Mifepristone and misoprostol compared with misoprostol alone for induction of labor in intrauterine fetal death: A randomized trial.
Topics: Adult; Double-Blind Method; Female; Fetal Death; Humans; Labor, Induced; Mifepristone; Misoprostol; Pregnancy | 2015 |
A randomized controlled trial evaluating same-day mifepristone and misoprostol compared to misoprostol alone for cervical preparation prior to second-trimester surgical abortion.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Female; Gestational Age; Humans; Labor Stage, First; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; United States; Young Adult | 2016 |
Randomized trial assessing home use of two pregnancy tests for determining early medical abortion outcomes at 3, 7 and 14days after mifepristone.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adolescent; Adult; Chorionic Gonadotropin; Female; Humans; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Pregnancy Tests; Ultrasonography; Vietnam; Young Adult | 2016 |
Mifepristone and misoprostol for cervical ripening in surgical abortion between 12 and 14 weeks of gestation: a randomized controlled trial.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Cervical Ripening; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Treatment Outcome; Young Adult | 2016 |
Self-administered multi-level pregnancy tests in simplified follow-up of medical abortion in Tunisia.
Topics: Abortion, Induced; Adolescent; Adult; Aftercare; Female; Gestational Age; Health Education; Humans; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Pregnancy Tests; Prospective Studies; Self Administration; Tunisia | 2016 |
Physical symptoms and emotional responses among women undergoing induced abortion protocols during the second trimester.
Topics: Abortifacient Agents; Abortion, Induced; Administration, Intravaginal; Administration, Intravenous; Administration, Oral; Adult; Diarrhea; Emotions; Female; Humans; Israel; Mifepristone; Misoprostol; Oxytocin; Pregnancy; Pregnancy Trimester, Second; Prospective Studies; Psychiatric Status Rating Scales; Shivering | 2016 |
Efficacy, Safety, and Acceptability of Low-Dose Mifepristone and Self-Administered Misoprostol for Ultra-Early Medical Abortion: A Randomized Controlled Trial.
Topics: Abortifacient Agents; Abortion, Induced; Administration, Oral; Adult; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Self Administration; Treatment Outcome; Young Adult | 2017 |
Two prophylactic medication approaches in addition to a pain control regimen for early medical abortion < 63 days' gestation with mifepristone and misoprostol: study protocol for a randomized, controlled trial.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Analgesics, Non-Narcotic; Analgesics, Opioid; Antiemetics; Clinical Protocols; Double-Blind Method; Drug Administration Schedule; Female; Humans; Ibuprofen; Metoclopramide; Mifepristone; Misoprostol; Pain; Pain Management; Postoperative Nausea and Vomiting; Pregnancy; Research Design; Tramadol; Young Adult | 2016 |
Simultaneous Administration Compared With a 24-Hour Mifepristone-Misoprostol Interval in Second-Trimester Abortion: A Randomized Controlled Trial.
Topics: Abortifacient Agents; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Double-Blind Method; Female; Humans; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Time Factors; Treatment Outcome | 2016 |
Efficacy of concurrent administration of mifepristone and misoprostol for termination of pregnancy.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Drug Administration Schedule; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Young Adult | 2017 |
Fast-track vs. delayed insertion of the levonorgestrel-releasing intrauterine system after early medical abortion - a randomized trial.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adult; Feasibility Studies; Female; Finland; Follow-Up Studies; Humans; Intention to Treat Analysis; Intrauterine Device Expulsion; Intrauterine Devices, Medicated; Mifepristone; Misoprostol; Patient Dropouts; Pilot Projects; Pregnancy; Pregnancy Trimester, First; Time Factors; Uterine Hemorrhage; Young Adult | 2017 |
Preoperative effects of mifepristone for dilation and evacuation after 19 weeks of gestation: a randomised controlled trial.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adult; Cervix Uteri; Combined Modality Therapy; Dilatation; Double-Blind Method; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Treatment Outcome | 2017 |
Mifepristone Pretreatment for the Medical Management of Early Pregnancy Loss.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Spontaneous; Administration, Intravaginal; Administration, Oral; Adult; Drug Therapy, Combination; Embryo, Mammalian; Female; Fetal Death; Gestational Sac; Hemorrhage; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Ultrasonography | 2018 |
Safety, Efficacy and Acceptability of Early First Trimester Abortion using Oral Mifepristone and Sublingual Misoprostol.
Topics: Abortion, Induced; Adult; Drug Administration Routes; Female; Humans; Mifepristone; Misoprostol; Nepal; Patient Satisfaction; Pregnancy; Pregnancy Trimester, First; Prospective Studies | 2018 |
Feasibility of a hospital outpatient day procedure for medication abortion at 13-18 weeks gestation: Findings from Nepal
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Ambulatory Care; Feasibility Studies; Female; Gestational Age; Humans; Middle Aged; Mifepristone; Misoprostol; Nepal; Pregnancy; Pregnancy Trimester, First; Pregnancy Trimester, Second; Prospective Studies; Young Adult | 2019 |
The use of an osmotic dilator for induction of miscarriage in patients with the second trimester missed miscarriage.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Abortion, Spontaneous; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second | 2021 |
Mifepristone and misoprostol versus misoprostol alone for uterine evacuation after early pregnancy failure: study protocol for a randomized double blinded placebo-controlled comparison (Triple M Trial).
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Incomplete; Adolescent; Adult; Cost-Benefit Analysis; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Multicenter Studies as Topic; Patient Satisfaction; Pregnancy; Pregnancy Trimester, First; Prospective Studies; Randomized Controlled Trials as Topic; Ultrasonography; Watchful Waiting; Young Adult | 2019 |
A non-inferiority study of outpatient mifepristone-misoprostol medical abortion at 64-70 days and 71-77 days of gestation.
Topics: Abortifacient Agents; Adult; Ambulatory Care; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Treatment Outcome; Ultrasonography; Young Adult | 2020 |
Mifepristone pretreatment followed by misoprostol 200 mcg buccal for the medical management of intrauterine fetal death at 14-28 weeks: A randomized, placebo-controlled, double blind trial.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Double-Blind Method; Female; Fetal Death; Humans; Mifepristone; Misoprostol; Placenta; Pregnancy | 2020 |
Cost-effectiveness of Mifepristone Pretreatment for the Medical Management of Nonviable Early Pregnancy: Secondary Analysis of a Randomized Clinical Trial.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Cost-Benefit Analysis; Embryo Loss; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Prospective Studies | 2020 |
Management of early pregnancy loss with mifepristone and misoprostol: clinical predictors of treatment success from a randomized trial.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Spontaneous; Adult; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Parity; Pregnancy; Treatment Outcome; Uterine Hemorrhage | 2020 |
Transcutaneous Electrical Nerve Stimulation to Reduce Pain With Medication Abortion: A Randomized Controlled Trial.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Female; Humans; Mifepristone; Misoprostol; Pain, Procedural; Self Care; Transcutaneous Electric Nerve Stimulation; Young Adult | 2021 |
Two prophylactic pain management regimens for medical abortion ≤63 days' gestation with mifepristone and misoprostol: A multicenter, randomized, placebo-controlled trial.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Pain; Pain Management; Pregnancy | 2021 |
Timing and efficacy of mifepristone pretreatment for medical management of early pregnancy loss.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Abortion, Spontaneous; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Treatment Outcome | 2021 |
Pretreatment With Mifepristone Compared With Misoprostol Alone for Delivery After Fetal Death Between 14 and 28 Weeks of Gestation: A Randomized Controlled Trial.
Topics: Abortifacient Agents; Abortion, Induced; Adult; Double-Blind Method; Female; Fetal Death; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Prospective Studies; Treatment Outcome; Young Adult | 2021 |
The effect of mifepristone pretreatment on bleeding and pain during medical management of early pregnancy loss.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Abortion, Spontaneous; Female; Humans; Mifepristone; Misoprostol; Pain; Pregnancy | 2021 |
Pain Associated With Cervical Priming for First-Trimester Surgical Abortion: A Randomized Controlled Trial.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Anesthesia, Obstetrical; Female; Humans; Mifepristone; Misoprostol; Pain Measurement; Pain, Postoperative; Pain, Procedural; Patient Satisfaction; Pregnancy; Pregnancy Trimester, First; Single-Blind Method; Young Adult | 2021 |
Cost-effectiveness of mifepristone and misoprostol versus misoprostol alone for the management of missed miscarriage: an economic evaluation based on the MifeMiso trial.
Topics: Abortifacient Agents; Abortion, Missed; Adolescent; Adult; Cost-Benefit Analysis; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Young Adult | 2021 |
Comparison of two home pregnancy tests for self-confirmation of medication abortion status: A randomized trial.
Topics: Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Pilot Projects; Pregnancy; Pregnancy Tests | 2021 |
Mifepristone prior to osmotic dilators for dilation and evacuation cervical preparation: A randomized, double-blind, placebo-controlled pilot study.
Topics: Abortion, Induced; COVID-19; Dilatation; Double-Blind Method; Female; Humans; Mifepristone; Misoprostol; Pilot Projects; Pregnancy; Pregnancy Trimester, Second; SARS-CoV-2 | 2022 |
Mifepristone and misoprostol versus placebo and misoprostol for resolution of miscarriage in women diagnosed with missed miscarriage: the MifeMiso RCT.
Topics: Abortion, Spontaneous; Cost-Benefit Analysis; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Technology Assessment, Biomedical | 2021 |
Prospective open-label non-inferiority randomised controlled trial comparing letrozole and mifepristone pretreatment in medical management of first trimester missed miscarriage: study protocol.
Topics: Abortion, Induced; Abortion, Spontaneous; Female; Humans; Letrozole; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Prospective Studies; Randomized Controlled Trials as Topic; Treatment Outcome | 2022 |
The experience of pain in real-time during medication abortion.
Topics: Abortion, Induced; Acetaminophen; Analgesics; Analgesics, Opioid; Female; Humans; Ibuprofen; Mifepristone; Misoprostol; Oxycodone; Pain; Pregnancy | 2022 |
Medical management of early pregnancy loss is cost-effective compared with office uterine aspiration.
Topics: Abortion, Spontaneous; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 2022 |
Patient-controlled intravenous versus on-demand oral, intramuscular or mcs intravenous administration of oxycodone during medical induced abortion from 64 to 128 days of Gestation: A randomized controlled trial.
Topics: Abortion, Induced; Administration, Oral; Analgesia, Patient-Controlled; Analgesics; Female; Humans; Infant; Infusions, Intravenous; Mifepristone; Misoprostol; Oxycodone; Pain; Pregnancy; Prospective Studies | 2022 |
A telemedicine model for abortion in South Africa: a randomised, controlled, non-inferiority trial.
Topics: Abortion, Induced; Abortion, Spontaneous; Female; Humans; Mifepristone; Misoprostol; Pregnancy; South Africa; Telemedicine | 2022 |
The role of mifepristone on first trimester miscarriage treatment - A double-blind randomized controlled trial - MiFirsT.
Topics: Abortion, Missed; Abortion, Spontaneous; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First | 2023 |
505 other study(ies) available for mifepristone and misoprostol
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Misoprostol, mifepristone, and abortion.
Topics: Abortion, Induced; Developing Countries; Drug Combinations; Family Planning Services; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 1992 |
Updating RU 486 development.
Topics: Abortifacient Agents, Steroidal; Cultural Diversity; Drug Approval; Drug Synergism; Female; France; Government Regulation; Humans; Internationality; Mifepristone; Misoprostol; Pregnant Women; Risk Assessment; Therapeutic Human Experimentation | 1992 |
Induction of abortion with mifepristone and misoprostol in early pregnancy.
Topics: Abortion, Induced; Adolescent; Adult; Drug Administration Schedule; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Parity; Pregnancy | 1992 |
Misoprostol and legal medical abortion.
Topics: Abortion, Legal; Clinical Trials as Topic; Costs and Cost Analysis; Developing Countries; Drug Therapy, Combination; Female; Humans; Internationality; Mifepristone; Misoprostol; Pregnancy; Pregnant Women; Risk Assessment | 1991 |
Early abortion induction by a combination of mifepristone and oral misoprostol.
Topics: Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 1995 |
Mid-trimester termination for fetal abnormality: advantages of a new regimen using mifepristone and misoprostol.
Topics: Abortion, Induced; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Female; Fetus; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second | 1995 |
Non-surgical abortion: who's for methotrexate?
Topics: Abortifacient Agents; Abortion, Induced; Drug-Related Side Effects and Adverse Reactions; Federal Government; Female; Government; Government Regulation; Human Experimentation; Humans; Methods; Methotrexate; Mifepristone; Misoprostol; Pharmaceutical Preparations; Physicians; Pregnancy; Pregnant Women; Professional Competence; Risk; Risk Assessment; Social Control, Formal; United Kingdom; United States; United States Food and Drug Administration | 1995 |
[Histopathology appearance of intrauterine residue after medical abortion by mifepristone and prostaglandin analogue].
Topics: Abortion, Induced; Carboprost; Dilatation and Curettage; Drug Synergism; Endometrium; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Uterine Hemorrhage | 1994 |
RU486 combined with PGE1 analog in voluntary termination of early pregnancy--a comparison of recent findings with gemeprost or misoprostol.
Topics: Abortion, Induced; Adult; Alprostadil; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Retrospective Studies; Time Factors; Uterine Hemorrhage | 1994 |
Early induction of abortion by a combination of oral mifepristone and misoprostol administered by the vaginal route.
Topics: Abortion, Induced; Administration, Oral; Adult; Diarrhea; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Time Factors; Vagina; Vomiting | 1994 |
[Treatment in miscarriage and abortion. Widened use of drugs has many advantages].
Topics: Abortion, Missed; Abortion, Spontaneous; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Receptors, Progesterone | 1994 |
[The use of sulprostone (Nalador) in the evacuation of uterine contents. Apropos of 32 cases at the Department of Gynecology, University Hospital Center, Nîmes, over 2 years (a retrospective study)].
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adolescent; Adult; Cicatrix; Contraindications; Dinoprostone; Drug Tolerance; Female; France; Gestational Age; Humans; Hydatidiform Mole; Infusions, Intravenous; Injections, Intramuscular; Injections, Intravenous; Mifepristone; Misoprostol; Polyhydramnios; Pregnancy; Retrospective Studies; Time Factors; Uterine Diseases; Uterine Neoplasms | 1993 |
[RU 486: safe and wrongfully maligned].
Topics: Abortion, Induced; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First | 1993 |
Clinical use of mifepristone (RU 486).
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Alprostadil; Dinoprostone; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 1993 |
Effect of antiprogestin, hCG and a prostaglandin analogue on human uterine contractility.
Topics: Administration, Oral; Adult; Chorionic Gonadotropin; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Menstruation; Middle Aged; Mifepristone; Misoprostol; Progesterone; Time Factors; Uterine Contraction | 1993 |
Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol.
Topics: Abortion, Induced; Administration, Oral; Adult; Female; Humans; Injections, Intramuscular; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First | 1993 |
Mifepristone (RU 486) in the United States. What does the future hold?
Topics: Abortion, Induced; Female; France; Health Policy; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; United States; United States Food and Drug Administration | 1993 |
Managing miscarriage medically.
Topics: Abortifacient Agents; Abortifacient Agents, Nonsteroidal; Abortion, Spontaneous; Dinoprostone; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 1993 |
Methotrexate and misoprostol to terminate early pregnancy.
Topics: Abortifacient Agents; Abortion, Induced; Female; Humans; Methotrexate; Mifepristone; Misoprostol; Pregnancy | 1996 |
Methotrexate and misoprostol to terminate early pregnancy.
Topics: Abortifacient Agents; Abortion, Induced; Female; Humans; Methotrexate; Mifepristone; Misoprostol; Neoplasms; Pregnancy | 1996 |
Uterine rupture during second trimester termination of pregnancy using mifepristone and a prostaglandin.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Therapeutic; Adult; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Uterine Rupture | 1996 |
Vaginal misoprostol administered at home after mifepristone (RU486) for abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Adolescent; Adult; Female; Humans; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Prospective Studies; Self Administration; United States; Uterine Hemorrhage | 1997 |
Termination of 2nd and 3rd trimester pregnancies with mifepristone and misoprostol.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Female; Humans; Mifepristone; Misoprostol; Parity; Pregnancy; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Time Factors | 1996 |
Abortion procedure.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Morals; Pregnancy | 1997 |
Mifepristone (RU486) and abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion Applicants; Abortion, Induced; Australia; Female; Humans; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy | 1997 |
[Labour induction in women at term with mifepristone and misoprostol].
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Adult; Drug Synergism; Female; Humans; Labor, Induced; Mifepristone; Misoprostol; Pregnancy | 1996 |
Pilot study on the use of a two-week course of oral misoprostol in patients after termination of pregnancy with mifepristone and misoprostol.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Adolescent; Adult; Diarrhea; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Parity; Pilot Projects; Pregnancy | 1998 |
Embryonic abnormalities at medical termination of pregnancy with mifepristone and misoprostol during first trimester: observational study.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Oral; Adolescent; Drug Combinations; Female; Fetus; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First | 1998 |
Effects of luteal phase administration of mifepristone (RU486) and prostaglandin analogue or inhibitor on endometrium in the rhesus monkey.
Topics: Animals; Contraceptives, Oral, Synthetic; Cyclooxygenase Inhibitors; Diclofenac; Drug Combinations; Endometrium; Female; Luteal Phase; Macaca mulatta; Male; Mifepristone; Misoprostol | 1998 |
Unsuccessful treatment of missed abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Missed; Female; Humans; Mifepristone; Misoprostol; Pain; Pregnancy; Uterine Hemorrhage | 1998 |
Fetal malformation and failed medical termination of pregnancy.
Topics: Abnormalities, Drug-Induced; Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Alprostadil; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Prostaglandins E, Synthetic; Risk Factors; Treatment Failure | 1998 |
Toward safe and effective medical abortion.
Topics: Abortifacient Agents; Abortion, Induced; Biomedical Research; Delivery of Health Care; Developing Countries; Female; Humans; Internationality; Legislation, Drug; Methotrexate; Mifepristone; Misoprostol; Pregnancy; Risk Assessment; Therapeutic Human Experimentation; Women's Health | 1998 |
Termination of pregnancy at 9-13 weeks' amenorrhoea with mifepristone and misoprostol.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Analgesics; Diarrhea; Female; Follow-Up Studies; Gestational Age; Humans; Mifepristone; Misoprostol; Pain; Patient Satisfaction; Pregnancy; Pregnancy Trimester, First; Uterine Hemorrhage; Vomiting | 1998 |
Mifepristone and misoprostol for termination of early pregnancy.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Clinical Trials as Topic; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Reproducibility of Results; United States | 1998 |
Antinidatory effect of luteal phase administration of mifepristone (RU486) is associated with changes in endometrial prostaglandins during the implantation window.
Topics: Animals; Cyclooxygenase Inhibitors; Diclofenac; Dinoprost; Dinoprostone; Embryo Implantation; Endometrium; Female; Hydroxyprostaglandin Dehydrogenases; Luteal Phase; Luteolytic Agents; Macaca mulatta; Male; Mifepristone; Misoprostol; Oxytocics; Prostaglandin-Endoperoxide Synthases; Prostaglandins | 1998 |
Update on early medical and surgical abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Female; Humans; Male; Methotrexate; Mifepristone; Misoprostol; Patient Selection; Pregnancy; Pregnancy Trimester, First; Vacuum Curettage | 1998 |
Mifepristone-misoprostol medical abortion: who will use it and why?
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 1998 |
Medical methods of early abortion in developing countries. Consensus statement. The Population Council.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Developing Countries; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First | 1998 |
Warning on low dose mifepristone use.
Topics: Abortion, Induced; Drug Therapy, Combination; Female; France; Humans; Legislation, Drug; Liability, Legal; Mifepristone; Misoprostol; Pregnancy | 1994 |
Providing mifepristone-misoprostol medical abortion: the view from the clinic.
Topics: Abortifacient Agents; Abortion, Induced; Adult; Attitude to Health; Female; Focus Groups; Humans; Male; Middle Aged; Mifepristone; Misoprostol; Surveys and Questionnaires; United States; Women's Health Services | 1999 |
Side effects of mifepristone-misoprostol abortion versus surgical abortion. Data from a trial in China, Cuba, and India.
Topics: Abortifacient Agents; Abortion, Induced; Abortion, Legal; Adult; China; Cuba; Drug Therapy, Combination; Female; Hemorrhage; Humans; India; Mifepristone; Misoprostol; Pain; Pregnancy | 1999 |
Medical termination of pregnancy at 63 to 83 days gestation.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Adolescent; Adult; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Prospective Studies; Treatment Outcome | 1999 |
Nonsurgical mid-trimester termination of pregnancy: a review of 500 consecutive cases.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Analgesia, Obstetrical; Female; Humans; Mifepristone; Misoprostol; Parity; Pregnancy; Pregnancy Trimester, Second; Prospective Studies; Retrospective Studies; Time Factors | 1999 |
Use of various ultrasonographic criteria to evaluate the efficacy of mifepristone and misoprostol for medical abortion.
Topics: Abortifacient Agents; Abortion, Induced; Clinical Trials as Topic; Crown-Rump Length; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Predictive Value of Tests; Pregnancy; Reference Values; Ultrasonography, Prenatal | 1999 |
Mifepristone-misoprostol medical abortion: home administration of misoprostol in Guadeloupe.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Female; Gestational Age; Guadeloupe; Humans; Mifepristone; Misoprostol; Patient Compliance; Pregnancy; Prospective Studies; Self Administration | 1999 |
Uterine anomalies and failed surgical termination of pregnancy: the role of routine preoperative transvaginal sonography.
Topics: Abortifacient Agents; Abortion, Legal; Adult; Female; Humans; Mass Screening; Mifepristone; Misoprostol; Pregnancy; Preoperative Care; Treatment Failure; Ultrasonography, Prenatal; Uterus; Vacuum Curettage; Vagina | 1999 |
Predictors of analgesia use during supervised medical abortion. The Mifepristone Clinical Trials Group.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Analgesia; Analgesics, Opioid; Community Health Services; Ethnicity; Family Planning Services; Female; Gestational Age; Hospitals, University; Humans; Logistic Models; Mifepristone; Misoprostol; Parity; Pregnancy | 2000 |
Research on regimens for early medical abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Female; Humans; Methotrexate; Mifepristone; Misoprostol; Pregnancy; Prostaglandins; Women's Health | 2000 |
A comparison of the Abortion Rights Mobilization and Population Council trials.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Clinical Trials as Topic; Female; Humans; Middle Aged; Mifepristone; Misoprostol; Nausea; Office Visits; Pregnancy; Vomiting | 2000 |
Is medical abortion acceptable to all American women: the impact of sociodemographic characteristics on the acceptability of mifepristone-misoprostol abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Attitude to Health; Demography; Educational Status; Ethnicity; Female; Health Care Surveys; Humans; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Social Class | 2000 |
Early medical abortion in India: three studies and their implications for abortion services.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Feasibility Studies; Female; Health Services Accessibility; Humans; India; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Rural Population; Urban Population | 2000 |
Medical abortion in China.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Incomplete; Abortion, Induced; Abortion, Legal; China; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Public Opinion; Vacuum Curettage | 2000 |
Acceptability of suction curettage and mifepristone abortion in the United States: a prospective comparison study.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Cohort Studies; Curettage; Female; Humans; Mifepristone; Misoprostol; Patient Acceptance of Health Care; Pregnancy; Prospective Studies; Suction; Treatment Failure; United States | 2000 |
Mifepristone (RU 486).
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Administration, Oral; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol | 2000 |
Termination of early pregnancy with a reduced oral dose of mifepristone and vaginal misoprostol.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Legal; Administration, Intravaginal; Administration, Oral; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Retrospective Studies; Treatment Outcome | 2000 |
The second abortion pill.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Legal; Drug Approval; Female; Humans; Methotrexate; Mifepristone; Misoprostol; Pregnancy; United States; United States Food and Drug Administration | 2000 |
Use of misoprostol in pregnancy.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Cervical Ripening; Drug Industry; Drug Labeling; Female; Government Regulation; Gynecology; Humans; Labor, Induced; Mifepristone; Misoprostol; Obstetrics; Oxytocics; Practice Guidelines as Topic; Pregnancy; Pregnant Women; Societies, Medical; United States | 2001 |
Supporting not punishing. A constructive approach to managing clinical errors.
Topics: Abortifacient Agents, Steroidal; Female; Fetal Death; Humans; Medication Errors; Mifepristone; Misoprostol; Nurse Midwives; Pregnancy; Risk Management | 2000 |
Can vaginal misoprostol be administered 1 to 3 days after mifepristone without loss of efficacy or an increase in adverse events?
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Female; Humans; Mifepristone; Misoprostol; Multicenter Studies as Topic; Patient Satisfaction; Pregnancy; Randomized Controlled Trials as Topic | 2001 |
Second trimester termination of pregnancy for fetal anomaly or death: comparing mifepristone/misoprostol to gemeprost.
Topics: Abnormalities, Multiple; Abortifacient Agents, Nonsteroidal; Abortion, Therapeutic; Administration, Intravaginal; Administration, Oral; Adult; Alprostadil; Female; Fetal Death; Humans; Maternal Age; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Reproductive History; Retrospective Studies; Treatment Outcome | 2001 |
[Study of histopathology of endometrium following termination of early pregnancy using mifepristone].
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Endometrium; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Uterine Hemorrhage | 1999 |
[The immunohistochemical studies on estradiol and progesterone receptors in human decidua after terminating early pregnancy by mifepristone].
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adult; Decidua; Female; Humans; Immunohistochemistry; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Receptors, Estradiol; Receptors, Progesterone | 1999 |
[Study on decidual and villous cells apoptosis and its control gene in medical abortion].
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Apoptosis; bcl-2-Associated X Protein; Chorionic Villi; Decidua; Female; Gene Expression Regulation; Genes, bcl-2; Humans; Mifepristone; Misoprostol; Pregnancy; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2 | 1999 |
A two-stage increase in the dose of misoprostol improves the efficacy of medical abortion with mifepristone and prostaglandins.
Topics: Abortifacient Agents; Abortion, Induced; Drug Administration Schedule; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 2001 |
Can women in less-developed countries use a simplified medical abortion regimen?
Topics: Abortifacient Agents; Abortion, Induced; Adult; Drug Administration Schedule; Female; Humans; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Prospective Studies; Tunisia; Vietnam | 2001 |
Curettage after mifepristone-induced abortion: frequency, timing, and indications.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Curettage; Female; Humans; Mifepristone; Misoprostol; Multicenter Studies as Topic; Pregnancy; Randomized Controlled Trials as Topic; Time Factors | 2001 |
ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Medical management of abortion.
Topics: Abortifacient Agents; Abortion, Induced; Counseling; Dilatation and Curettage; Drug Administration Schedule; Female; Gynecology; Humans; Methotrexate; Mifepristone; Misoprostol; Obstetrics; United States | 2001 |
Medical management of early fetal demise using a combination of mifepristone and misoprostol.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Adult; Curettage; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Fetal Death; Humans; Mifepristone; Misoprostol; Pregnancy; Uterine Hemorrhage | 2001 |
Any sale in U.S. of abortion pill still years away.
Topics: Abortion, Induced; Biomedical Research; Contraception; Drug Industry; Economics; France; Government Regulation; Humans; Liability, Legal; Mifepristone; Misoprostol; Pharmaceutical Preparations; Politics; Research; Social Control, Formal; United States; United States Food and Drug Administration | 1988 |
The abortion cocktail.
Topics: Abortion, Induced; Drug-Related Side Effects and Adverse Reactions; Ethics Committees; Ethics Committees, Research; Federal Government; Government; Government Regulation; Human Experimentation; Humans; Methotrexate; Mifepristone; Misoprostol; Pharmaceutical Preparations; Pregnancy; Pregnant Women; Research Design; Research Personnel; Risk; Risk Assessment; Scientific Misconduct; Social Control, Formal | 1996 |
Vascular endothelial growth factor mRNA and its protein expression in decidua after terminating early pregnancy by mifepristone plus misoprostol.
Topics: Abortifacient Agents; Abortion, Induced; Adult; Decidua; Endothelial Growth Factors; Enzyme-Linked Immunosorbent Assay; Female; Humans; Lymphokines; Mifepristone; Misoprostol; Pregnancy; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2001 |
Mifepristone: new preparation. Avoids or facilitates cervical dilatation before vacuum aspiration of pregnancy.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Cervical Ripening; Cervix Uteri; Clinical Trials as Topic; Dilatation; Female; France; Hormone Antagonists; Humans; Laminaria; Mifepristone; Misoprostol; Pregnancy; Prostaglandins | 2001 |
[Voluntary pharmacologic termination of pregnancy].
Topics: Abortifacient Agents; Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 2002 |
Medical abortion: overview and management.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Clinical Protocols; Female; Humans; Mifepristone; Misoprostol; United States; United States Food and Drug Administration | 2001 |
Medical management of late intrauterine death using a combination of mifepristone and misoprostol.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Adult; Drug Therapy, Combination; Female; Fetal Death; Gestational Age; Humans; Mifepristone; Misoprostol; Pregnancy; Scotland; Sepsis; Ultrasonography | 2002 |
Medical management of early fetal demise using sublingual misoprostol.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Sublingual; Adolescent; Adult; Drug Therapy, Combination; Female; Fetal Death; Humans; Mifepristone; Misoprostol; Pilot Projects; Pregnancy; Prospective Studies; Scotland | 2002 |
Medical abortion with mifepristone and misoprostol: a clinical trial in Taiwanese women.
Topics: Abortion, Induced; Chorionic Gonadotropin; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Prospective Studies; Single-Blind Method | 2002 |
Users' perspectives on medical abortion in Finland.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adult; Attitude to Health; Female; Finland; Gestational Age; Humans; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy | 2002 |
Not assuming the obvious: failed surgical termination of pregnancy and multiple fetal abnormalities.
Topics: Abnormalities, Multiple; Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Drug Combinations; Female; Fetus; Humans; Mifepristone; Misoprostol | 2002 |
Abortion drug is effective and safe, U.S. study says.
Topics: Abortifacient Agents; Abortion, Induced; Americas; Biology; Developed Countries; Endocrine System; Family Planning Services; Hormone Antagonists; Hormones; Mifepristone; Misoprostol; North America; Physiology; Prostaglandins; Prostaglandins, Synthetic; Research; United States | 1998 |
Clinical study on the termination of 388 high-risk early pregnancies with mifepristone and misoprostol.
Topics: Abortifacient Agents; Abortion, Induced; Asia; Asia, Eastern; Biology; China; Developing Countries; Endocrine System; Family Planning Services; Hormone Antagonists; Hormones; Mifepristone; Misoprostol; Physiology; Prostaglandins; Prostaglandins, Synthetic; Research | 1998 |
Medical abortion options may advance in 1998.
Topics: Abortion, Induced; Americas; Biology; Clinical Trials as Topic; Commerce; Developed Countries; Economics; Endocrine System; Family Planning Services; Government Agencies; Hormone Antagonists; Hormones; Jurisprudence; Mifepristone; Misoprostol; North America; Organization and Administration; Organizations; Physiology; Private Sector; Program Development; Prostaglandins; Prostaglandins, Synthetic; Research; United States; United States Food and Drug Administration; United States Public Health Service | 1997 |
Women find mifepristone safe, acceptable method.
Topics: Abortifacient Agents; Abortion, Induced; Americas; Behavior; Biology; Developed Countries; Endocrine System; Family Planning Services; Hormone Antagonists; Hormones; Mifepristone; Misoprostol; North America; Personal Satisfaction; Physiology; Prostaglandins; Prostaglandins, Synthetic; Psychology; Research; United States | 1998 |
Clinical observation on termination of early pregnancy of 213 cases after caesarian section with repeated use of mifepristone and misoprostol.
Topics: Abortion, Induced; Asia; Asia, Eastern; Biology; Cesarean Section; China; Developing Countries; Endocrine System; Evaluation Studies as Topic; Family Planning Services; General Surgery; Hormone Antagonists; Hormones; Mifepristone; Misoprostol; Obstetric Surgical Procedures; Physiology; Prostaglandins; Prostaglandins, Synthetic; Research; Risk Assessment; Therapeutics | 1999 |
Mifepristone and vaginal misoprostol on the same day for abortion from 50 to 63 days' gestation.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Incomplete; Abortion, Induced; Administration, Intravaginal; Adolescent; Adult; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pilot Projects; Pregnancy; Prospective Studies; Vacuum Curettage | 2002 |
[Medical abortion with mifepristone and misoprostol: study of the efficacy, somatic tolerance and perception of medical abortion].
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Eugenic; Adaptation, Psychological; Adolescent; Adult; Counseling; Female; Humans; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Prospective Studies; Switzerland | 2002 |
Factors affecting the outcome of early medical abortion: a review of 4132 consecutive cases.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Adult; Drug Therapy, Combination; Female; Humans; Logistic Models; Mifepristone; Misoprostol; Parity; Pregnancy; Pregnancy Trimester, First; Prospective Studies; Regression Analysis; Tablets; Treatment Outcome | 2002 |
Knowledge and attitudes about the differences between emergency contraception and medical abortion among middle-class women and men of reproductive age in Mexico City.
Topics: Abortifacient Agents; Abortion, Induced; Adolescent; Adult; Contraception; Contraceptives, Postcoital; Female; Focus Groups; Health Education; Health Knowledge, Attitudes, Practice; Humans; Male; Mifepristone; Misoprostol | 2002 |
Termination of pregnancy with mifepristone and prostaglandin suppresses transiently circulating glucocorticoid bioactivity.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Biological Assay; Drug Synergism; Female; Glucocorticoids; Humans; Hydrocortisone; Mifepristone; Misoprostol; Pregnancy | 2003 |
[Effect of total glycoside from Clinopodium polycephalum on uterine bleeding quantity in drug abortion model rats].
Topics: Abortion, Induced; Animals; Drugs, Chinese Herbal; Female; Glycosides; Hemostatics; Lamiaceae; Male; Mifepristone; Misoprostol; Phytotherapy; Plants, Medicinal; Pregnancy; Rats; Rats, Wistar; Uterine Hemorrhage | 2002 |
The learning curve is rapid in medical termination of pregnancy--first-year results from the Helsinki area.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Analgesia; Female; Finland; Hemorrhage; Humans; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Pregnancy Trimester, First; Surveys and Questionnaires | 2003 |
Mifepristone and misoprostol and methotrexate/misoprostol in clinical practice for abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Adult; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Injections, Intramuscular; Methotrexate; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Prospective Studies; Self Administration; Time Factors; Treatment Outcome | 2003 |
Legal termination of pregnancy.
Topics: Abortifacient Agents; Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Legal; Adolescent; Adult; Female; Humans; Mifepristone; Misoprostol; Pregnancy; South Africa | 2003 |
Gestational trophoblastic tumor after medical abortion.
Topics: Abortifacient Agents, Steroidal; Abortion, Therapeutic; Adult; Antineoplastic Agents; Female; Gestational Trophoblastic Disease; Humans; Methotrexate; Mifepristone; Misoprostol; Oxytocics; Pregnancy; Pregnancy Trimester, First | 2003 |
Medical abortion at 64 to 91 days of gestation: a review of 483 consecutive cases.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Drug Administration Schedule; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Retreatment; Treatment Outcome; Vacuum Curettage | 2003 |
Mifepristone and misoprostol for early medical abortion: 18 months experience in the United States.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Anti-Bacterial Agents; Blood Transfusion; Female; Gestational Age; Humans; Hypersensitivity; Infections; Mifepristone; Misoprostol; Pregnancy; United States; Uterine Hemorrhage; Vacuum Curettage | 2003 |
[Large variation in clinical regimens use to induce medical abortion in Denmark].
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Alprostadil; Denmark; Female; Follow-Up Studies; Humans; Mifepristone; Misoprostol; Practice Patterns, Physicians'; Pregnancy; Surveys and Questionnaires | 2003 |
Mifepristone and misoprostol for medical termination of pregnancy: the effectiveness of a flexible regimen.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Abortion, Legal; Administration, Intravaginal; Adolescent; Adult; Drug Therapy, Combination; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Time Factors; Treatment Outcome; United Kingdom | 2003 |
[Mifepristone for induction of second trimester abortion].
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Prospective Studies | 2003 |
Synergistic effects of DL111-IT in combination with mifepristone and misoprostol on termination of early pregnancy in preclinical studies.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Animals; Columbidae; Drug Synergism; Drug Therapy, Combination; Female; Guinea Pigs; Male; Mice; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Rats; Rats, Sprague-Dawley; Triazoles; Uterus; Vomiting | 2003 |
[Medical abortion--the first Norwegian experiences].
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First | 2003 |
Report from the Faculty of Family Planning and Reproductive Health Care AGM, May 2003: Medical termination of pregnancy in the late first trimester.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Legal; Administration, Intravaginal; Administration, Oral; Adult; Cohort Studies; Family Planning Services; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Time Factors; Treatment Outcome; United Kingdom | 2003 |
Differential kinetics of serum and cervical insulin-like growth factor-binding protein-1 during mifepristone-misoprostol-induced medical termination of early pregnancy.
Topics: Abortifacient Agents, Steroidal; Female; Humans; Insulin-Like Growth Factor Binding Protein 1; Kinetics; Mifepristone; Misoprostol; Pregnancy; Somatomedins | 2004 |
Medical management of first trimester miscarriage (blighted ovum and missed abortion): is it effective?
Topics: Abortion, Missed; Abortion, Spontaneous; Administration, Oral; Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Endosonography; Female; Follow-Up Studies; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Prospective Studies; Risk Assessment; Treatment Outcome | 2004 |
[Luteal phase treatment with mifepristone and misoprostol for prevention of pregnancy].
Topics: Adult; Contraception, Postcoital; Contraceptives, Postcoital; Female; Humans; Luteal Phase; Mifepristone; Misoprostol | 2003 |
Medical treatment of miscarriage in a district general hospital is safe and effective up to 12 weeks' gestation.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Spontaneous; Adult; Female; Hospitals, District; Hospitals, General; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Retrospective Studies; Ultrasonography; United Kingdom | 2003 |
Midtrimester medical termination of pregnancy: a review of 1002 consecutive cases.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Oral; Adolescent; Adult; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Obstetric Surgical Procedures; Parity; Pregnancy; Pregnancy Trimester, Second; Retrospective Studies; Treatment Outcome | 2004 |
The medical abortion experiences of married and unmarried women in Tunis, Tunisia.
Topics: Abortifacient Agents; Abortion, Induced; Adult; Drug Administration Schedule; Drug Therapy, Combination; Female; Home Care Services; Humans; Marital Status; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Surveys and Questionnaires; Tunisia | 2004 |
Self-administration of misoprostol for termination of pregnancy: safety and efficacy.
Topics: Abortifacient Agents; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Retrospective Studies; Self Administration; Treatment Outcome | 2004 |
One- and 2-day mifepristone-misoprostol intervals are both effective in medical termination of second-trimester pregnancy.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Time Factors | 2004 |
Role of routine ultrasonography in monitoring the outcome of medical abortion in a clinical setting.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Alprostadil; Ambulatory Care Facilities; Diagnostic Tests, Routine; Female; Follow-Up Studies; Humans; Mifepristone; Misoprostol; Pregnancy; Reproducibility of Results; Retrospective Studies; Treatment Outcome; Ultrasonography; Uterus | 2004 |
[Medical termination of pregnancy at 9-14 weeks gestation. Prospective study of 105 cases in Saint-Laurent-du-Maroni (French Guyana)].
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Abortion, Legal; Administration, Intravaginal; Administration, Oral; Administration, Sublingual; Adolescent; Adult; Analgesics, Opioid; Drug Therapy, Combination; Female; Humans; Length of Stay; Mifepristone; Misoprostol; Nalbuphine; Pregnancy; Pregnancy Trimester, First; Prospective Studies; Safety; Time Factors; Treatment Outcome | 2004 |
Ultrasound evaluation of the endometrium after medical termination of pregnancy.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Endometrium; Female; Humans; Mifepristone; Misoprostol; Retrospective Studies; Ultrasonography | 2004 |
Medical management for termination of second and third trimester pregnancies: a comparison of strategies.
Topics: Abortifacient Agents; Abortion, Induced; Dinoprostone; Female; Fetal Death; Fetal Diseases; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Retrospective Studies; Treatment Outcome | 2004 |
Analgesia requirements and predictors of analgesia use for women undergoing medical abortion up to 22 weeks of gestation.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adult; Analgesia; Analgesia, Obstetrical; Analgesics; Female; Humans; Mifepristone; Misoprostol; Pain; Pregnancy; Pregnancy Trimester, Second; Regression Analysis; Retrospective Studies | 2004 |
[Pregnancy termination in the second trimester with vaginally administered dinoprostone followed by intravenous sulprostone, for the indication 'foetal congenital defects'; results of a retrospective study].
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Dinoprostone; Female; Humans; Mifepristone; Misoprostol; Placenta, Retained; Pregnancy | 2004 |
Rupture in an unscarred uterus during second trimester pregnancy termination with mifepristone and misoprostol.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Uterine Rupture | 2004 |
Medical abortion: the Tunisian experience.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Treatment Outcome; Tunisia | 2004 |
Increased risk for medical abortion failure for multiparous women.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Adult; Female; Finland; Humans; Medical Records; Mifepristone; Misoprostol; Parity; Pregnancy; Retrospective Studies; Risk Factors; Treatment Failure | 2004 |
Accounting for time: insights from a life-table analysis of the efficacy of medical abortion.
Topics: Abortifacient Agents; Abortion, Therapeutic; Adolescent; Adult; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Gestational Age; Humans; India; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Pregnancy Outcome; Probability; Risk Assessment; Statistics as Topic; Treatment Outcome | 2004 |
Management of late intrauterine death using a combination of mifepristone and misoprostol--experience of two regimens.
Topics: Abortifacient Agents; Delivery, Obstetric; Drug Therapy, Combination; Female; Fetal Death; Gestational Age; Humans; Labor, Induced; Mifepristone; Misoprostol; Pregnancy; Time Factors; Treatment Outcome | 2005 |
The true cost differential between mifepristone and misoprostol and misoprostol-alone regimens for medical abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Costs and Cost Analysis; Female; Follow-Up Studies; Humans; India; Mifepristone; Misoprostol; Pregnancy; United States | 2005 |
Birth control: more & safer choices.
Topics: Abortion, Induced; Condoms; Consumer Behavior; Consumer Product Safety; Contraception; Contraceptive Agents, Female; Estrogens; Female; Humans; Insurance Coverage; Male; Mifepristone; Misoprostol; Pregnancy; Progestins; Sterilization, Reproductive | 2005 |
Hematosalpinx: an unusual complication after medical abortion with oral mifepristone and misoprostol.
Topics: Abortifacient Agents; Adult; Fallopian Tube Diseases; Female; Hematometra; Humans; Mifepristone; Misoprostol; Pregnancy | 2005 |
Medical abortion at 9-13 weeks' gestation: a review of 1076 consecutive cases.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Abortion, Missed; Administration, Intravaginal; Adult; Drug Administration Schedule; Drug Combinations; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Retrospective Studies | 2005 |
[Mifepristone 100 mg for early medical abortion].
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Female; Humans; Mifepristone; Misoprostol; Parity; Pregnancy; Retrospective Studies; Treatment Outcome | 2005 |
Introduction of early medical abortion in New Zealand: an audit of the first 67 cases.
Topics: Abortifacient Agents, Steroidal; Abortion, Legal; Adolescent; Adult; Child; Dilatation and Curettage; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gestational Age; Humans; Length of Stay; Medical Audit; Middle Aged; Mifepristone; Misoprostol; New Zealand; Pregnancy; Treatment Outcome | 2005 |
Clostridium sordellii toxic shock syndrome after medical abortion with mifepristone and intravaginal misoprostol--United States and Canada, 2001-2005.
Topics: Abortifacient Agents; Abortion, Induced; Canada; Clostridium Infections; Clostridium sordellii; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Shock, Septic; United States | 2005 |
Abortion procedures in a tertiary care institution in India.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Dinoprostone; Female; Humans; India; Mifepristone; Misoprostol; Oxytocics; Pregnancy; Pregnancy Trimester, First; Pregnancy Trimester, Second; Retrospective Studies | 2005 |
[Expression of T-lymphocytes and cytokines in the decidua of mifepristone with misoprostol for terminating early pregnancy].
Topics: Abortifacient Agents; Abortion, Induced; Case-Control Studies; Cytokines; Decidua; Drug Therapy, Combination; Female; Flow Cytometry; Humans; Killer Cells, Natural; Lymphocytes; Lymphotoxin-alpha; Mifepristone; Misoprostol; Pregnancy; T-Lymphocyte Subsets; Tumor Necrosis Factor-alpha | 2001 |
Deaths associated with medication abortion.
Topics: Abortion, Induced; Clostridium Infections; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 2005 |
An outpatient regimen of combined oral mifepristone 400 mg and misoprostol 400 microg for first-trimester legal medical abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Administration, Oral; Female; Follow-Up Studies; Gestational Age; Humans; Mifepristone; Misoprostol; Pain; Pregnancy; Pregnancy Trimester, First; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2005 |
Comment: pathophysiology of mifepristone-induced septic shock due to Clostridium sordellii.
Topics: Abortifacient Agents; Adult; Clostridium; Clostridium Infections; Female; Humans; Mifepristone; Misoprostol; Shock, Septic; Vaginal Diseases | 2005 |
Availability of medical abortion pills and the role of chemists: a study from Bihar and Jharkhand, India.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Data Collection; Female; Humans; India; Male; Mifepristone; Misoprostol; Pharmacists; Pregnancy; Professional Role | 2005 |
Study supports the introduction of early medical abortion in Turkey.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Choice Behavior; Data Collection; Female; Humans; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Turkey | 2005 |
Availability and acceptability of medical abortion in Nepal: health care providers' perspectives.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Aged; Aged, 80 and over; Attitude of Health Personnel; Female; Humans; Interviews as Topic; Male; Middle Aged; Mifepristone; Misoprostol; Nepal; Pregnancy | 2005 |
Fatal toxic shock syndrome associated with Clostridium sordellii after medical abortion.
Topics: Abdominal Pain; Abortifacient Agents; Abortion, Induced; Adolescent; Adult; Clostridium Infections; Clostridium sordellii; Diagnosis, Differential; Endometritis; Fatal Outcome; Female; Humans; Hypotension; Mifepristone; Misoprostol; Polymerase Chain Reaction; Pregnancy; Pregnancy Trimester, First; RNA, Ribosomal, 16S; Shock, Septic; Tachycardia; Uterus; Vomiting | 2005 |
Medical vs. surgical management of early pregnancy failure.
Topics: Abortifacient Agents; Abortion, Induced; Abortion, Spontaneous; Clostridium Infections; Clostridium sordellii; Endometritis; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Shock, Septic | 2005 |
Consistency of medical abortion efficacy from 5 through 14 weeks' gestation.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Animals; Female; Humans; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Pregnancy Trimester, Second; Retrospective Studies; Treatment Outcome | 2006 |
Medical abortion: a fact sheet.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Contraindications; Developed Countries; Developing Countries; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimesters | 2005 |
Termination of pregnancy in patients with previous cesarean section.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Adult; Cesarean Section; Dinoprost; Female; France; Humans; Mifepristone; Misoprostol; Oxytocics; Pregnancy; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Retrospective Studies; Ultrasonography, Prenatal | 2006 |
Mifepristone vaginally in an early medical abortion regimen: a pilot study.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Adolescent; Adult; Female; Humans; Mifepristone; Misoprostol; Pilot Projects; Time Factors | 2006 |
Deaths from Clostridium sordellii after medical abortion.
Topics: Abortifacient Agents; Abortion, Induced; Administration, Intravaginal; Antibiotic Prophylaxis; Clostridium Infections; Clostridium sordellii; Endometritis; Female; France; Humans; Mifepristone; Misoprostol; Pregnancy | 2006 |
Deaths from Clostridium sordellii after medical abortion.
Topics: Abortifacient Agents; Abortion, Induced; Administration, Oral; Antibiotic Prophylaxis; Clostridium Infections; Clostridium sordellii; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 2006 |
Induction of second trimester abortion (12-20 weeks) with mifepristone and misoprostol: a review of 386 consecutive cases.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Retrospective Studies | 2006 |
Simultaneous very low dose mifepristone and vaginal misoprostol for medical abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Drug Administration Schedule; Female; Humans; Mifepristone; Misoprostol; Pilot Projects; Pregnancy | 2006 |
Death after RU-486.
Topics: Abortifacient Agents; Abortion, Induced; Death, Sudden; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnant Women | 2006 |
[First trimester medical abortion: a good method that is seldom used in The Netherlands].
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Netherlands; Pregnancy; Pregnancy Trimester, First; Safety | 2006 |
infectious disease. RU-486-linked deaths open debate about risky bacteria.
Topics: Abortifacient Agents, Steroidal; Abortion, Spontaneous; Abortion, Therapeutic; Animals; Clostridioides difficile; Clostridium Infections; Clostridium sordellii; Enterocolitis, Pseudomembranous; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Complications, Infectious | 2006 |
[Medicamentous abortion with mifepristone and misoprostol in Serbia and Montenegro].
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Adult; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 2006 |
Early abortion in Ontario: options and costs.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Drug Synergism; Drug Therapy, Combination; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Ontario; Pregnancy; Treatment Outcome | 2006 |
Providing medication abortion information to diverse communities: use patterns of a multilingual web site.
Topics: Abortifacient Agents; Abortion, Induced; Female; Humans; Information Services; Internet; Language; Methotrexate; Mifepristone; Misoprostol; Pregnancy | 2006 |
Mortality associated with mifepristone-misoprostol medical abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 2006 |
Ultrasound diagnosis of uterine dehiscence following mifepristone/misoprostol regime in early second trimester termination.
Topics: Abortifacient Agents; Abortion, Induced; Adult; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Ultrasonography; Uterine Rupture | 2006 |
Self-administration of vaginal misoprostol after mifepristone for termination of pregnancy: patient acceptability.
Topics: Abortifacient Agents; Abortion, Induced; Administration, Intravaginal; Adolescent; Adult; Female; Humans; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Self Administration | 2006 |
Clostridium sordellii infection in medical abortion.
Topics: Abortifacient Agents; Abortion, Induced; Clostridium Infections; Clostridium sordellii; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 2006 |
Mifepristone- and misoprostol-induced mid-trimester termination of pregnancy: a review of 272 cases.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Female; Humans; Medical Audit; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Retrospective Studies | 2006 |
Monitoring medical abortion using mifepristone/misoprostol combination with ultrasonogram and serum human chorionic gonadotropin.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Incomplete; Abortion, Induced; Adult; Chorionic Gonadotropin; Drug Combinations; Female; Humans; Logistic Models; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Ultrasonography | 2006 |
Mifepristone and misoprostol in the induction of labor at term.
Topics: Adult; Cervical Ripening; Delivery, Obstetric; Drug Therapy, Combination; Female; Hormone Antagonists; Humans; Labor, Induced; Mifepristone; Misoprostol; Oxytocics; Pilot Projects; Pregnancy; Prospective Studies; Term Birth | 2007 |
Influence of epidural analgesia on labor in mid and late termination of pregnancy: an observational study.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Age Factors; Amides; Analgesia, Epidural; Analgesia, Obstetrical; Anesthetics, Intravenous; Anesthetics, Local; Female; Humans; Labor, Induced; Mifepristone; Misoprostol; Pain; Pregnancy; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Retrospective Studies; Ropivacaine; Sufentanil | 2007 |
[Results of pregnancy termination for foetal congenital or chromosomal disorders or intrauterine foetal death by oral mifepristone and/or intravaginal misoprostol; results of a retrospective study].
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Adult; Female; Fetal Death; Fetal Diseases; Humans; Mifepristone; Misoprostol; Parity; Pregnancy; Pregnancy Trimester, Second; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2007 |
Medication abortion in the private sector in South Africa.
Topics: Abortifacient Agents; Abortion, Induced; Female; Gynecology; Health Services Accessibility; Humans; Mifepristone; Misoprostol; Practice Patterns, Physicians'; Pregnancy; Private Practice; South Africa; Women's Health Services | 2006 |
Risk factors for unsuccessful medical abortion with mifepristone and misoprostol.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Abortion, Spontaneous; Adolescent; Adult; Chorionic Gonadotropin, beta Subunit, Human; Drug Therapy, Combination; Female; Humans; Logistic Models; Middle Aged; Mifepristone; Misoprostol; Parity; Pregnancy; Retrospective Studies; Risk Factors; Treatment Failure; Treatment Outcome; Ultrasonography; Uterus | 2007 |
Misoprostol-only versus mifepristone plus misoprostol in induction of labor following intrauterine fetal death.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Adolescent; Adult; Drug Therapy, Combination; Female; Fetal Death; Humans; Labor, Induced; Mifepristone; Misoprostol; Pregnancy; Retrospective Studies; Statistics, Nonparametric | 2007 |
Increasing access to safe abortion services in rural India: experiences with medical abortion in a primary health center.
Topics: Abortifacient Agents; Abortion, Induced; Adolescent; Adult; Feasibility Studies; Female; Health Services Accessibility; Humans; India; Mifepristone; Misoprostol; Pregnancy; Primary Health Care; Rural Health Services; Safety Management; Women's Health Services | 2007 |
One or two day mifepristone-misoprostol interval for second trimester abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Adult; Cohort Studies; Female; Gestational Age; Gravidity; Humans; Mifepristone; Misoprostol; Parity; Pregnancy; Pregnancy Trimester, Second; Retrospective Studies; Time Factors; Treatment Outcome | 2007 |
Medical abortion in the first trimester: the use of serum hCG and endometrial thickness as markers of completeness.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Chorionic Gonadotropin; Endometrium; Female; Humans; Middle Aged; Mifepristone; Misoprostol; Norway; Pregnancy; Pregnancy Trimester, First; Prospective Studies; Time Factors; Treatment Outcome; Ultrasonography | 2007 |
[Induced abortion at home].
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Administration, Intravaginal; Adult; Female; Follow-Up Studies; Humans; Mifepristone; Misoprostol; Patient Education as Topic; Patient Satisfaction; Pregnancy; Self Administration; Self Care; Socioeconomic Factors; Surveys and Questionnaires | 2007 |
Toxic shock associated with Clostridium sordellii and Clostridium perfringens after medical and spontaneous abortion.
Topics: Abortifacient Agents; Abortion, Therapeutic; Administration, Intravaginal; Bacterial Toxins; Clostridium Infections; Clostridium perfringens; Clostridium sordellii; Fatal Outcome; Female; Humans; Laminaria; Mifepristone; Misoprostol; Necrosis; Pregnancy; Shock, Septic; Uterus | 2007 |
[Clinical value of transcervical resection under hysteroscope for placental remnants].
Topics: Abortifacient Agents, Nonsteroidal; Adult; Chorionic Gonadotropin, beta Subunit, Human; Combined Modality Therapy; Electrosurgery; Female; Humans; Hysteroscopy; Methotrexate; Mifepristone; Misoprostol; Placenta, Retained; Pregnancy; Retrospective Studies; Treatment Outcome; Ultrasonography | 2007 |
[Clinical study of terminating biochemical pregnancy and early clinical pregnancy with mifepristone and misoprostol].
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Chorionic Gonadotropin, beta Subunit, Human; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pregnancy; Retrospective Studies; Treatment Outcome | 2007 |
Möbius syndrome in a neonate after mifepristone and misoprostol elective abortion failure.
Topics: Abnormalities, Drug-Induced; Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Female; Humans; Infant, Newborn; Male; Mifepristone; Misoprostol; Mobius Syndrome; Pregnancy; Pregnancy Trimester, First | 2008 |
Late second-trimester abortions induced with mifepristone, misoprostol and oxytocin: a report of 428 consecutive cases.
Topics: Abortion, Induced; Administration, Intravaginal; Administration, Oral; Adult; Female; Humans; Mifepristone; Misoprostol; Oxytocin; Pregnancy; Pregnancy Trimester, Second; Safety; Treatment Outcome | 2008 |
Using telemedicine for termination of pregnancy with mifepristone and misoprostol in settings where there is no access to safe services.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Buccal; Administration, Oral; Adolescent; Adult; Drug Therapy, Combination; Female; Health Services Accessibility; Humans; Internet; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Pregnancy Outcome; Telemedicine | 2008 |
Medical abortion practices: a survey of National Abortion Federation members in the United States.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Abortion, Legal; Ambulatory Care Facilities; Female; Health Care Surveys; Humans; Mifepristone; Misoprostol; Practice Patterns, Physicians'; Pregnancy; Pregnancy Trimester, First; Surveys and Questionnaires; United States; United States Food and Drug Administration | 2008 |
Re: Using telemedicine for termination of pregnancy with mifepristone and misoprostol in settings where there is no access to safe services.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Female; Health Services Accessibility; Humans; Mifepristone; Misoprostol; Pregnancy; Telemedicine | 2008 |
Re: Using telemedicine for termination of pregnancy with mifepristone and misoprostol in settings where there is no access to safe services.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Ethics, Medical; Female; Health Services Accessibility; Humans; Mifepristone; Misoprostol; Pregnancy; Telemedicine | 2008 |
First and second trimester induced abortions in women with cardiac disorders: a 12-year analysis from a developing country.
Topics: Abortifacient Agents; Abortion, Induced; Adult; Developing Countries; Female; Heart Diseases; Humans; India; Mifepristone; Misoprostol; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy Trimester, First; Pregnancy Trimester, Second; Retrospective Studies | 2008 |
How much supervision is necessary for women taking mifepristone and misoprostol for early medical abortion?
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Drug Administration Schedule; Drug Utilization; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pregnancy; Treatment Outcome | 2008 |
The role of parity in medical abortion up to 49 days of amenorrhoea.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Amenorrhea; Chorionic Gonadotropin; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Mifepristone; Misoprostol; Parity; Pregnancy; Retrospective Studies; Risk Factors; ROC Curve; Young Adult | 2008 |
Group a Streptococcus causing necrotizing fasciitis and toxic shock syndrome after medical termination of pregnancy.
Topics: Abortifacient Agents; Abortion, Induced; Amputation, Surgical; Fasciitis, Necrotizing; Female; Humans; Mifepristone; Misoprostol; Shock, Septic; Streptococcal Infections; Streptococcus pyogenes; Young Adult | 2009 |
Effect of previous live birth and prior route of delivery on the outcome of early medical abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Cesarean Section; Delivery, Obstetric; Drug Combinations; Female; Humans; Live Birth; Logistic Models; Mifepristone; Misoprostol; Multivariate Analysis; Parity; Pregnancy; Retrospective Studies; Risk Factors; Treatment Outcome | 2009 |
Frequency and risk factors for repeat abortions after surgical compared with medical termination of pregnancy.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Age Factors; Cohort Studies; Dilatation and Curettage; Female; Gestational Age; Humans; Marital Status; Maternal Age; Middle Aged; Mifepristone; Misoprostol; Parity; Pregnancy; Registries; Risk Factors; Social Class; Socioeconomic Factors; Vacuum Extraction, Obstetrical; Young Adult | 2009 |
Abnormal expression of MMP-9 and imbalance of MMP-9/TIMP-1 is associated with prolonged uterine bleeding after a medical abortion with mifepristone and misoprostol.
Topics: Abortifacient Agents; Abortion, Induced; Adult; Cross-Sectional Studies; Female; Humans; Matrix Metalloproteinase 9; Mifepristone; Misoprostol; Pregnancy; Tissue Inhibitor of Metalloproteinase-1; Uterine Hemorrhage | 2009 |
Understanding women's experiences with medical abortion: In-depth interviews with women in two Indian clinics.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Family Planning Services; Female; Health Knowledge, Attitudes, Practice; Humans; Interviews as Topic; Mifepristone; Misoprostol; Pregnancy; Women; Young Adult | 2010 |
Choosing medical or surgical terminations of pregnancy in the first trimester: what is the difference?
Topics: Abortifacient Agents; Abortion, Induced; Adult; Choice Behavior; Drug Administration Schedule; Drug Therapy, Combination; Female; Gravidity; Humans; Mifepristone; Misoprostol; New Zealand; Patient Participation; Pregnancy; Pregnancy Trimester, First; Retrospective Studies; Vacuum Curettage; Young Adult | 2009 |
Mifepristone and Misoprostol for the management of placenta accreta - a new alternative approach.
Topics: Administration, Oral; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Oxytocics; Placenta Accreta; Pregnancy | 2009 |
Increasing women's choices in medical abortion: a study of misoprostol 400 microg swallowed immediately or held sublingually following 200 mg mifepristone.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Oral; Administration, Sublingual; Adult; Female; Follow-Up Studies; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Turkey; Young Adult | 2009 |
Effectiveness of medical abortion with mifepristone and buccal misoprostol through 59 gestational days.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Buccal; Adult; Female; Gestational Age; Humans; Logistic Models; Mifepristone; Misoprostol; Pregnancy; Retrospective Studies; Urban Population; Young Adult | 2009 |
Unexpected heaping in reported gestational age for women undergoing medical abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pregnancy; Ultrasonography, Prenatal; Urban Population | 2009 |
[Determination of serum antioxidant capacity after induced abortion].
Topics: Abortifacient Agents; Abortion, Induced; Adult; Antioxidants; Female; Humans; Mifepristone; Misoprostol; Oxidative Stress; Pregnancy; Serum; Time Factors; Young Adult | 2009 |
[Termination of pregnancy in the 2nd trimester: mifepriston/misoprostol preferable to sulprostone].
Topics: Abortifacient Agents; Abortion, Induced; Adult; Cohort Studies; Dinoprostone; Female; Fetal Diseases; Humans; Middle Aged; Mifepristone; Misoprostol; Parity; Pregnancy; Pregnancy Trimester, Second; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Young Adult | 2009 |
Timing and indication for curettage after medical abortion in early pregnant women with prior uterine incision.
Topics: Abortifacient Agents; Abortion, Incomplete; Abortion, Induced; Cesarean Section; Curettage; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 2010 |
Women's opinions on the home management of early medical abortion in the UK.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Attitude to Health; Female; Health Surveys; Humans; Logistic Models; Middle Aged; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Self Care; Surveys and Questionnaires; United Kingdom; Young Adult | 2010 |
Alternatives to a routine follow-up visit for early medical abortion.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Continuity of Patient Care; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Ultrasonography; Uterus | 2010 |
Mifepristone-misoprostol midtrimester abortion: impact of gestational age on the induction-to-abortion interval.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pregnancy; Retrospective Studies; Time Factors; Treatment Outcome | 2010 |
Feasibility of telephone follow-up after medical abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Cohort Studies; Drug Administration Schedule; Female; Humans; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Pregnancy Tests; Prospective Studies; Telephone; Treatment Outcome | 2010 |
A comparison of transabdominal and transvaginal ultrasonography for determination of gestational age and clinical outcomes in women undergoing early medical abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Patient Satisfaction; Pilot Projects; Pregnancy; Treatment Outcome; Ultrasonography, Prenatal | 2010 |
Home self-administration of vaginal misoprostol for medical abortion at 50-63 days compared with gestation of below 50 days.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Adolescent; Adult; Ambulatory Care Facilities; Female; Gestational Age; Home Care Services; Humans; Middle Aged; Mifepristone; Misoprostol; Outpatient Clinics, Hospital; Patient Satisfaction; Pregnancy; Prospective Studies; Self Administration; Surveys and Questionnaires; Young Adult | 2010 |
Sonographic quantification of endometrial changes after abortion with computer-assisted image analysis.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Endometrium; Female; Humans; Image Processing, Computer-Assisted; Least-Squares Analysis; Mifepristone; Misoprostol; Pregnancy; Retrospective Studies; Sensitivity and Specificity; Ultrasonography | 2010 |
Mifepristone and second trimester pregnancy termination for fetal abnormality in Western Australia: Worth the effort.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Adult; Congenital Abnormalities; Critical Pathways; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Length of Stay; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Western Australia | 2010 |
Acute coronary artery vasospasm associated with misoprostol for termination of pregnancy.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adult; Alprostadil; Analgesics; Chest Pain; Coronary Vasospasm; Coronary Vessels; Female; Humans; Ketoprofen; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Tromethamine | 2010 |
Issues in second trimester induced abortion (medical/surgical methods).
Topics: Abortifacient Agents; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Patient Selection; Pregnancy; Pregnancy Trimester, Second; Vacuum Curettage | 2010 |
Late termination of pregnancy and foetal reduction for foetal anomaly.
Topics: Abortifacient Agents; Administration, Intravaginal; Administration, Oral; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Reduction, Multifetal; Pregnancy Trimester, Second; United Kingdom; Vacuum Curettage | 2010 |
Medical abortion at 63 to 90 days of gestation.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Case-Control Studies; Chorionic Gonadotropin, beta Subunit, Human; Female; Humans; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Young Adult | 2010 |
Is there evidence to decrease the approved dose of 600 mg of mifepristone for medical abortion?
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Drug Therapy, Combination; Female; Humans; Meta-Analysis as Topic; Mifepristone; Misoprostol; Pregnancy | 2010 |
Feticide followed by mifepristone-misoprostol regimen for midtrimester termination of pregnancy in two cases of complete placenta previa.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Therapeutic; Administration, Oral; Female; Humans; Mifepristone; Misoprostol; Placenta Previa; Postpartum Hemorrhage; Potassium Chloride; Pregnancy; Pregnancy Trimester, Second | 2010 |
Evaluation of the introduction of a new treatment for the termination of pregnancy in The Netherlands.
Topics: Abortifacient Agents; Abortion, Induced; Abortion, Missed; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gynecology; Humans; Mifepristone; Misoprostol; Netherlands; Obstetrics; Off-Label Use; Practice Patterns, Physicians'; Pregnancy; Pregnancy Trimesters; Premedication; Surveys and Questionnaires; Vacuum Curettage | 2010 |
Home abortion - experiences of male involvement.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Aftercare; Attitude to Health; Family Characteristics; Female; Humans; Interviews as Topic; Male; Middle Aged; Mifepristone; Misoprostol; Sexual Partners; Social Support | 2010 |
Fatal Clostridium sordellii infections after medical abortions.
Topics: Abortifacient Agents; Abortion, Induced; Administration, Intravaginal; Adult; Antibiotic Prophylaxis; Clostridium Infections; Clostridium sordellii; Fatal Outcome; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy in Diabetics; Shock, Septic; Young Adult | 2010 |
Clinical efficacy of mifepristone and misoprostol in second trimester pregnancy termination.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Therapeutic; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Cohort Studies; Drug Therapy, Combination; Female; Finland; Follow-Up Studies; Humans; Logistic Models; Mifepristone; Misoprostol; Multivariate Analysis; Pregnancy; Pregnancy Outcome; Pregnancy Trimester, Second; Retrospective Studies; Risk Assessment; Statistics, Nonparametric; Treatment Outcome; Young Adult | 2010 |
The effect of parity and gravidity on the outcome of medical termination of pregnancy.
Topics: Abortifacient Agents; Abortion, Induced; Adult; Cohort Studies; Female; Gravidity; Humans; Israel; Mifepristone; Misoprostol; Parity; Pregnancy; Retrospective Studies; Treatment Outcome | 2010 |
Misuse of abortion pill by unauthorized persons is a serious concern in India.
Topics: Abortifacient Agents, Nonsteroidal; Adult; Female; Humans; India; Mifepristone; Misoprostol; Nonprescription Drugs; Substance-Related Disorders; Young Adult | 2010 |
The contraceptive implant for long acting reversible contraception in patients undergoing first trimester medical termination of pregnancy.
Topics: Abortifacient Agents; Abortion, Induced; Administration, Cutaneous; Adolescent; Adult; Contraceptive Agents, Female; Drug Administration Schedule; Female; Humans; Mifepristone; Misoprostol; Observation; Pilot Projects; Pregnancy; Pregnancy Trimester, First; Pregnancy, Unplanned; Progestins; Prospective Studies; Treatment Outcome; United Kingdom; Young Adult | 2010 |
Defining reality: the potential role of pharmacists in assessing the impact of progesterone receptor modulators and misoprostol in reproductive health.
Topics: Abortifacient Agents; Contraceptives, Postcoital, Synthetic; Female; Health Policy; Humans; Mifepristone; Misoprostol; Nonprescription Drugs; Norpregnadienes; Off-Label Use; Pharmacists; Product Surveillance, Postmarketing; Professional Role; Receptors, Progesterone; Reproductive Medicine; Risk Assessment; United States; United States Food and Drug Administration | 2011 |
Mifepristone followed by home administration of buccal misoprostol for medical abortion up to 70 days of amenorrhoea in a general practice in Curaçao.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Buccal; Adult; Ambulatory Care Facilities; Amenorrhea; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Mifepristone; Misoprostol; Netherlands Antilles; Pregnancy; Prospective Studies; Self Administration; Treatment Outcome; Young Adult | 2011 |
Mifepristone and misoprostol for early pregnancy failure: a cohort analysis.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Spontaneous; Adolescent; Adult; Cohort Studies; Drug Administration Schedule; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Treatment Outcome | 2011 |
Ruling prevents women taking second abortion pill at home.
Topics: Contraceptives, Postcoital, Synthetic; Female; Home Care Services; Humans; Mifepristone; Misoprostol; Self Administration; United Kingdom | 2011 |
Time to misoprostol after mifepristone: still a bone of contention!
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Time Factors | 2011 |
Severity of infection following the introduction of new infection control measures for medical abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Buccal; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Doxycycline; Female; Humans; Infection Control; Mifepristone; Misoprostol; Pregnancy; Retrospective Studies | 2011 |
Pain during medical abortion: predicting factors from gynecologic history and medical staff evaluation of severity.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Female; Humans; Medical Staff; Mifepristone; Misoprostol; Pain; Pain Measurement; Pregnancy; Statistics, Nonparametric; Surveys and Questionnaires; Young Adult | 2011 |
Misoprostol: life-saving.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Young Adult | 2011 |
Comparison of rates of adverse events in adolescent and adult women undergoing medical abortion: population register based study.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Incomplete; Abortion, Induced; Adolescent; Adult; Age Distribution; Chlamydia Infections; Female; Finland; Hemorrhage; Humans; Incidence; Mifepristone; Misoprostol; Pregnancy; Pregnancy Complications, Cardiovascular; Registries; Risk Factors; Young Adult | 2011 |
Medical abortion for adolescents.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First | 2011 |
Second- and third-trimester management of medical termination of pregnancy and fetal death in utero after prior caesarean section.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Oral; Adult; Cesarean Section; Dose-Response Relationship, Drug; Female; Fetal Death; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Retrospective Studies; Risk Factors; Time Factors; Uterine Rupture | 2011 |
Medical abortion in women with impaired renal function.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Female; Humans; Kidney Diseases; Mifepristone; Misoprostol; Pregnancy; Pregnancy Complications; Severity of Illness Index | 2011 |
Medical abortion and the 'golden rule' of statutory interpretation. BPAS v the Secretary of State for Health [2011] EWHC 235.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Safety; Self Administration; Time Factors; United Kingdom | 2011 |
Clinical guidelines. Labor induction abortion in the second trimester.
Topics: Abortifacient Agents; Abortion, Induced; Cesarean Section; Drug Administration Routes; Female; Gestational Age; Humans; Labor Stage, Third; Labor, Induced; Laminaria; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Uterine Rupture | 2011 |
[Medical abortion from 12 through 14 weeks' gestation: a retrospective study with 126 patients].
Topics: Abortifacient Agents; Abortion, Induced; Adolescent; Adult; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Outcome; Pregnancy Trimester, First; Retrospective Studies; Vacuum Curettage; Young Adult | 2011 |
Re: Comparing medical versus surgical termination of pregnancy at 13-20 weeks of gestation: a randomised controlled trial.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Vacuum Extraction, Obstetrical | 2011 |
Effectiveness and acceptability of medical abortion provided through telemedicine.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Buccal; Administration, Oral; Adolescent; Adult; Cohort Studies; Female; Humans; Middle Aged; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Telemedicine; Voluntary Health Agencies; Young Adult | 2011 |
The combination of mifepristone and misoprostol for the termination of pregnancy.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Drug Therapy, Combination; Female; Fetal Death; Gestational Age; Humans; Labor, Induced; Mifepristone; Misoprostol; Pregnancy | 2011 |
Second trimester abortion in women with and without previous uterine scar: Eleven years experience from a developing country.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adult; Case-Control Studies; Cicatrix; Developing Countries; Dinoprost; Female; Humans; India; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Retrospective Studies; Uterine Diseases; Uterine Rupture | 2011 |
Regional differences in surgical intervention following medical termination of pregnancy provided by telemedicine.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Female; Follow-Up Studies; Gestational Age; Gynecologic Surgical Procedures; Humans; Logistic Models; Middle Aged; Mifepristone; Misoprostol; Outcome Assessment, Health Care; Patient Satisfaction; Pregnancy; Prospective Studies; Self Administration; Surveys and Questionnaires; Telemedicine; Young Adult | 2012 |
Medical versus surgical abortion methods for pregnancy in China: a cost-minimization analysis.
Topics: Abortifacient Agents; Abortion, Induced; Adolescent; Adult; China; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Treatment Outcome; Vacuum Curettage; Young Adult | 2011 |
Outcomes of medical abortion through 63 days in women with twin gestations.
Topics: Abortifacient Agents; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Adult; Female; Humans; Mifepristone; Misoprostol; Pain Measurement; Postoperative Complications; Pregnancy; Pregnancy, Multiple; Randomized Controlled Trials as Topic; Treatment Outcome; Twins; Uterine Hemorrhage | 2011 |
Effects of leonurine hydrochloride on medically induced incomplete abortion in early pregnancy rats.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Incomplete; Abortion, Induced; Animals; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Estradiol; Female; Gallic Acid; In Vitro Techniques; Mifepristone; Misoprostol; Organ Size; Pregnancy; Random Allocation; Rats; Rats, Sprague-Dawley; Uterine Contraction; Uterine Hemorrhage; Uterus | 2011 |
Clinical outcomes from a prospective study evaluating the role of ambulation during medical termination of pregnancy.
Topics: Abortifacient Agents; Abortion, Induced; Adult; Female; Humans; Mifepristone; Misoprostol; Patient Preference; Pregnancy; Prospective Studies; Treatment Outcome; United Kingdom; Walking | 2012 |
Mifepristone+misoprostol vs. misoprostol alone for early medical abortion.
Topics: Abortifacient Agents; Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 2012 |
Can women accurately assess the outcome of medical abortion based on symptoms alone?
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Case-Control Studies; Diagnostic Self Evaluation; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Retrospective Studies; Treatment Failure; Young Adult | 2012 |
Obstetrician-gynecologists' knowledge of and attitudes toward medical abortion in Guatemala.
Topics: Abortifacient Agents; Abortion, Induced; Adult; Attitude of Health Personnel; Data Collection; Dose-Response Relationship, Drug; Female; Guatemala; Gynecology; Health Knowledge, Attitudes, Practice; Health Services Accessibility; Humans; Logistic Models; Male; Middle Aged; Mifepristone; Misoprostol; Multivariate Analysis; Obstetrics; Physicians; Pregnancy | 2012 |
Medication abortion within a student health care clinic: a review of the first 46 consecutive cases.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Chicago; Female; Humans; Mifepristone; Misoprostol; Retrospective Studies; Student Health Services; Students; Treatment Outcome; Universities; Young Adult | 2012 |
Pharmacy workers' knowledge and provision of abortifacients in Ho Chi Minh City, Vietnam.
Topics: Abortifacient Agents; Abortion, Criminal; Adult; Cross-Sectional Studies; Data Collection; Female; Health Knowledge, Attitudes, Practice; Humans; Male; Mifepristone; Misoprostol; Patient Simulation; Pharmaceutical Services; Pregnancy; Vietnam | 2012 |
Induction of delivery by mifepristone and misoprostol in termination of pregnancy and intrauterine fetal death: 2nd and 3rd trimester induction of labour.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Female; Fetal Death; Humans; Labor, Induced; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Pregnancy Trimester, Third | 2012 |
Ob/Gyn training in abortion care: results from a national survey.
Topics: Abortifacient Agents; Abortion, Induced; Female; Gynecology; Health Care Surveys; Humans; Internship and Residency; Male; Mifepristone; Misoprostol; Obstetrics; Physicians; Postoperative Complications; Pregnancy; Pregnancy Trimester, First; Pregnancy Trimester, Second; Reproductive Health Services; United States; Vacuum Curettage; Workforce | 2012 |
Prospective study of medical abortion in Nepal Medical College Teaching Hospital (NMCTH). A one year experience.
Topics: Abortifacient Agents; Abortion, Induced; Adult; Female; Gestational Age; Hospitals, Teaching; Humans; Mifepristone; Misoprostol; Nepal; Pregnancy; Prospective Studies; Time Factors; Young Adult | 2011 |
Knowledge of medical abortion among Brazilian medical students.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adult; Brazil; Clinical Competence; Female; Humans; Male; Mifepristone; Misoprostol; Students, Medical; Young Adult | 2012 |
Introducing medical abortion in Turkey: perspectives of physicians.
Topics: Abortifacient Agents; Abortion, Induced; Adult; Attitude of Health Personnel; Clinical Competence; Female; Health Knowledge, Attitudes, Practice; Humans; Male; Middle Aged; Mifepristone; Misoprostol; Turkey | 2012 |
Results of a 4-year study on 15,447 medical abortions provided by privately practicing general practitioners and gynecologists in France.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Chorionic Gonadotropin; Drug Therapy, Combination; Female; France; General Practice; Gynecology; Health Services Accessibility; Humans; Middle Aged; Mifepristone; Misoprostol; Practice Patterns, Physicians'; Private Practice; Prospective Studies; Self Administration; Ultrasonography; Young Adult | 2013 |
Early medical abortion--available and safe.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 2012 |
Medical termination of pregnancy in cynomolgus macaques.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Animals; Female; Gestational Age; Macaca fascicularis; Methotrexate; Mifepristone; Misoprostol; Pregnancy; Treatment Outcome | 2012 |
Medical versus surgical termination of pregnancy in primigravid women--is the next delivery differently at risk? A population-based register study.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Birth Intervals; Dilatation and Curettage; Drug Combinations; Female; Gravidity; Humans; Infant, Low Birth Weight; Infant, Newborn; Infant, Small for Gestational Age; Maternal Age; Mifepristone; Misoprostol; Pregnancy; Pregnancy Complications; Pregnancy Trimester, First; Registries; Risk Factors; Socioeconomic Factors; Young Adult | 2013 |
Silent rupture of an unscarred uterus at third-trimester abortion correlated with an unrecognized perforation.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Third; Suture Techniques; Uterine Perforation; Uterine Rupture | 2012 |
Effectiveness of early medical abortion using low-dose mifepristone and buccal misoprostol in women with no defined intrauterine gestational sac.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Therapeutic; Administration, Buccal; Administration, Oral; Adolescent; Adult; Female; Follow-Up Studies; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Pregnancy, Ectopic; Retrospective Studies; Treatment Failure; Ultrasonography, Prenatal; Uterus; Young Adult | 2013 |
Significant adverse events and outcomes after medical abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Incomplete; Abortion, Induced; Anti-Bacterial Agents; Blood Transfusion; Communicable Diseases; Emergency Treatment; Evidence-Based Medicine; Female; Humans; Maternal Mortality; Mifepristone; Misoprostol; Patient Admission; Pregnancy; Pregnancy, Ectopic | 2013 |
Continuation of pregnancy after first-trimester exposure to mifepristone: an observational prospective study.
Topics: Abortifacient Agents, Steroidal; Abortion, Spontaneous; Adult; Congenital Abnormalities; Female; Follow-Up Studies; France; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Outcome; Pregnancy Trimester, First; Premature Birth; Prospective Studies | 2013 |
Acceptability and feasibility of the use of 400 μg of sublingual misoprostol after mifepristone for medical abortion up to 63 days since the last menstrual period: evidence from Uzbekistan.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Sublingual; Adult; Drug Therapy, Combination; Feasibility Studies; Female; Humans; Mifepristone; Misoprostol; Patient Acceptance of Health Care; Pregnancy; Pregnant Women; Prospective Studies; Self Administration; Uzbekistan; Young Adult | 2013 |
Reviewer's commentary on 'Continuation of pregnancy after first-trimester exposure to mifepristone: an observational prospective study'.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Outcome; Pregnancy Trimester, First; Prospective Studies; Teratogens | 2013 |
The association between serum progesterone and outcome of medical management of early fetal demise: a pilot study.
Topics: Abortifacient Agents; Abortion, Missed; Adolescent; Adult; Female; Humans; Mifepristone; Misoprostol; Pilot Projects; Pregnancy; Progesterone; Prospective Studies; Treatment Failure; Young Adult | 2013 |
Serum angiopoietin-2 and β-hCG as predictors of prolonged uterine bleeding after medical abortion in the first trimester.
Topics: Abortion, Induced; Adult; Angiopoietin-2; Chorionic Gonadotropin, beta Subunit, Human; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Prospective Studies; Uterine Hemorrhage; Young Adult | 2013 |
Acceptability and feasibility of mifepristone-misoprostol for menstrual regulation in Bangladesh.
Topics: Abortifacient Agents; Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adult; Bangladesh; Female; Focus Groups; Humans; Menstruation; Menstruation-Inducing Agents; Mifepristone; Misoprostol; Patient Satisfaction; Young Adult | 2013 |
Women's satisfaction with early home medical abortion with telephone follow-up: a questionnaire-based study in the U.K.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy Tests; Self Care; Surveys and Questionnaires; Telephone; United Kingdom | 2013 |
Medical abortion: a path to safe, high-quality abortion care in Latin America and the Caribbean.
Topics: Abortifacient Agents; Abortion, Induced; Abortion, Legal; Adolescent; Adult; Caribbean Region; Female; Health Services Accessibility; Humans; Latin America; Mifepristone; Misoprostol; Pregnancy; Pregnancy, Unwanted | 2013 |
Labor induction outcomes in third-trimester stillbirths.
Topics: Adolescent; Adult; Amnion; Cervical Ripening; Delivery, Obstetric; Female; Humans; Labor, Induced; Mifepristone; Misoprostol; Oxytocics; Oxytocin; Postpartum Hemorrhage; Pregnancy; Pregnancy Trimester, Third; Retrospective Studies; Stillbirth; Time Factors; Urinary Catheterization; Young Adult | 2013 |
Efficacy of mifepristone for cervical priming for second-trimester surgical termination of pregnancy.
Topics: Abortifacient Agents; Abortion, Induced; Female; Humans; Laminaria; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Retrospective Studies | 2014 |
A pilot study on the combined use of letrozole, mifepristone and misoprostol in termination of first trimester pregnancy up to 9 weeks' gestation.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Aromatase Inhibitors; Female; Humans; Letrozole; Mifepristone; Misoprostol; Nitriles; Pilot Projects; Pregnancy; Triazoles | 2013 |
Prostaglandins are essential for cervical ripening in LPS-mediated preterm birth but not term or antiprogestin-driven preterm ripening.
Topics: Animals; Cervical Ripening; Cervix Uteri; Female; Flow Cytometry; Gene Expression Regulation; Lipopolysaccharides; Mice; Mifepristone; Misoprostol; Obstetric Labor, Premature; Pregnancy; Pregnancy, Animal; Premature Birth; Progestins; Prostaglandins; Pyrazoles; Steroids; Sulfonamides; Term Birth | 2014 |
Elevated expression levels of matrix metalloproteinase-9 in placental villi and tissue inhibitor of metalloproteinase-2 in decidua are associated with prolonged bleeding after mifepristone-misoprostol medical abortion.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Chorionic Villi; Decidua; Female; Follow-Up Studies; Gene Expression Regulation, Enzymologic; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mifepristone; Misoprostol; Postoperative Hemorrhage; Pregnancy; Time Factors; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Young Adult | 2014 |
[Pregnancy termination in Bulgaria – past, present and future perspectives. Drugs induced abortion – guidelines by WHO].
Topics: Abortifacient Agents; Abortion, Induced; Bulgaria; Female; History, 20th Century; History, 21st Century; Humans; Mifepristone; Misoprostol; Practice Guidelines as Topic; Pregnancy; World Health Organization | 2013 |
[Again about the drug induced abortion].
Topics: Abortifacient Agents; Abortion, Induced; Bulgaria; Female; Gestational Age; Humans; Methotrexate; Mifepristone; Misoprostol; Pregnancy | 2013 |
Medical management of early pregnancy failure (EPF): a retrospective analysis of a combined protocol of mifepristone and misoprostol used in clinical practice.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Spontaneous; Adolescent; Adult; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Logistic Models; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Retrospective Studies; Young Adult | 2014 |
Knowledge and provision practices regarding medical abortion among public providers in Hanoi, Khanh Hoa, and Ho Chi Minh City, Vietnam.
Topics: Abortifacient Agents; Abortion, Induced; Adult; Attitude of Health Personnel; Cross-Sectional Studies; Female; Health Care Surveys; Health Knowledge, Attitudes, Practice; Humans; Male; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Rural Health Services; Surveys and Questionnaires; Urban Health Services; Vietnam; Young Adult | 2014 |
Cervical preparation for second-trimester surgical abortion prior to 20 weeks' gestation: SFP Guideline #2013-4.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Female; Humans; Labor Stage, First; Laminaria; Magnesium Sulfate; Mifepristone; Misoprostol; Polymers; Polyvinyl Alcohol; Pregnancy; Pregnancy Trimester, Second | 2014 |
Acceptability and feasibility of medical abortion with mifepristone and misoprostol in Nigeria.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Oral; Adult; Ambulatory Care; Feasibility Studies; Female; Follow-Up Studies; Gestational Age; Humans; Mifepristone; Misoprostol; Nigeria; Patient Satisfaction; Pregnancy; Quality of Health Care; Young Adult | 2014 |
Practice bulletin no. 143: medical management of first-trimester abortion.
Topics: Abortifacient Agents; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Clinical Protocols; Directive Counseling; Drug Administration Schedule; Female; Humans; Methotrexate; Mifepristone; Misoprostol; Patient Selection; Pregnancy; Pregnancy Trimester, First; Tamoxifen | 2014 |
Changes in sexual function after medical or surgical termination of pregnancy.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Coitus; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Outcome Assessment, Health Care; Pregnancy; Pregnancy Trimester, First; Prospective Studies | 2014 |
Achievements of the FIGO Initiative for the Prevention of Unsafe Abortion and its Consequences in South-Southeast Asia.
Topics: Abortion, Incomplete; Abortion, Induced; Aftercare; Asia, Southeastern; Contraception; Drug Approval; Female; Humans; International Agencies; Midwifery; Mifepristone; Misoprostol; Pregnancy; Vacuum Curettage | 2014 |
Medical abortion with mifepristone and home administration of misoprostol up to 63 days' gestation.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Drug Therapy, Combination; Female; Gestational Age; Health Services Accessibility; Humans; Mifepristone; Misoprostol; Odds Ratio; Pain; Patient Acceptance of Health Care; Patient Satisfaction; Pregnancy; Prospective Studies; Self Administration; Travel; Uterine Hemorrhage | 2014 |
Medical management of first-trimester abortion.
Topics: Abortifacient Agents; Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Chorionic Gonadotropin; Counseling; Evidence-Based Medicine; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pregnancy; United States; United States Food and Drug Administration | 2014 |
When pregnancy must end in the second trimester.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 2014 |
Group A Streptococcus endometritis following medical abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Endometritis; Female; Humans; Mifepristone; Misoprostol; Streptococcal Infections; Streptococcus pyogenes | 2014 |
Acceptability and feasibility of mifepristone medical abortion in the early first trimester in Azerbaijan.
Topics: Abortifacient Agents; Abortion, Induced; Adolescent; Adult; Azerbaijan; Female; Humans; Middle Aged; Mifepristone; Misoprostol; Patient Acceptance of Health Care; Patient Satisfaction; Pregnancy; Pregnancy Trimester, First; Prospective Studies; Self Administration; Young Adult | 2014 |
Sequential use of mifepristone and misoprostol in treatment of early pregnancy failure appears more effective than misoprostol alone: a retrospective study.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Spontaneous; Administration, Intravaginal; Administration, Oral; Adult; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Retrospective Studies; Treatment Outcome | 2014 |
Medical management of unwanted pregnancy in France: modalities and outcomes. The aMaYa study.
Topics: Abortifacient Agents; Abortion, Induced; Adolescent; Adult; Drug Therapy, Combination; Female; France; Humans; Middle Aged; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Pregnancy Trimester, First; Pregnancy, Unwanted; Prospective Studies; Treatment Outcome; Young Adult | 2015 |
[Medical abortion--evidence-based practice].
Topics: Abortifacient Agents; Abortion, Induced; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimesters | 2014 |
Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Buccal; Adolescent; Adult; Cohort Studies; Drug Therapy, Combination; Evidence-Based Medicine; Female; Gestational Age; Humans; Logistic Models; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Retrospective Studies; Treatment Outcome; Young Adult | 2015 |
Clinical analyses of 66 cases of mid-trimester pregnancy termination in women with prior cesarean.
Topics: Abortion, Induced; Cesarean Section; Ethacridine; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimesters; Retrospective Studies; Uterine Rupture | 2015 |
Towards safe abortion access: an exploratory study of medical abortion in Cambodia.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Ambulatory Care Facilities; Cambodia; Drug Combinations; Female; Health Knowledge, Attitudes, Practice; Health Services Accessibility; Humans; Male; Mifepristone; Misoprostol; Patient Satisfaction; Pharmacists; Pregnancy; Sexual Partners; Young Adult | 2015 |
The introduction of first trimester medical abortion in Armenia.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Armenia; Drug Combinations; Female; Humans; Interviews as Topic; Middle Aged; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Pregnancy Trimester, First; Young Adult | 2015 |
Safety, efficacy and acceptability of outpatient mifepristone-misoprostol medical abortion through 70 days since last menstrual period in public sector facilities in Mexico City.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Drug Combinations; Female; Humans; Mexico; Middle Aged; Mifepristone; Misoprostol; Outpatients; Patient Acceptance of Health Care; Patient Satisfaction; Pregnancy; Pregnancy Trimester, First; Public Sector; Treatment Outcome; Young Adult | 2015 |
Pharmacy workers in Nepal can provide the correct information about using mifepristone and misoprostol to women seeking medication to induce abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Clinical Competence; Drug Combinations; Education, Pharmacy, Continuing; Female; Humans; Male; Mifepristone; Misoprostol; Nepal; Pharmacists; Pregnancy | 2015 |
Early serum human chorionic gonadotropin (hCG) trends after medication abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Chorionic Gonadotropin; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pregnancy; Retrospective Studies | 2015 |
Delivering medical abortion at scale: a study of the retail market for medical abortion in Madhya Pradesh, India.
Topics: Abortion, Induced; Abortion, Spontaneous; Adult; Female; Humans; India; Male; Mifepristone; Misoprostol; Pharmacists; Pregnancy; Private Sector | 2015 |
Association between ultrasonographic parameters of Cesarean scar defect and outcome of early termination of pregnancy.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adult; Cesarean Section; Cicatrix; Female; Humans; Mifepristone; Misoprostol; Myometrium; Postoperative Complications; Pregnancy; Retrospective Studies; Ultrasonography | 2016 |
Uterine artery Doppler in the management of early pregnancy loss: a prospective, longitudinal study.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Incomplete; Abortion, Spontaneous; Adult; Cohort Studies; Dilatation and Curettage; Disease Management; Female; Humans; Longitudinal Studies; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Prognosis; Prospective Studies; Pulsatile Flow; Ultrasonography, Doppler; Uterine Artery; Vascular Resistance; Young Adult | 2015 |
If we can do it for misoprostol, why not for mifepristone? The case for taking mifepristone out of the office in medical abortion.
Topics: Abortifacient Agents; Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Off-Label Use; Office Visits; Pregnancy; Self Administration; United States; United States Food and Drug Administration | 2015 |
Mifepristone by prescription: a dream in the United States but reality in Australia.
Topics: Abortifacient Agents; Abortion, Induced; Australia; Certification; Female; Humans; Mifepristone; Misoprostol; Nonprescription Drugs; Pharmacies; Pharmacists; Physicians; Pregnancy; United States | 2015 |
Medical abortion: the hidden revolution.
Topics: Abortifacient Agents; Abortion, Induced; Commerce; Drug Utilization; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 2015 |
Reaching women where they are: eliminating the initial in-person medical abortion visit.
Topics: Abortifacient Agents; Abortion, Induced; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Office Visits; Pregnancy; Telemedicine; United States; United States Food and Drug Administration; Women's Health | 2015 |
Off-label indications for mifepristone in gynecology and obstetrics.
Topics: Abortifacient Agents; Abortion, Induced; Drug Therapy, Combination; Evidence-Based Medicine; Female; Gynecology; Humans; Mifepristone; Misoprostol; Obstetrics; Off-Label Use; Pregnancy | 2015 |
Introducing medication abortion into public sector facilities in KwaZulu-Natal, South Africa: an operations research study.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Contraception; Feasibility Studies; Female; Humans; Mifepristone; Misoprostol; Operations Research; Patient Satisfaction; Pregnancy; South Africa; Treatment Outcome; Young Adult | 2015 |
Medication abortion failure in women with and without previous cesarean delivery.
Topics: Abortifacient Agents; Abortion, Induced; Adolescent; Adult; Cesarean Section; Female; Humans; Logistic Models; Mifepristone; Misoprostol; Parity; Pregnancy; Retrospective Studies; Treatment Failure; Young Adult | 2015 |
The Evolution of Medication Abortion Care: Using Science to Achieve Quality.
Topics: Abortifacient Agents; Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First | 2015 |
[Practical guidance for termination of pregnancy at 8 to 16 weeks gestation with mifepristone and misoprostol].
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Practice Guidelines as Topic; Pregnancy; Pregnancy Trimester, First; Treatment Outcome | 2015 |
Comment on the combination of mifepristone and misoprostol for the termination of second-trimester pregnancy.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 2015 |
Feasibility and effectiveness of unintended pregnancy prevention with low-dose mifepristone combined with misoprostol before expected menstruation.
Topics: Abortifacient Agents; Adolescent; Adult; Chorionic Gonadotropin; Contraceptive Agents; Drug Therapy, Combination; Female; Humans; Menstrual Cycle; Menstruation; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Treatment Outcome; Young Adult | 2015 |
Pain during medical abortion: a multicenter study in France.
Topics: Abdominal Pain; Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Age Factors; Analgesics; Female; France; Gravidity; Humans; Middle Aged; Mifepristone; Misoprostol; Pain Measurement; Pain, Postoperative; Pregnancy; Surveys and Questionnaires; Young Adult | 2015 |
Mifepristone With Buccal Misoprostol for Medical Abortion: A Systematic Review.
Topics: Abortifacient Agents; Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 2015 |
In Reply.
Topics: Abortifacient Agents; Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 2015 |
First-trimester medical abortion service in Hong Kong.
Topics: Abdominal Pain; Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Clinical Protocols; Diarrhea; Drug Hypersensitivity; Female; Fever; Hong Kong; Humans; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Treatment Failure; Young Adult | 2015 |
Women's experiences with medication for menstrual regulation in Bangladesh.
Topics: Abortifacient Agents; Adult; Attitude to Health; Bangladesh; Decision Making; Drug Costs; Family Planning Services; Female; Humans; Menstruation; Mifepristone; Misoprostol; Qualitative Research; Rural Population; Urban Population; Young Adult | 2016 |
[Methods of induction of labor in termination of pregnancy after 22weeks: About 3procedures].
Topics: Abortifacient Agents; Abortion, Induced; Adult; Female; Humans; Labor, Induced; Laminaria; Mifepristone; Misoprostol; Outcome and Process Assessment, Health Care; Pregnancy; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Retrospective Studies | 2016 |
Short versus Standard Mifepristone and Misoprostol Regimen for Second- and Third-Trimester Termination of Pregnancy for Fetal Anomaly.
Topics: Abortifacient Agents; Abortion, Induced; Adult; Female; Fetal Diseases; Humans; Mifepristone; Misoprostol; Pregnancy; Retrospective Studies | 2016 |
Role of laparoscopy as a minimally invasive procedure in treatment of ruptured uterine scar during second-trimester induction of abortion.
Topics: Abortion, Induced; Adult; Cesarean Section; Cicatrix; Female; Humans; Laparoscopy; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Ultrasonography; Uterine Rupture | 2016 |
[Medical termination of pregnancy by mifepristone and misoprostol - evaluation of succes rate, complications and satisfaction of patients].
Topics: Abortifacient Agents; Abortion, Induced; Adult; Cohort Studies; Dilatation and Curettage; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Nausea; Personal Satisfaction; Pregnancy; Retrospective Studies; Surveys and Questionnaires; Treatment Outcome; Uterine Hemorrhage; Vomiting | 2015 |
Elevated mRNA expression of PGF2α receptor splice variant 2(FP-V2) in human decidua is associated with incomplete mifepristone-misoprostol-induced early medical abortion by regulation of interleukin-8.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Analysis of Variance; Case-Control Studies; Cytokines; Decidua; Dinoprost; Female; Humans; Interleukin-8; Mifepristone; Misoprostol; Protein Isoforms; Real-Time Polymerase Chain Reaction; Receptors, Prostaglandin; RNA, Messenger; Young Adult | 2016 |
Feasibility of self-performed urine pregnancy testing for follow-up after medical abortion.
Topics: Abortifacient Agents; Abortion, Induced; Adult; Aftercare; Chorionic Gonadotropin; Feasibility Studies; Female; Humans; Longitudinal Studies; Lost to Follow-Up; Mifepristone; Misoprostol; Patient Acceptance of Health Care; Pregnancy; Pregnancy Tests; Prospective Studies; Young Adult | 2016 |
[Protocol to induce abortion using Mifepristone and Misoprostol].
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Anti-Bacterial Agents; Female; Humans; Mifepristone; Misoprostol | 2015 |
Progestin-based contraceptive on the same day as medical abortion.
Topics: Abortion, Induced; Adolescent; Adult; Contraceptive Agents, Female; Contraceptive Devices, Female; Desogestrel; Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Progestins; Retrospective Studies; South Africa; Time Factors; Young Adult | 2016 |
"In patient" medical abortion versus surgical abortion: patient's satisfaction.
Topics: Abortifacient Agents; Abortion, Induced; Adolescent; Adult; Anesthesia, General; Female; Follow-Up Studies; Humans; Inpatients; Mifepristone; Misoprostol; Patient Outcome Assessment; Patient Satisfaction; Vacuum Curettage; Young Adult | 2016 |
Efficacy of early induced medical abortion with mifepristone when beginning progestin-only contraception on the same day.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Contraception; Female; Gravidity; Humans; Mexico; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Progestins; Self Administration; Ultrasonography; Vacuum Curettage; Young Adult | 2016 |
Woman in Northern Ireland who bought abortion pills online is given suspended sentence.
Topics: Abortifacient Agents; Abortion, Criminal; Abortion, Spontaneous; Female; Humans; Internet; Mifepristone; Misoprostol; Northern Ireland; Pregnancy; Punishment; Young Adult | 2016 |
Uncomplicated abortion with mifepristone and misoprostol in a hemophilia A carrier.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Female; Hemophilia A; Humans; Mifepristone; Misoprostol; Pregnancy; Young Adult | 2016 |
Comparing office and telephone follow-up after medical abortion.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; California; Female; Follow-Up Studies; Gestational Age; Humans; Lost to Follow-Up; Middle Aged; Mifepristone; Misoprostol; Office Visits; Patient Satisfaction; Pregnancy; Telephone; Young Adult | 2016 |
Exploring Canadian women's knowledge of and interest in mifepristone: results from a national qualitative study with abortion patients.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Female; Health Knowledge, Attitudes, Practice; Humans; Interviews as Topic; Mifepristone; Misoprostol; Ontario; Pregnancy; Qualitative Research; Quebec; Young Adult | 2016 |
[Influence of early amniotomy and parity on induction-to-delivery interval during termination of pregnancy].
Topics: Abortion, Induced; Adult; Female; Fetal Membranes, Premature Rupture; Gestational Age; Humans; Mifepristone; Misoprostol; Parity; Pregnancy; Time Factors; Treatment Outcome | 2016 |
Refocusing the Undue Burden Test: Inconsistent Interpretations Pose a Substantial Obstacle to Constitutional Legislation.
Topics: Abortifacient Agents, Steroidal; Abortion, Legal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Mifepristone; Misoprostol; Off-Label Use; Pregnancy; United States; United States Food and Drug Administration | 2016 |
Prospective study of home use of mifepristone and misoprostol for medical abortion up to 10weeks of pregnancy in Kazakhstan.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Ambulatory Care; Female; Humans; Kazakhstan; Mifepristone; Misoprostol; Outcome Assessment, Health Care; Pregnancy; Pregnancy Trimester, First; Prospective Studies; Women's Health Services; Young Adult | 2016 |
Assessing abortion coverage in nurse practitioner programs in Canada: a national survey of program directors.
Topics: Abortion, Induced; Abortion, Spontaneous; Canada; Curriculum; Female; Humans; Male; Mifepristone; Misoprostol; Nurse Practitioners; Physician Executives; Pregnancy; Reproductive Health Services; Surveys and Questionnaires | 2016 |
Acceptability and feasibility of 400 μg buccal misoprostol after 200 mg mifepristone for early medical abortion in Georgia.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Buccal; Adult; Feasibility Studies; Female; Georgia (Republic); Humans; Mifepristone; Misoprostol; Patient Acceptance of Health Care; Patient Satisfaction; Prospective Studies; Self Administration; Treatment Outcome; Young Adult | 2016 |
Medical abortion in women with large uterine fibroids: a case series.
Topics: Abortifacient Agents; Abortion, Induced; Administration, Intravaginal; Adult; Drug Administration Schedule; Female; Gestational Age; Humans; Leiomyoma; Maryland; Mifepristone; Misoprostol; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, First; Pregnancy Trimester, Second; Uterine Neoplasms | 2016 |
Mifepristone and misoprostol is safe and effective method in the second-trimester pregnancy termination.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adolescent; Adult; Female; Humans; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Retrospective Studies; Young Adult | 2016 |
Marked improvement in the success rate of medical management of early pregnancy failure following the implementation of a novel institutional protocol and treatment guidelines: a follow-up study.
Topics: Abortifacient Agents; Abortion, Spontaneous; Administration, Intravaginal; Adolescent; Adult; Clinical Protocols; Female; Follow-Up Studies; Humans; Middle Aged; Mifepristone; Misoprostol; Practice Guidelines as Topic; Pregnancy; Retrospective Studies | 2016 |
Comparison of Outcomes before and after Ohio's Law Mandating Use of the FDA-Approved Protocol for Medication Abortion: A Retrospective Cohort Study.
Topics: Abortion, Induced; Adult; Clinical Protocols; Drug Therapy, Combination; Female; Humans; Legislation, Drug; Mifepristone; Misoprostol; Ohio; Pregnancy; Retrospective Studies; Treatment Outcome; United States; United States Food and Drug Administration; Young Adult | 2016 |
Factors related to completeness of medical abortion with mifepristone and misoprostol.
Topics: Abortion, Induced; Adolescent; Adult; Female; Humans; Insulin-Like Growth Factor I; Mifepristone; Misoprostol; Pregnancy; Receptors, Estrogen; RNA, Messenger; Vascular Endothelial Growth Factor A; Young Adult | 2017 |
Serum human chorionic gonadotropin (hCG) trend within the first few days after medical abortion: a prospective study.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Chorionic Gonadotropin; Female; Humans; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Prospective Studies; Time Factors; United States; Young Adult | 2017 |
Second trimester medical abortion with mifepristone followed by unlimited dosing of buccal misoprostol in Armenia.
Topics: Abortifacient Agents; Abortion, Induced; Administration, Buccal; Adult; Armenia; Drug Administration Schedule; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Time Factors; Treatment Outcome | 2017 |
Implementing medical abortion with mifepristone and misoprostol in Norway 1998-2013.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Drug Therapy, Combination; Female; Gestational Age; Health Services Accessibility; Humans; Logistic Models; Middle Aged; Mifepristone; Misoprostol; Multivariate Analysis; Norway; Patient Satisfaction; Pregnancy; Prospective Studies; Registries; Self Administration; Surveys and Questionnaires; Young Adult | 2017 |
Serial multilevel urine pregnancy testing to assess medical abortion outcome: a meta-analysis.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Chorionic Gonadotropin; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Tests; Sensitivity and Specificity; Time Factors; Treatment Outcome | 2017 |
Abortion choices among women in Cambodia after introduction of a socially marketed medicated abortion product.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adolescent; Adult; Cambodia; Choice Behavior; Cross-Sectional Studies; Female; Humans; Maternal Mortality; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Social Marketing; Surveys and Questionnaires; Vacuum Curettage; Young Adult | 2017 |
Efficacy and safety of mifepristone-buccal misoprostol for early medical abortion in an Australian clinical setting.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Buccal; Administration, Oral; Adolescent; Adult; Australia; Female; Gestational Age; Humans; Maternal Age; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Prospective Studies; Young Adult | 2017 |
Putting research into practice at the 2017 National Abortion Federation Annual Meeting.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Biomedical Research; Canada; Congresses as Topic; Female; Health Personnel; Humans; Mifepristone; Misoprostol; Pregnancy; United States | 2017 |
Doctors, pharmacists push back on medical abortion rules.
Topics: Abortifacient Agents; Abortion, Induced; Confidentiality; Government Agencies; Health Policy; Humans; Mifepristone; Misoprostol; Pharmacists; Physicians | 2017 |
Self-management of first trimester medical termination of pregnancy: a qualitative study of women's experiences.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Decision Making; Female; Humans; Mifepristone; Misoprostol; Nurse-Patient Relations; Pain Management; Patient Education as Topic; Patient Satisfaction; Pregnancy; Pregnancy Trimester, First; Qualitative Research; Scotland; Self Administration; Self-Management; Young Adult | 2017 |
Self reported outcomes and adverse events after medical abortion through online telemedicine: population based study in the Republic of Ireland and Northern Ireland.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Female; Follow-Up Studies; Gestational Age; Humans; Internet; Ireland; Middle Aged; Mifepristone; Misoprostol; Northern Ireland; Pregnancy; Self Report; Telemedicine; Treatment Outcome; Young Adult | 2017 |
Medical abortion is fundamental to women's health care.
Topics: Abortion, Induced; Australia; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Women's Health | 2017 |
Updates to the US Food and Drug Administration Regulations for Mifepristone: Implications for Clinical Practice and Access to Abortion.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Drug and Narcotic Control; Drug Labeling; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Gestational Age; Government Regulation; Health Personnel; Humans; Midwifery; Mifepristone; Misoprostol; Nurse Midwives; Nurse Practitioners; Physician Assistants; Pregnancy; Professional Practice; United States; United States Food and Drug Administration | 2017 |
Medical treatment of second-trimester fetal miscarriage; A retrospective analysis.
Topics: Abortion, Spontaneous; Adult; Drug Administration Schedule; Female; Humans; Length of Stay; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Retrospective Studies | 2017 |
Feasibility of assessing the safety and effectiveness of menstrual regulation medications purchased from pharmacies in Bangladesh: a prospective cohort study.
Topics: Adult; Bangladesh; Feasibility Studies; Female; Humans; Menstruation-Inducing Agents; Mifepristone; Misoprostol; Outcome Assessment, Health Care; Patient Acceptance of Health Care; Pharmaceutical Services; Pharmacies; Pregnancy; Prospective Studies | 2018 |
Case report of induced medical abortion following depot administration of medroxyprogesterone acetate.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Ambulatory Care; Contraception; Contraceptive Agents, Female; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Therapy, Combination; Female; Humans; Medroxyprogesterone Acetate; Mifepristone; Misoprostol; Pregnancy; Treatment Outcome | 2017 |
Barriers to accessing abortion services and perspectives on using mifepristone and misoprostol at home in Great Britain.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adult; Female; Health Services Accessibility; Humans; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Self Administration; United Kingdom; Young Adult | 2018 |
First trimester medication abortion practice in the United States and Canada.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Aged; Aged, 80 and over; Ambulatory Care Facilities; Canada; Cross-Sectional Studies; Evidence-Based Practice; Female; Health Personnel; Humans; Male; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Surveys and Questionnaires; United States | 2017 |
Self-sourced online and self-directed at home: a new frontier for abortion in the United States.
Topics: Abortion, Induced; Abortion, Spontaneous; Female; Humans; Internet; Mifepristone; Misoprostol; Pregnancy; United States | 2018 |
Exploring the feasibility of obtaining mifepristone and misoprostol from the internet.
Topics: Abortion, Induced; Counterfeit Drugs; Drug Costs; Drug Therapy, Combination; Female; Health Services Accessibility; Humans; Internet; Mifepristone; Misoprostol; Pregnancy; United States | 2018 |
Cervical preparation prior to surgical abortion in real-life conditions and factors driving the prescription: A national observational study.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adolescent; Adult; Cervix Uteri; Drug Prescriptions; Female; Humans; Middle Aged; Mifepristone; Misoprostol; Prospective Studies; Young Adult | 2017 |
Mifepristone-misoprostol for menstrual regulation in public sector facilities in Bangladesh.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adult; Bangladesh; Drug Therapy, Combination; Female; Hospitals, Public; Humans; Menstruation-Inducing Agents; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Prospective Studies; Treatment Outcome; Young Adult | 2018 |
Provision of medical abortion by midlevel healthcare providers in Kyrgyzstan: testing an intervention to expand safe abortion services to underserved rural and periurban areas.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adult; Contraception; Female; Health Personnel; Humans; Kyrgyzstan; Medically Underserved Area; Midwifery; Mifepristone; Misoprostol; Nurse Midwives; Pregnancy; Rural Health Services; Rural Population; Urban Health Services | 2018 |
Combination therapy with mifepristone and misoprostol for the management of first trimester miscarriage: Improved success.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Spontaneous; Adult; Cohort Studies; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Retrospective Studies; Treatment Outcome | 2018 |
Simplified medical abortion screening: a demonstration project.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Oral; Administration, Sublingual; Adolescent; Adult; Female; Humans; Mexico; Mifepristone; Misoprostol; Moldova; Patient Satisfaction; Pregnancy; Pregnancy Trimester, First; Pregnancy, Ectopic; Prospective Studies; Ultrasonography; United States; Uterus; Young Adult | 2018 |
Provision of menstrual regulation with medication among pharmacies in three municipal districts of Bangladesh: a situation analysis.
Topics: Adult; Bangladesh; Cities; Contraceptive Agents; Cross-Sectional Studies; Female; Humans; Menstruation-Inducing Agents; Mifepristone; Misoprostol; Pharmaceutical Services; Pharmacies; Pregnancy; Urban Health Services | 2018 |
Medical abortion pills have the potential to change everything about abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Personal Autonomy; Pregnancy | 2018 |
Self-assessment of medical abortion outcome using symptoms and home pregnancy testing.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Female; Humans; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Pregnancy Tests; Self-Assessment; Treatment Outcome; United States; Young Adult | 2018 |
Effectiveness and safety of early medication abortion provided in pharmacies by auxiliary nurse-midwives: A non-inferiority study in Nepal.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Female; Health Services Accessibility; Humans; Mifepristone; Misoprostol; Nepal; Nurse Midwives; Pharmacies; Pregnancy; Public Health Nursing; Safety; Treatment Outcome; Young Adult | 2018 |
Simultaneous Compared With Interval Medical Abortion Regimens Where Home Use Is Restricted.
Topics: Abortifacient Agents; Abortion, Induced; Adult; Databases, Factual; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Logistic Models; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Retrospective Studies; Treatment Outcome; United Kingdom; Young Adult | 2018 |
Early IUD insertion after medically induced abortion.
Topics: Abortifacient Agents; Abortion, Induced; Adult; Female; Humans; Intrauterine Device Expulsion; Intrauterine Devices, Copper; Mifepristone; Misoprostol; Patient Satisfaction; Prospective Studies; Socioeconomic Factors; Time Factors; Young Adult | 2018 |
Mifepristone.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Canada; Drug Therapy, Combination; Family Planning Services; Female; Guidelines as Topic; Humans; Insurance Coverage; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Pregnancy Trimester, Second | 2018 |
The costs and cost effectiveness of providing second-trimester medical and surgical safe abortion services in Western Cape Province, South Africa.
Topics: Abortifacient Agents; Abortion, Induced; Abortion, Spontaneous; Adult; Cost-Benefit Analysis; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Pregnancy Trimester, Second; South Africa | 2018 |
Early medical abortion with self-administered low-dose mifepristone in combination with misoprostol.
Topics: Abortifacient Agents; Abortion, Induced; Adult; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Outcome Assessment, Health Care; Self Administration; Young Adult | 2018 |
ACOG Practice Bulletin No. 200: Early Pregnancy Loss.
Topics: Abortifacient Agents; Abortion, Spontaneous; Dilatation and Curettage; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Rh Isoimmunization; Rho(D) Immune Globulin; Ultrasonography; Watchful Waiting | 2018 |
Acceptability and feasibility of outpatient medical abortion with mifepristone and misoprostol up to 70 days gestation in Singapore.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Feasibility Studies; Female; Humans; Mifepristone; Misoprostol; Patient Acceptance of Health Care; Pilot Projects; Prospective Studies; Young Adult | 2018 |
Use of an at-home multilevel pregnancy test and an automated call-in system to follow-up the outcome of medical abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adolescent; Adult; Female; Follow-Up Studies; Humans; Mexico; Mifepristone; Misoprostol; Outcome Assessment, Health Care; Pilot Projects; Pregnancy; Pregnancy Tests; Prospective Studies; Telephone; Young Adult | 2019 |
Contraception after medication abortion should be determined by convenience and choice.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Contraception; Female; Humans; Mifepristone; Misoprostol | 2018 |
Response to 'Home use of misoprostol: is it really safe and appreciated?'
Topics: Abortifacient Agents, Nonsteroidal; Mifepristone; Misoprostol | 2018 |
Dosing interval between mifepristone and misoprostol in second and third trimester termination.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Retrospective Studies | 2019 |
Serum hCG threshold to assess medical abortion success.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adult; Chorionic Gonadotropin; Female; Gestational Age; Humans; Logistic Models; Mifepristone; Misoprostol; Odds Ratio; Outcome Assessment, Health Care; Pregnancy; Pregnancy Trimester, First; Prospective Studies; Reference Values; Treatment Outcome | 2018 |
ACOG Practice Bulletin No. 200 Summary: Early Pregnancy Loss.
Topics: Abortifacient Agents; Abortion, Spontaneous; Dilatation and Curettage; Female; Humans; Mifepristone; Misoprostol; Practice Guidelines as Topic; Pregnancy; Pregnancy Trimester, First; Rh Isoimmunization; Rho(D) Immune Globulin; Ultrasonography; Watchful Waiting | 2018 |
Could second-trimester medical abortion be offered as a day service? Assessing the feasibility of a 1-day outpatient procedure using pooled data from six clinical studies.
Topics: Abortifacient Agents; Abortion, Induced; Adolescent; Adult; Ambulatory Care; Feasibility Studies; Female; Gestational Age; Humans; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Randomized Controlled Trials as Topic; Time Factors; Young Adult | 2019 |
Pharmacy Provision of Medication Abortion in Nepal: Pharmacy Owner and Worker Perspectives.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adult; Attitude of Health Personnel; Female; Health Knowledge, Attitudes, Practice; Health Services Accessibility; Humans; Interviews as Topic; Male; Middle Aged; Mifepristone; Misoprostol; Nepal; Pharmacies; Pharmacists | 2018 |
Risk factors for surgical intervention of early medical abortion.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Cesarean Section; Cohort Studies; Delivery, Obstetric; Female; Gestational Age; Humans; Maternal Age; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Risk Factors; Vacuum Curettage; Young Adult | 2019 |
Medical management of first trimester missed miscarriage: the efficacy and complication rate.
Topics: Abortifacient Agents; Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Missed; Adolescent; Adult; Chorionic Gonadotropin, beta Subunit, Human; Curettage; Female; Gestational Age; Humans; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Retrospective Studies; Uterine Hemorrhage; Young Adult | 2019 |
Abortion providers' experiences and views on self-managed medication abortion: an exploratory study.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Incomplete; Abortion, Induced; Adult; Female; Gestational Age; Humans; Logistic Models; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Reproductive Health; Self Administration; Young Adult | 2019 |
Outcomes During Early Implementation of Mifepristone-Buccal Misoprostol Abortions up to 63 Days of Gestation in a Canadian Clinical Setting.
Topics: Abortifacient Agents; Abortion, Induced; Administration, Oral; Adolescent; Adult; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Retrospective Studies; Young Adult | 2019 |
Pathways to seeking medication abortion care: A qualitative research in Uttar Pradesh, India.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Decision Making; Female; Gynecology; Health Knowledge, Attitudes, Practice; Humans; India; Male; Mifepristone; Misoprostol; Patient Acceptance of Health Care; Pharmacies; Pregnancy; Qualitative Research; Young Adult | 2019 |
Medical abortion with mifepristone and vaginal misoprostol between 64 and 70 days' gestation.
Topics: Abortifacient Agents; Abortion, Incomplete; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Drug Therapy, Combination; Female; Humans; Middle Aged; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Pregnancy Trimester, First; Treatment Outcome; United Kingdom; Young Adult | 2019 |
TelAbortion: evaluation of a direct to patient telemedicine abortion service in the United States.
Topics: Abortifacient Agents; Abortion, Induced; Adolescent; Adult; Female; Humans; Middle Aged; Mifepristone; Misoprostol; Outcome Assessment, Health Care; Patient Satisfaction; Pregnancy; Self Administration; Telemedicine; United States; Young Adult | 2019 |
Current and future expectations of mifepristone treatment in early pregnancy failure: a survey among Dutch gynaecologists.
Topics: Abortifacient Agents; Abortion, Spontaneous; Female; Gynecology; Humans; Mifepristone; Misoprostol; Netherlands; Pregnancy; Surveys and Questionnaires | 2019 |
The Benefits of a Guideline on Safe Termination of Pregnancy for Legal Indications: An Illustrative Case Report of a Hydranencephaly.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Administration, Oral; Adult; Female; Humans; Hydranencephaly; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Treatment Outcome | 2019 |
A comparison between labor induction with only Dilapan-S and a combination of mifepristone and Dilapan-S in nulliparous women: a prospective pilot study.
Topics: Cervical Ripening; Female; Humans; Infant, Newborn; Labor, Induced; Mifepristone; Misoprostol; Oxytocics; Parity; Pilot Projects; Polymers; Pregnancy; Prospective Studies | 2021 |
Clinical application of low-dose misoprostol in the induced labor of 16 to 28 weeks pathological pregnancies (a STROBE-compliant article).
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adult; Asian People; China; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Oligohydramnios; Pregnancy; Pregnancy Complications; Pregnancy Trimester, Second; Time Factors; Uterine Rupture | 2019 |
Drug Seller Provision Practices and Knowledge of Misoprostol in Bangladesh.
Topics: Abortifacient Agents, Nonsteroidal; Adult; Attitude of Health Personnel; Bangladesh; Cross-Sectional Studies; Female; Humans; Menstruation-Inducing Agents; Mifepristone; Misoprostol; Outcome Assessment, Health Care; Pharmaceutical Services; Pharmacies | 2019 |
Label comprehension of a combined mifepristone and misoprostol product for medical abortion: A pilot study in South Africa.
Topics: Abortifacient Agents; Adolescent; Adult; Drug Labeling; Drug Therapy, Combination; Female; Health Literacy; Humans; Middle Aged; Mifepristone; Misoprostol; Non-Randomized Controlled Trials as Topic; Pilot Projects; Pregnancy; South Africa; Young Adult | 2020 |
Effect of the addition of osmotic dilators to medical induction of labor abortion: A before-and-after study.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Female; Humans; Labor, Induced; Mifepristone; Misoprostol; Polymers; Pregnancy; Retrospective Studies; Young Adult | 2020 |
Efficacy of mifepristone and misoprostol for medical treatment of missed miscarriage in clinical practice-A cohort study.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Missed; Adolescent; Adult; Drug Therapy, Combination; Female; Humans; Middle Aged; Mifepristone; Misoprostol; Organ Size; Pregnancy; Pregnancy Trimesters; Treatment Outcome; Ultrasonography; Uterus; Young Adult | 2020 |
PURL: Early pregnancy loss: Pretreat with mifepristone?
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Spontaneous; Administration, Oral; Adult; Drug Therapy, Combination; Family Practice; Female; Humans; Mifepristone; Misoprostol; Practice Guidelines as Topic; Pregnancy | 2019 |
A cross-sectional analysis of mifepristone, misoprostol, and combination mifepristone-misoprostol package inserts obtained in 20 countries.
Topics: Abortifacient Agents; Abortion, Induced; Alprostadil; Cross-Sectional Studies; Developing Countries; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Product Labeling; Treatment Outcome | 2020 |
When patients change their minds after starting an abortion: Guidance from the National Abortion Federation's Clinical Policies Committee.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Decision Making; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First | 2020 |
Medication abortion use among low-income and rural Texans before and during state-imposed restrictions and after FDA-updated labeling.
Topics: Abortifacient Agents; Abortion, Induced; Ambulatory Care Facilities; Drug Labeling; Female; Geographic Mapping; Health Services Accessibility; Healthcare Disparities; Humans; Mifepristone; Misoprostol; Poverty; Pregnancy; Retrospective Studies; Rural Population; Spatial Analysis; Texas; Travel; United States; United States Food and Drug Administration | 2020 |
"It gives you autonomy over your own choices": A qualitative study of Canadian abortion patients' experiences with mifepristone and misoprostol.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Abortion, Spontaneous; Canada; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 2020 |
Commentary: No-test medication abortion: A sample protocol for increasing access during a pandemic and beyond.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Coronavirus; Coronavirus Infections; Female; Humans; Mifepristone; Misoprostol; Pandemics; Pneumonia, Viral; Practice Guidelines as Topic | 2020 |
Complication rates of dilation and evacuation and labor induction in second-trimester abortion for fetal indications: A retrospective cohort study.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Dilatation; Female; Humans; Labor, Induced; Mifepristone; Misoprostol; Placenta; Pregnancy; Pregnancy Trimester, Second; Retrospective Studies | 2020 |
Effectiveness of self-managed medication abortion between 13 and 24 weeks gestation: A retrospective review of case records from accompaniment groups in Argentina, Chile, and Ecuador.
Topics: Abortion, Induced; Abortion, Spontaneous; Argentina; Chile; Ecuador; Female; Humans; Mifepristone; Misoprostol; Placenta; Pregnancy; Retrospective Studies | 2020 |
Mifepristone-misoprostol versus misoprostol-alone regimen for medication abortion at ≥24 weeks' gestation.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pregnancy; Retrospective Studies | 2020 |
A repeat dose of misoprostol 800 mcg following mifepristone for outpatient medical abortion at 64-70 and 71-77 days of gestation: A retrospective chart review.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Outpatients; Pregnancy; Prospective Studies; Retrospective Studies | 2020 |
2017-19 governmental decisions to allow home use of misoprostol for early medical abortion in the UK.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Abortion, Spontaneous; Female; Humans; Mifepristone; Misoprostol; Pregnancy; United Kingdom | 2020 |
Risk of surgical evacuation and risk of major surgery following second-trimester medical abortion in Denmark: A nationwide cohort study.
Topics: Abortion, Induced; Cohort Studies; Denmark; Female; Humans; Infant, Newborn; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second | 2020 |
Evaluation of shorter mifepristone to misoprostol intervals for second trimester medical abortion: a retrospective cohort study.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Female; Humans; Infant; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Retrospective Studies | 2020 |
Medication Abortion Up to 70 Days of Gestation: ACOG Practice Bulletin, Number 225.
Topics: Abortifacient Agents; Abortion, Induced; Clinical Protocols; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; United States | 2020 |
Medication Abortion Up to 70 Days of Gestation.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Clinical Protocols; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pregnancy; United States; United States Food and Drug Administration | 2020 |
Medical management of miscarriage with mifepristone.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Spontaneous; Double-Blind Method; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 2020 |
Mifepristone Combination Therapy Compared With Misoprostol Monotherapy for the Management of Miscarriage: A Cost-Effectiveness Analysis.
Topics: Abortifacient Agents; Abortion, Incomplete; Abortion, Induced; Cost-Benefit Analysis; Dilatation and Curettage; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Monte Carlo Method; Practice Patterns, Physicians'; Pregnancy | 2020 |
Efficacy of mifepristone - Prostaglandin analogue combination in medical termination of pregnancy up to and beyond 7 weeks of amenorrhea: The RYMMa study.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adult; Amenorrhea; Female; France; Humans; Longitudinal Studies; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Prospective Studies; Young Adult | 2020 |
Uterine Rupture During Medical Induction for Second Trimester Abortion.
Topics: Abortion, Induced; Adult; Female; Humans; Mifepristone; Misoprostol; Nepal; Pregnancy; Pregnancy Trimester, Second; Uterine Rupture | 2020 |
Medication Abortion Up to 70 Days of Gestation: ACOG Practice Bulletin Summary, Number 225.
Topics: Abortifacient Agents; Abortion, Induced; Clinical Protocols; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Practice Guidelines as Topic; Pregnancy; Pregnancy Trimester, First; United States | 2020 |
Self-managed medication abortion outcomes: results from a prospective pilot study.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Abortion, Spontaneous; Female; Humans; Mifepristone; Misoprostol; Pilot Projects; Pregnancy; Prospective Studies; Self Administration; Self-Management; Treatment Outcome | 2020 |
Cost of goods sold analysis and recommendations to reduce costs of co-packaged mifepristone-misoprostol for medical abortion.
Topics: Abortion, Induced; Bangladesh; China; Cost-Benefit Analysis; Female; Humans; India; Mifepristone; Misoprostol; Pregnancy | 2020 |
Task-sharing in menstrual regulation services: Implementation efforts and lessons learned in Bangladesh.
Topics: Abortion, Induced; Bangladesh; Family Planning Services; Female; Humans; Menstrual Cycle; Mifepristone; Misoprostol; Pregnancy; Vacuum Curettage | 2020 |
Abortion Self-Care: A Forward-Looking Solution To Inequitable Access.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy, Unwanted; Self Care | 2020 |
Misoprostol before to first-trimester surgical abortion: do not jump on the bandwagon, not all evidence is created equal.
Topics: Abortifacient Agents, Nonsteroidal; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First | 2020 |
"False positive" urine pregnancy test results after successful medication abortion.
Topics: Abortion, Induced; Abortion, Spontaneous; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Tests | 2021 |
Second trimester medical abortion in a primigravida with lupus nephritis and rapidly progressive renal failure: challenges and outcome.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Female; Humans; Lupus Nephritis; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Renal Insufficiency; Treatment Outcome | 2021 |
[Mifepristone in primary care: no impediments against its use in management of missed miscarriage].
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Legal; Abortion, Missed; Adult; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Netherlands; Pilot Projects; Pregnancy; Primary Health Care | 2021 |
Out-of-clinic and self-managed abortion in Bangladesh: menstrual regulation provider perspectives.
Topics: Abortion, Induced; Bangladesh; Family Planning Services; Female; Humans; Menstruation; Mifepristone; Misoprostol; Pregnancy; Self-Management | 2021 |
Expansion of a direct-to-patient telemedicine abortion service in the United States and experience during the COVID-19 pandemic.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; COVID-19; Female; Humans; Middle Aged; Mifepristone; Misoprostol; Postal Service; Pregnancy; SARS-CoV-2; Telemedicine; United States; Young Adult | 2021 |
Provision of medication abortion in Hawai'i during COVID-19: Practical experience with multiple care delivery models.
Topics: Abortifacient Agents; Abortion, Induced; Adult; Aftercare; COVID-19; Female; Hawaii; Humans; Mifepristone; Misoprostol; Outcome Assessment, Health Care; Pregnancy; Retrospective Studies; Telemedicine; Ultrasonography, Prenatal | 2021 |
Missing mifepristone at tribal health facilities serving native Americans.
Topics: Abortion, Induced; Abortion, Spontaneous; American Indian or Alaska Native; Female; Health Facilities; Humans; Mifepristone; Misoprostol; Pregnancy | 2021 |
Mifepristone and Misoprostol for Early Pregnancy Loss and Medication Abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Abortion, Spontaneous; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Prenatal Care | 2021 |
Deaths and Severe Adverse Events after the use of Mifepristone as an Abortifacient from September 2000 to February 2019.
Topics: Abortifacient Agents; Abortifacient Agents, Steroidal; Abortion, Induced; COVID-19; Female; Humans; Mifepristone; Misoprostol; Pandemics; Pregnancy; SARS-CoV-2 | 2021 |
"I'll just deal with this on my own": a qualitative exploration of experiences with self-managed abortion in the United States.
Topics: Abortion, Induced; Abortion, Spontaneous; Adult; Female; Health Services Accessibility; Humans; Interviews as Topic; Mifepristone; Misoprostol; Motivation; Pregnancy; Qualitative Research; Self-Management; United States | 2021 |
Client satisfaction and experience of telemedicine and home use of mifepristone and misoprostol for abortion up to 10 weeks' gestation at British Pregnancy Advisory Service: A cross-sectional evaluation.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Consultants; Cross-Sectional Studies; Female; Humans; Mifepristone; Misoprostol; Personal Satisfaction; Pregnancy; Referral and Consultation; Telemedicine; Telephone | 2021 |
The disproportionate burdens of the mifepristone REMS.
Topics: Abortifacient Agents; Abortifacient Agents, Steroidal; Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 2021 |
Factors Associated With Use of an Online Telemedicine Service to Access Self-managed Medical Abortion in the US.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Cross-Sectional Studies; Female; Humans; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Self-Management; Telemedicine; Young Adult | 2021 |
Women's experiences of a telemedicine abortion service (up to 12 weeks) implemented during the coronavirus (COVID-19) pandemic: a qualitative evaluation.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adult; COVID-19; Female; Health Services Accessibility; Humans; Mifepristone; Misoprostol; Patient Satisfaction; Pregnancy; Qualitative Research; SARS-CoV-2; Scotland; Self Administration; State Medicine; Telemedicine | 2021 |
Clinical analysis of second-trimester pregnancy termination after previous caesarean delivery in 51 patients with placenta previa and placenta accreta spectrum: a retrospective study.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Adult; Cesarean Section; China; Female; Humans; Hysterotomy; Labor, Induced; Mifepristone; Misoprostol; Placenta Accreta; Placenta Previa; Pregnancy; Pregnancy Trimester, Second; Retrospective Studies; Vaginal Birth after Cesarean; Young Adult | 2021 |
Effect of mifepristone and lithospermum combination regimen on medical abortion in early pregnancy rats.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Animals; Lithospermum; Mifepristone; Misoprostol; Pregnancy; Rats; Rats, Sprague-Dawley | 2021 |
Same-day mifepristone prior to second-trimester induction termination with misoprostol: A retrospective cohort study.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Retrospective Studies | 2022 |
Mail-order pharmacy dispensing of mifepristone for medication abortion after in-person clinical assessment.
Topics: Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Pharmacy; Postal Service; Pregnancy; Prospective Studies | 2022 |
Predictive value of peripheral blood α1-acid glycoprotein in medical abortion outcomes with mifepristone and relativity of concentration.
Topics: Abortion, Incomplete; Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Orosomucoid; Pregnancy | 2022 |
Bleeding pattern after medical management of early pregnancy loss with mifepristone-misoprostol and its prognostic value: a prospective observational cohort study.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Abortion, Spontaneous; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Prognosis; Prospective Studies; Uterine Hemorrhage | 2022 |
Adherence to treatment and prevalence of side effects when medical abortion is delivered via telemedicine: a prospective observational cohort study during COVID-19.
Topics: Abortion, Induced; Anti-Bacterial Agents; Antiemetics; COVID-19; Female; Headache; Humans; Mifepristone; Misoprostol; Pain; Pregnancy; Prevalence; Prospective Studies; Referral and Consultation; Telemedicine; Telephone | 2022 |
A descriptive analysis of medical abortion commodity availability and pricing at retail outlets in 44 countries across four regions globally.
Topics: Abortion, Induced; Costs and Cost Analysis; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 2021 |
Effectiveness of self-managed medication abortion with accompaniment support in Argentina and Nigeria (SAFE): a prospective, observational cohort study and non-inferiority analysis with historical controls.
Topics: Abortifacient Agents; Abortion, Induced; Argentina; Cohort Studies; COVID-19; Female; Humans; Mifepristone; Misoprostol; Nigeria; Pregnancy; Prospective Studies; Self Administration; Self-Management; Surveys and Questionnaires | 2022 |
Making the case for advance provision of mifepristone and misoprostol for abortion in the United States.
Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Abortion, Spontaneous; Female; Humans; Mifepristone; Misoprostol; Pregnancy; United States | 2022 |
The Excessive Regulation of Early Abortion Medication in the UK: The Case for Reform.
Topics: Abortion, Induced; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pharmaceutical Preparations; Pregnancy | 2022 |
Accuracy of self-assessment of gestational duration among people seeking abortion.
Topics: Abortion, Induced; Abortion, Spontaneous; COVID-19; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pregnancy; Self-Assessment | 2022 |
Expanding Access to Medication Abortions.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Legal; Adolescent; Adult; COVID-19; Criminal Law; Drug Prescriptions; Female; Humans; Middle Aged; Mifepristone; Misoprostol; Pandemics; Pharmaceutical Services, Online; Pharmacists; Pregnancy; Pregnancy Trimester, First; Risk Evaluation and Mitigation; Self Administration; Self Medication; Self-Management; Telemedicine; United States; United States Food and Drug Administration; Young Adult | 2022 |
Integrating self-managed medication abortion with medical care.
Topics: Abortion, Induced; Abortion, Spontaneous; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Self-Management | 2022 |
Integrating mifepristone into primary care in Canada's capital: A multi-methods exploration of the Medical Abortion Access Project.
Topics: Abortion, Induced; Abortion, Spontaneous; Canada; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Primary Health Care | 2022 |
Mifepristone-Misoprostol Use for Second- and Third-Trimester Medical Termination of Pregnancy in a Canadian Tertiary Care Centre.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Canada; Cohort Studies; Female; Fetal Death; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Retrospective Studies; Tertiary Care Centers | 2022 |
Second- and Third-Trimester Medical Abortion Providers and Services in 2019: Results From the Canadian Abortion Provider Survey.
Topics: Abortion, Induced; Canada; Cross-Sectional Studies; Female; Humans; Mifepristone; Misoprostol; Physicians, Family; Pregnancy; Pregnancy Trimester, Third | 2022 |
Efficacy of a low-sensitivity urine pregnancy test for identifying ongoing pregnancy after medication abortion at 64 to 70 days of gestation.
Topics: Abortion, Induced; Abortion, Spontaneous; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Tests | 2022 |
Provision of first-trimester medication abortion in 2019: Results from the Canadian abortion provider survey.
Topics: Abortion, Induced; Abortion, Spontaneous; Canada; Cross-Sectional Studies; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First | 2022 |
Mifepristone at home.
Topics: Abortifacient Agents, Steroidal; Humans; Mifepristone; Misoprostol | 2022 |
Combination of mifepristone and misoprostol vs misoprostol monotherapy for treatment of second-trimester pregnancy loss.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Cross-Sectional Studies; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Retrospective Studies | 2022 |
Should COVID-specific arrangements for abortion continue? The views of women experiencing abortion in Britain during the pandemic.
Topics: COVID-19; Female; Humans; Mifepristone; Misoprostol; Pandemics; Pregnancy; United Kingdom | 2022 |
Termination of pregnancy in the second trimester - the course of different therapy regimens.
Topics: Abortifacient Agents; Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Retrospective Studies | 2022 |
Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Abortion, Spontaneous; Chorionic Gonadotropin; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy, Ectopic; Retrospective Studies | 2022 |
Validation of a Spanish-language scale for evaluating perceived quality of care of medical abortions before 9 weeks gestation.
Topics: Abortion, Induced; Female; Humans; Language; Mifepristone; Misoprostol; Pregnancy; Surveys and Questionnaires | 2022 |
Comprehension of an Over-the-Counter Drug Facts Label Prototype for a Mifepristone and Misoprostol Medication Abortion Product.
Topics: Abortion, Induced; Adolescent; Comprehension; Female; Humans; Mifepristone; Misoprostol; Nonprescription Drugs; Pregnancy | 2022 |
Utility and Limitations of Human Chorionic Gonadotropin Levels for Remote Follow-up After Medical Management of Early Pregnancy Loss.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Abortion, Spontaneous; Chorionic Gonadotropin; Female; Follow-Up Studies; Humans; Mifepristone; Misoprostol; Pregnancy | 2022 |
Analysis of the Clinical Efficacy of Conservative Treatment for an Unruptured Cornual Pregnancy.
Topics: Conservative Treatment; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy, Cornual; Retrospective Studies; Treatment Outcome | 2022 |
Complications of second-trimester medical termination of pregnancy for fetal anomalies compared with intrauterine fetal demise.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adult; Female; Fetal Death; Fetal Diseases; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Retrospective Studies; Stillbirth | 2023 |
The effects of mifepristone on the structure of human decidua and chorion and Bax and Bcl-2 expression at early stage of pregnancy.
Topics: bcl-2-Associated X Protein; Chorionic Villi; Decidua; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Proto-Oncogene Proteins c-bcl-2 | 2022 |
The method for termination of mid-trimester pregnancy with placenta previa: A case study.
Topics: Cesarean Section; Ethacridine; Female; Humans; Mifepristone; Misoprostol; Placenta; Placenta Previa; Pregnancy; Retrospective Studies | 2022 |
[Simultaneous determination and pharmacokinetic study of five compounds from total extract of Clinopodium chinense in abnormal uterine bleeding rat plasma by UPLC-MS/MS].
Topics: Administration, Oral; Animals; Apigenin; Chromatography, High Pressure Liquid; Chromatography, Liquid; Drugs, Chinese Herbal; Female; Flavonoids; Hesperidin; Lamiaceae; Mifepristone; Misoprostol; Oleanolic Acid; Plant Extracts; Rats; Saponins; Tandem Mass Spectrometry; Uterine Hemorrhage | 2022 |
Trend of serum beta-human chorionic gonadotropin levels after medical abortion in the early first trimester of pregnancy.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Administration, Intravaginal; Chorionic Gonadotropin; Chorionic Gonadotropin, beta Subunit, Human; Female; Humans; Infant; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First | 2023 |
Pharmacist direct dispensing of mifepristone for medication abortion in Canada: a survey of community pharmacists.
Topics: Abortion, Induced; Canada; Female; Humans; Mifepristone; Misoprostol; Pharmacists; Pregnancy; Surveys and Questionnaires | 2022 |
Predictor assessment of complete miscarriage after medical treatment for early pregnancy loss in women with previous cesarean section.
Topics: Abortion, Spontaneous; Cesarean Section; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First | 2022 |
Development of a Spanish-language drug facts label prototype for a combination mifepristone and misoprostol medication abortion product.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Adolescent; Adult; Female; Humans; Language; Middle Aged; Mifepristone; Misoprostol; Pregnancy; Young Adult | 2023 |
Very early medical abortion: treatment with mifepristone and misoprostol before ultrasonographic visualisation of an intrauterine pregnancy.
Topics: Abortion, Induced; Abortion, Spontaneous; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy, Ectopic; Retrospective Studies | 2023 |
Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First | 2022 |
[Single dose of misoprostol for abortion until 9 weeks of gestation].
Topics: Abortion, Induced; Administration, Intravaginal; Female; Gestational Age; Humans; Mifepristone; Misoprostol; Pain; Pain Management; Pregnancy | 2023 |
How much will it hurt? Factors associated with pain experience in women undergoing medication abortion during the first trimester.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Dysmenorrhea; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First | 2023 |
Single dose letrozole and misoprostol for termination of pregnancy through 63 days' gestation: A pilot study.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Administration, Intravaginal; Female; Humans; Letrozole; Mifepristone; Misoprostol; Pilot Projects; Pregnancy | 2023 |
Integrative transcriptomics and proteomics analyses to reveal the therapeutic effect and mechanism of Buxue Yimu Pills in medical-induced incomplete abortion rats.
Topics: Abortion, Incomplete; Abortion, Induced; Abortion, Spontaneous; Animals; Dinoprost; Female; Matrix Metalloproteinase 7; Mifepristone; Misoprostol; Pregnancy; Proteomics; Rats; Transcriptome | 2023 |
Summary for Patients: Short-Term Adverse Outcomes After Mifepristone-Misoprostol Versus Procedural Induced Abortion.
Topics: Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Treatment Outcome | 2023 |
Short-Term Adverse Outcomes After Mifepristone-Misoprostol Versus Procedural Induced Abortion : A Population-Based Propensity-Weighted Study.
Topics: Abortion, Induced; Abortion, Spontaneous; Adult; Cohort Studies; Female; Humans; Mifepristone; Misoprostol; Ontario; Pregnancy; Pregnancy Trimester, First | 2023 |
At-home urine pregnancy test assessment after mifepristone and misoprostol for undesired pregnancy of unknown location.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Abortion, Spontaneous; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Tests | 2023 |
Medical Methods for First-Trimester Abortion.
Topics: Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Pregnancy Trimester, Second | 2023 |
History and Politics of Medication Abortion in the United States and the Rise of Telemedicine and Self-Managed Abortion.
Topics: Abortion, Induced; COVID-19; Female; Humans; Mifepristone; Misoprostol; Pandemics; Politics; Pregnancy; Self-Management; Telemedicine; United States | 2023 |
In-country availability of medical abortion medicines: a description of the framework and methodology of the WHO landscape assessments.
Topics: Abortion, Induced; Abortion, Spontaneous; Female; Humans; Mifepristone; Misoprostol; Pregnancy; World Health Organization | 2023 |
Mailing abortion pills does not delay care: A cohort study comparing mailed to in-person dispensing of abortion medications in the United States.
Topics: Abortion, Induced; Cohort Studies; Female; Humans; Mifepristone; Misoprostol; Pharmaceutical Services; Pharmacies; Pregnancy; United States | 2023 |
Advancing Reproductive Health through Policy-Engaged Research in Abortion Care.
Topics: Abortion, Spontaneous; Canada; Female; Health Policy; Humans; Mifepristone; Misoprostol; Pregnancy; Reproductive Health; United States | 2022 |
Telemedicine medical abortion service in Georgia: an evaluation of a strategy with reduced number of in-Clinic visits.
Topics: Ambulatory Care; Female; Georgia; Humans; Mifepristone; Misoprostol; Pregnancy; Prospective Studies; Self Administration; Telemedicine | 2023 |
In brief: Expanded acess to mifepristone.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Drug Therapy, Combination; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 2023 |
Mifepristone priming and subsequent misoprostol for second trimester medical abortion in women with previous caesarean delivery.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Cesarean Section; Female; Humans; Mifepristone; Misoprostol; Placenta; Pregnancy; Pregnancy Trimester, Second; Retrospective Studies; Uterine Rupture | 2023 |
Medication abortion with misoprostol-only: A sample protocol.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 2023 |
A prospective, comparative study of clinical outcomes following clinic-based versus self-use of medical abortion.
Topics: Abortion, Induced; Ambulatory Care Facilities; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Prospective Studies | 2023 |
Effectiveness and acceptability of home use of misoprostol for medical abortion up to 10 weeks of pregnancy.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Administration, Intravaginal; Female; Humans; Infant; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Prospective Studies | 2023 |
Availability of medical abortion medicines in eight countries: a descriptive analysis of key findings and opportunities.
Topics: Abortifacient Agents; Abortion, Induced; Drug Industry; Female; Health Services Accessibility; Humans; Internationality; Mifepristone; Misoprostol; Pregnancy; South Africa | 2023 |
Mifepristone remains available in US until midnight on 19 April.
Topics: Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 2023 |
Implications of using home urine pregnancy tests versus facility-based tests for assessment of outcome following medication abortion provided via telemedicine.
Topics: Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Tests; Telemedicine; United States | 2023 |
Maternal complications associated with second trimester medical abortion using mifepristone priming and subsequent misoprostol.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adult; Female; Humans; Infant; Mifepristone; Misoprostol; Placenta; Pregnancy; Pregnancy Trimester, Second; Retrospective Studies | 2023 |
The Mifepristone Case and the Legitimacy of the FDA.
Topics: Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Pregnancy; United States; United States Food and Drug Administration | 2023 |
The effect of induced fetal demise on induction to expulsion interval during later medication abortion: A retrospective cohort.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Digoxin; Female; Fetal Death; Humans; Lidocaine; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Retrospective Studies | 2023 |
In brief: Alternatives to mifepristone for medication abortion.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 2023 |
Clinical outcomes of medication abortion using misoprostol-only: A retrospective chart review at an abortion provider organization in the United States.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Abortion, Spontaneous; COVID-19; Female; Humans; Mifepristone; Misoprostol; Pandemics; Pregnancy; Retrospective Studies; United States | 2023 |
Approved but Unavailable: A Mystery-Caller Survey of Mifepristone Access in a Large Ontario City.
Topics: Abortion, Induced; Female; Health Services Accessibility; Humans; Mifepristone; Misoprostol; Ontario; Pregnancy; Prescriptions | 2023 |
Management of early pregnancy loss among obstetrician-gynecologists in Massachusetts and barriers to mifepristone use.
Topics: Abortion, Induced; Abortion, Spontaneous; Female; Gynecologists; Humans; Massachusetts; Mifepristone; Misoprostol; Obstetricians; Pregnancy | 2023 |
Effectiveness of Self-Managed Medication Abortion Between 9 and 16 Weeks of Gestation.
Topics: Abortion, Induced; Ambulatory Care Facilities; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Prospective Studies; Self-Management | 2023 |
Trends in the Use of Mifepristone for Medical Management of Early Pregnancy Loss From 2016 to 2020.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Abortion, Spontaneous; Female; Humans; Mifepristone; Misoprostol; Pregnancy | 2023 |
Clinical analysis of the regimens for terminating the second-trimester pregnancy in cesarean section women.
Topics: Cesarean Section; Ethacridine; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Retrospective Studies | 2023 |
Preabortion ultrasound - a patient perspective.
Topics: Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Northern Ireland; Pregnancy; Surveys and Questionnaires | 2023 |
Medical abortion in the second trimester - an update.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Prostaglandins | 2023 |
Medication Abortion Safety and Effectiveness With Misoprostol Alone.
Topics: Abortion, Induced; Abortion, Spontaneous; Female; Humans; Mifepristone; Misoprostol; Pregnancy; Prospective Studies | 2023 |